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  Abstract 
 
The works presented in this thesis examine the neural effects of treatment on different features of 
depression, such as affective biases, working memory impairments and dysfunctional thinking.  The 
thesis opens with a review of longitudinal studies that examined the effects of antidepressants and 
psychological therapies on the neural correlates of affective and cognitive processing.  Motivated by 
the paucity in the number of fMRI studies that examined psychotherapy in depression, Chapter 2 
examines the effects of Cognitive Behavioural Therapy (CBT) on dysfunctional thinking in 
depression.  In Chapter 3, the effects of a dual acting serotonin norepinephrine reuptake inhibitor, 
duloxetine, on affective biases are examined using implicit affective paradigms comprising happy and 
sad facial expressions.  Chapter 4 investigates the neural effects of duloxetine on working memory in 
depression utilizing a modified version of the Sternberg Working Memory Task.  Another key focus 
in the thesis is to examine the potential of structural neuroimaging data to identify depression and 
predict clinical remission using machine learning algorithms in a sample of wide ethnic diversity from 
the community.  Findings from this study are presented in Chapter 5. 
Overall, the results showed antidepressant treatment related increases in posterior cingulate during sad 
facial effect processing, consistent with preliminary findings that show increases in this region with 
antidepressants that potentiate the noradrenergic systems.  The neural correlates of working memory, 
on the other hand, showed a significant group by time interaction during the rehearsal phase, such that 
there was a tendency for reductions in brain activations at the follow up scan compared to baseline in 
healthy controls in a network of brain areas extending from the prefrontal, to the cingulate, temporal 
and cerebellar regions, while no change was observed in patients.  The tendency for decreased 
activations in controls in the follow up scan is perhaps indicative of less recruitment of these regions 
with increased familiarity with the task, while no change in activation in patients may reflect 
persistent recruitment of regions associated with working memory to maintain task performance.  In 
the CBT study, an interaction effect was found in the left parahippocampal gyrus, which showed less 
attenuation in patients relative to controls at the follow up scan, perhaps reflecting an improvement in 
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dysfunctional thinking with CBT with some persistent vulnerability.  Investigation of neuroimaging-
based biomarkers in depression indicated that structural neuroanatomy combining white and grey 
matter distinguished patients from controls at the highest accuracy of 81% with the most stable pattern 
being at around 70%.  In contrast, the whole brain structural correlates of depression showed limited 
potential as a prognostic marker.  These findings suggest some distinct neural effects of treatment on 
cognitive and affective processing and provide preliminary evidence to indicate that identification of 
























The important findings from this chapter have been published in two papers 
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Major Depressive Disorder (MDD) is characterised by persistent depressed mood and/or a loss of 
interest or pleasure in activities.  Additional features include fatigue, feelings of worthlessness or 
guilt, marked changes in weight, sleep patterns, psychomotor activity, diminished concentration, 
recurrent thoughts of death, suicidal ideation or suicide attempt (American Psychiatric Association, 
2013).  For a diagnosis of MDD to be made, the individual has to exhibit a minimum of five 
symptoms, and at least one of which must be depressed mood or anhedonia.  The core symptoms must 
be present for a minimum duration of two weeks (American Psychiatric Association, 2000).  The 
median age for onset for depression is 32 years (Kessler et al., 2005).  MDD is a debilitating disorder 
and it is one of the leading contributors to the global burden of disease, regularly identified amongst 
the top five disabling conditions worldwide (Murray & Lopez, 2013).   
MDD is often associated with recurrences and relapses, and the risk for relapse becomes more likely 
with increasing number of previous episodes (Kessing et al., 2004).  It has been proposed that the 
processes mediating relapse grow progressively independent and are less linked to environmental 
stressors (Kendler et al., 2000).  Hence, preventing relapse and recurrence is an essential feature in the 
clinical management of the disorder.  At the present time, the diagnosis of major depression is based 
solely on clinical signs and symptoms, and there are no biological tests that are used to diagnose the 
disorder or to predict clinical response to a particular treatment or the course of the illness.   
Diagnostic classification systems, such as the Diagnostic and Statistical Manual of Mental Disorders 
(DSM) regards depression as a consistent syndrome, in which the key focus for diagnosis is the 
number of symptoms that a patient presents with, which is totalled to give a sum-score (Fried & 
Nesse, 2015a,b).  With such a classification system, often individuals with a wide range of symptoms 
are lumped together into one unified category.  According to Shorter (2014), this is a “nosological 
disaster’ as MDD is a very heterogeneous disorder.  For instance, it is possible for two individuals 
who meet criteria for MDD with the DSM-V to have no symptoms in common (Fried & Nesse, 
2015a).  Hence, ignoring the heterogeneity of the disorder by having a broad diagnostic category 
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raises concerns with respect to treatment of patients with diverse symptomatic profiles (Shorter, 
2014).  A recent study that included over three thousand seven hundred patients with depression 
identified 1030 different symptom profiles (Fried & Nesse, 2015a).  Examining different 
manifestations of the same disorder is imperative as they may have potential aetiological and/or 
therapeutic implications.  Moreover, different symptoms are likely to have varying impacts on 
psychosocial functioning.  Amongst the different symptoms, sad mood, difficulty concentrating and 
fatigue are considered most debilitating (Fried & Nesse, 2014), and therefore makes it crucial to 
examine different dimensions of the disorder, i.e. the affective, cognitive and somatic symptoms, 
rather than focussing on the total number of symptoms.   
In addition, evidence from recent studies indicate that one must not consider diagnostic classification 
systems as a monolith for diagnosis.  For example, a large multi-centre study based on 5635 adults in 
a major depressive episode found that, although only 16% met DSM-IV-TR criteria for bipolar 
disorder, 47% of them met criteria for the bipolarity specifier (Angst et al., 2011).  This suggests the 
importance of considering factors such as family history, clinical status and illness course before 
making a diagnosis, especially to avoid ineffective treatment regimen (Angst et al., 2011).  
An alternate approach to having a broad diagnostic label such as ‘Major Depressive Disorder’ has 
been to classify the different ‘subtypes’ of depression by looking for similar patterns, either in 
symptomology, aetiology or both.  A meta-review of 754 reviews identified 15 subtypes of depression 
that differ on five aspects: symptom, aetiology, gender, time of onset and treatment resistance (Harald 
& Gordon, 2012).  Unfortunately, even with such a classification system, there is still a considerable 
overlap between the different subtypes (Harald & Gordon, 2012),and therefore casts doubts on its 
utility.  
The DSM, in fact, recognises some specifiers of depression that can provide more detailed 
information about the person’s condition.  Specifiers detailed in the most recent version of the DSM 
(i.e. version V), include MDD with anxious-distress features, mixed features, melancholic features, 
atypical features, catatonia, seasonal pattern, peripartum onset, and mood congruent or incongruent 
psychotic features (American Psychiatric Association, 2013).  The differing pathophysiology of the 
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MDD subtypes, especially melancholic and atypical depression are extensively investigated (ex. 
Karlović et al., 2012; Dunjic-Kostic et al., 2013; Gold & Chrousos, 2013; Lamers et al., 2013).  In 
general, melancholic depression is considered to be a more severe form of MDD with biological 
origins (Maes et al., 1991; Lamers et al., 2013), and patients with melancholic features are likely to 
respond better to antidepressant treatment (Guelfi et al., 1995; Herschfeld, 1999) than to placebo.  
There is also some evidence that tricyclic antidepressants may be better in treating depression with 
melancholic features compared with serotonin-specific reuptake inhibitors (Perry, 1996), but this has 
not been widely replicated (ex. Herschfeld, 1999).  While melancholic features have been considered 
to have good clinical outcomes with electro-convulsive therapy (ECT) (Abrams, 2002; Taylor & Fink, 
2006), a much larger study on 311 MDD patients with melancholic depression and 178 patients 
without melancholic features concluded that melancholia was associated with poorer treatment 
outcomes, compared to non-melancholic features, with acute ECT, although relapse rates reduced 
with continuation ECT when compared to continuation medication treatment (Fink et al., 2007).  
Atypical depression is usually associated with symptoms such as increased appetite, over sleeping, 
leaden paralysis, and interpersonal rejection sensitivity (American Psychiatric Association, 2013).  
However, there are no treatment options that are seen as specifically useful for atypical depression 
and recent studies showed that serotonin reuptake inhibitors did not sufficiently discriminate 
treatment outcome in patients with atypical depression compared to those without atypical features 
(Stewart et al., 2010; Uher et al., 2011).  An improved framework that is better able to capture the 
heterogeneity associated with the disorder, bearing in mind the impact of the symptoms on patients’ 
psychosocial functioning, in addition to considering factors such as  history and the course of the 
illness prior to the current major depressive episode may be an initial step towards having 
personalized treatments.  
In the following paragraphs, biases in affective processing, which is a common feature of depression, 




1.2 Affective bias in MDD and improvements with treatment 
MDD is associated with specific biases and abnormalities which may lead to the onset and 
maintenance of the disorder.  MDD is associated with a negative affective bias in several 
neurocognitive domains.  In particular, MDD patients show a greater recollection of negative 
information relative to healthy controls, such as words (Bradley et al., 1995) and facial expressions 
(Ridout et al., 2003).  There is a selective attention towards negative stimuli in MDD (Beck, 2008), 
including towards negatively valenced words (Donaldson et al., 2007) and mood-congruent images 
(Eizenman et al., 2003), and away from positive stimuli, such as happy facial expressions (Leppänen, 
2006).  Furthermore, mood congruent attentional bias in depression was apparent even with some 
patients already on antidepressant medications (Eizenman et al., 2003).  The attentional bias towards 
negative stimuli manifests more in anxiety disorders (such as Generalised Anxiety Disorder; GAD), 
while in depression, it is usually evident when the target stimuli is presented over a relatively long 
duration of time, allowing more extensive processing (Mogg & Bradley, 2005).  With facial 
expressions, MDD patients have difficulties discerning affective facial expressions, namely happy and 
sad expressions, which contribute to the psychosocial and interpersonal difficulties that are seen in 
patients with major depression (Persad & Polivy, 1993).  They also tend to misinterpret happy, neutral 
or ambiguous faces as being sad or less happy (Bourke et al., 2010).  Moreover, the selective 
attentional bias towards negative facial expressions is evident even in recovered patients (Bhagwagar 
et al., 2004; Joormann & Gotlib, 2007), while the induction of a mild negative mood in recovered 
patients can reinstate some of the negative biases observed in acutely depressed patients (Gemar et al., 
2001).   
Evidence based treatments for MDD include antidepressant medications or psychological therapies or 
both and treatment decisions are usually based on the severity and course of the disorder, patient 
preference and previous response to treatment.  Both pharmacological and psychological treatments 
have shown to alter the emotional processing bias evident in depression.  A 2-week antidepressant 
treatment  enhanced recognition of both negative as well as positive emotions in MDD patients 
(Tranter et al., 2009), and a single dosage of citalopram normalised the bias towards fearful faces in 
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MDD patients in remission (Bhagwagar et al., 2004).  Even in healthy controls, a single dose of 
citalopram had improved their attention towards positive words though it had also increased their 
recognition of fearful faces (Browning et al., 2007).  Likewise, cognitive bias modification 
techniques, involving positive interpretations of auditory stimuli using imagery, have been associated 
with improvements in mood and cognitive biases in medication-free MDD patients (Blackwell & 
Holmes, 2010).  Furthermore, enhancement of the recognition of happy faces following antidepressant 
treatment was linked with improvements in symptoms, wellbeing and social functioning (Tranter et 
al., 2009), suggesting that these emotional processing biases may be a state rather than them being 
persistent trait-related features of depression.   
 In this chapter, functional neural correlates of the effects of antidepressants and psychological 
therapies in major depression are discussed.  Furthermore, predictors of clinical response and the 
potential to develop neuroimaging-based markers are reviewed. 
 
1.3 Magnetic resonance imaging in MDD 
Neuroimaging studies have extensively examined brain abnormalities that are associated with 
depression and its subsequent modulation with treatment.  The use of neuroimaging techniques in 
clinical psychiatry helps understand the pathophysiology underlying different mental illnesses and it 
also facilitates identification of neurobiological markers for such disorders.  This could have potential 
value for optimizing treatment regimens for patients and also in identifying early markers of disease 
prognosis and response prediction (Fu & Costafreda, 2013).   
MDD patients show both structural and functional brain alterations in regions associated with 
affective processing and cognitive control, primarily in the limbic and prefrontal areas (Atkinson et 
al., 2014).  Structural Magnetic Resonance Imaging studies (sMRI) have extensively employed 
region-of-interest (ROI) and Voxel-Based-Morphometry (VBM) methods to investigate 
neuroanatomical changes in MDD patients.  Functional neuroimaging studies on the other hand were 
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typically performed using Positron Emission Tomography (PET) and Single Photon Emission 
Computerized Tomography (SPECT) techniques on individuals during resting state.  Although, these 
modes of functional imaging have been effective, poor special resolution as well as contact with 
radioactive tracers limit frequency of scans being repeated on the same patient (ex. Greicius et al., 
2007).  Functional Magnetic Resonance Imaging (fMRI) methods overcome such limitations and they 
have been of considerable use in studying regional brain activations in MDD patients during an acute 
depressive episode. 
fMRI studies have applied various experimental paradigms in order to examine the networks 
underlying the affective biases (ex. Elliott et al., 2002; Lawrence et al., 2004; Surguladze et al., 2005; 
Frodl et al., 2009) and cognitive impairments (ex. Harvey et al., 2005; Wagner et al., 2006; Walter et 
al., 2007; Fitzgerald et al., 2008; Mitterschiffthaler et al., 2008) in MDD.  In order to distinguish 
neural features that are state-specific from trait-related ones, it is important to consider the depressive 
state of the MDD sample (i.e.  whether patients are in an acute depressive episode, in recovery, or in 
remission) and whether the study is a cross sectional analysis of patients in different mood states or 
whether it is a longitudinal investigation of patients following treatment.  For instance, fMRI studies 
have investigated impairments during an acute depressive episode (Harvey et al., 2005; Grimm et al., 
2008; Mitterschiffthaler et al., 2008) as well as the changes following treatment (Sheline et al., 2001; 
Fu et al., 2004, 2007; Walsh et al., 2007; Fu et al., 2008a; Victor et al., 2010; Arnone et al., 2012).  
The majority of studies have examined the effects of pharmacological treatments (Sheline et al., 2001; 
Davidson et al., 2003; Fu et al., 2004, 2007; Walsh et al., 2007; López-Solà et al., 2010; Victor et al., 
2010; Arnone et al., 2012; Rosenblau et al., 2012; Stoy et al., 2012) and to a lesser extent on the 
effects of psychological interventions (Fu et al., 2008a; Dichter et al., 2009, 2010; Ritchey et al., 
2011; Buchheim et al., 2012; Sankar et al., 2014; Yoshimura et al., 2014).  It is unclear whether the 
regional changes seen after treatment is specific to antidepressants or whether such changes are 
common across treatment methods. 
Generally longitudinal fMRI studies investigating affective processing have used standardized series 
of facial expressions (ex.  Ekman & Friesen, 1976) or emotional pictures (ex. International Affective 
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Picture System (IAPS); Lang et al., 1999).  Emotional processing tasks used in fMRI studies are 
usually either implicit or explicit in nature.  For example, in a task involving the presentation of 
emotional faces, the explicit instruction may be to identify the gender of the presented face while the 
emotional expression is processed implicitly, or the explicit instruction may be to identify the emotion 
expressed by the presented face which becomes explicit processing of the emotion.  fMRI studies 
often use implicit rather than explicit emotional processing tasks as they are associated with greater 
probability of engaging key limbic regions within the MDD network, such as the amygdala 
(Costafreda et al., 2008).  The majority of the longitudinal MDD studies have focussed on the 
functional correlates of treatment in response to emotional processing (Davidson et al., 2003; Fu et al., 
2004, 2007, 2008a; Victor et al., 2010; Ritchey et al., 2011; Arnone et al., 2012).  Other emotional 
processes, such as reward (Dichter et al., 2009; Stoy et al., 2012) and painful stimuli (López-Solà et 
al., 2010), as well as cognitive processes, such as verbal working memory (Walsh et al., 2007) and 
cognitive control (Wagner et al., 2010), have also been investigated.   
 
1.4  Neural effects of antidepressant treatment on negative emotional processing in 
MDD 
An influential model that elucidates the neural correlates of depression was proposed by Helen 
Mayberg (1997).  The model postulates that depression stems primarily from disruptions in the 
cortico-limbic pathway, which constitutes three main components, the interactions among which are 
essential for the regulation of mood and associated behaviours (Mayberg, 1997; Mayberg et al., 
1999).  The proposed model consists of the dorsal component, comprising a network of neocortical 
(eg. dorsolateral prefrontal and inferior parietal regions) and midline limbic structures (such as 
cingulate, hypothalamus, hippocampus, amygdala) which mediate the attentional and cognitive 
impairments evident in depression (Mayberg, 1997; Mayberg et al., 1999).  The ventral component 
comprises a distributed network of regions including the hypothalamus-pituitary-adrenal (HPA) axis, 
subgenual cingulate (Brodmann area 25), insula and brain stem, and are involved with the vegetative 
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and somatic features of the disorder.  The dorsal and the ventral components have reciprocal 
connections within each other as well as between components via the cingulate cortex, thalamus and 
hippocampus (Mayberg 1997).  The third component, rostral cingulate has reciprocal connections 
with the dorsal and ventral part of the anterior cingulate (Mayberg, 1997).  According to Mayberg 
(Mayberg et al., 1999), there is a reciprocal relationship between the limbic and cortical regions, and 
depression is characterised by decreases in the dorsal cortical structures, and increases in limbic and 
paralimbic activity (amygdala and subgenual cingulate), mediated by disruptions in the rostral anterior 
cingulate.  Therefore, increased activations in the limbic regions leads to dysregulated activity in the 
dorsal cortical regions, decreasing the ability of the latter to regulate limbic hyperactivity.   
Mayberg’s model (Mayberg, 1997; Mayberg et al., 1999) is shown to have implications in the 
diagnosis of depression and in predicting antidepressant response.  It is however important to note that 
more recent investigations suggest that depression may not just involve altered reciprocal connections 
between regions in the limbic and dorsal cortical network that form a vicious cycle, as initially 
speculated.  For instance, resting state studies in major depressive disorder indicate that depression 
may be associated with decreased ability to downregulate activity within the default mode network 
(DMN); cortical and subcortical regions that are activated during internally directed thought 
processing (Sheline et al., 2009; review: Whitfield-Gabrieli & Ford et al., 2012).  In MDD patients, 
there is also evidence that show decreased functional connectivity (Zhu et al., 2012) as well as 
reduced correlations in the caudate (Bluhm et al., 2009) with the precuneus and posterior cingulate, 
core regions of the DMN, albeit with some inconsistencies, with findings of increased connectivity 
between the dorsomedial prefrontal cortex and regions within the DMN (Sheline et al., 2010).  
Moreover, findings from Mayberg’s studies revealed normalization of the increased limbic and 
paralimbic activations as well as improvement in the initially attenuated dorsal prefrontal activations 
with successful response to treatment (Mayberg et al., 1999; 2000), suggesting that they may be state 
factors in depression.  However,  even individuals who are at high risk for depression have shown 
greater limbic activations, for instance, in bilateral amygdala, in comparison with low-risk individuals 
in response to fearful stimuli (Monk et al., 2008).  Similarly, remitted MDD patients relative to 
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controls showed elevated amygdala activity during masked sad facial processing, with a pattern of 
activations similar to acutely depressed patients (Victor et al., 2010).  This suggests that even in 
vulnerable patients, negative mood induction may mediate amygdala hyperactivity, similar to what is 
seen in acutely depressed patients.   
Apart from analysis of resting state networks, the study of affective cognition is gathering momentum 
and is considered important in gaining insight into the pathophysiology of mood and anxiety disorders 
and in understanding the mechanism of antidepressant drug action.  Affective cognition, or the 
response to affective stimuli during cognitive evaluation, involves many sub-processes, which include 
perception, recognition and in some instances categorization of different emotions (Elliott et al., 
2011).  Different paradigms have been employed to examine affective cognition, and these include 
standardized series of facial expressions (ex.  Ekman & Friesen, 1976), emotional pictures (ex. 
International Affective Picture System (IAPS); Lang et al., 1999), memory and attentional bias task 
with emotional components, and social and moral emotion paradigms (see Elliott et al., 2011 for a 
selective review).  The amygdala plays a key role in emotion recognition, categorization and also 
emotion memory (Berntson et al., 2007).  In addition to amygdalar responses, affective cognition 
modulates the ventromedial prefrontal region, especially during social and moral emotions, and the 
connections between the regions; and disruptions in affective cognition are a core feature of 
depression (Elliott et al., 2011).   
Thus, taking into account evidence from resting state studies as well as those that employed different 
functional paradigms, it seems that depression may be mediated by dysregulation in the cortico-limbic 
network, as postulated by Mayberg; however different paradigms (whether cognitive, affective or 
both) or even resting state are likely to probe different components of the same network.  Moreover, 
due to the heterogeneous nature of MDD, there may be distinct neural correlates associated with 
varying symptomatic profiles, which requires investigation.  More recently, multi-network model of 
psychopathology has provided novel insight into understanding the dysfunctional neural systems in 
depression (Menon, 2011).  This model elucidates three important networks, the DMN, the salience 
and the central executive networks.  Unlike the DMN, the central executive network (CEN) is most 
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active during cognitive processing, especially during tasks of memory and attention and constitutes 
regions of the dorslateral prefrontal cortex and posterior parietal regions (Corbetta & Shulman, 2002; 
Rogers et al., 2004; Sridharan et al., 2008).  The salience network (SN) on the other hand plays a key 
role in emotional processing and emotional control, and comprises the amygdala, insula, dorsal 
anterior cingulate and the temporal cortex (Mulders et al., 2015).  In this network-based model 
approach, the default mode network, the salience network and the central executive network that 
characterise neural function during rest, affective and cognitive processing are altered in depression 
(Menon, 2011).  A very recent review of resting state connectivity studies found increased 
connectivity in the anterior DMN in depression, and between the anterior DMN and the salience 
network, decreased connectivity between the posterior DMN and the central-executive network, and 
changed connectivity between the anterior and posterior nodes of the DMN, thus providing support 
for the notion that depression may be a network-based disorder (Mulders et al., 2015).   
In the following paragraphs, I review the effects of treatment, both antidepressant as well as 
psychotherapies on the functional correlates of depression.  
Neuroimaging studies indicate that healthy emotional regulation depends on the interplay between 
frontal and limbic regions, in particular the amygdala.  A frequently applied strategy of emotion 
regulation involves reinterpreting the meaning of a situation in order to reduce the affective impact, 
which may be termed cognitive reappraisal (Gross, 2002).  The neural correlates of the process of 
reappraisal involve cognitive control regions within the prefrontal cortex and modulation of emotion-
related activity in the amygdala (meta-analysis: Buhle et al., 2014).  The amygdala plays a key role in 
processing of emotional stimuli, both negative and positive, although there is a higher probability of 
amygdalar response to stimuli which evoke fear and disgust relative to those which give rise to 
happiness (Costafreda et al., 2008).  Studies of the neural correlates of emotional processing in MDD 
have demonstrated increased amygdala activation during an acute depressive episode as compared to 
controls in response to a variety of negative stimuli, such as sad faces (Fu et al., 2004; Victor et al., 
2010; Arnone et al., 2012), fearful or angry faces (Sheline et al., 2001; Ruhe et al., 2012), and 
negatively valenced pictures (Anand et al., 2005; Rosenblau et al., 2012).   
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The effect of treatments on negative affective processing has been studied widely due to the mood 
congruent processing bias evident in patients with depression.  With the current psychiatric drug 
nomenclature, the different categories are neither based on which neurotransmitters the drugs act on, 
nor do they reflect the differing mechanism of action of the drug.  Such a nomenclature that is centred 
on earlier understanding of neuropsychopharmacology is less likely to aid clinicians in selecting the 
best possible treatment course for the patients (Zohar et al., 2014; Ghaemi, 2015).  There is a proposal 
for a new and revised nomenclature from the four major schools of neuropsychology (i.e. the 
European College of Neuropsychopharmacology, the American College of 
Neuropsychopharmacology, the Collegium Internationale de Neuropsychopharmacologie, and 
theAsian College of Neuropsychopharmacology), that is instead based on five exes (1) target or class 
(primary pharmacological action and mechanism), (2) family (relevant neurotransmitter and 
mechanism), (3) neurobiological activities, (4) efficacy and side effects, and (5) approved indications 
(Zohar et al., 2014).   
Within the category of antidepressants, there are different classes, and in general, the pharmacological 
action of antidepressants is enhancing synaptic action of one or more of the monoamines, namely, 
serotonin, norepinephrine and dopamine, consistent with the monoamine hypothesis of depression. 
According to this theory, the entire monoaminergic system may be dysregulated in the different neural 
circuits, and the patients’ symptoms vary depending on the involvement of the different monoamine 
neurotransmitters (Stahl, 2013).  The most important antidepressant classes, stratified broadly based 
on their mechanisms of action include older antidepressants such as are tricyclic antidepressants 
(TCA) and monoamine oxidase inhibitors (MAO-I), reuptake inhibitors like serotonin selective 
reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), selective 
norepinephrine reuptake inhibitors (NRI), and norepinephrine and dopamine reuptake inhibitors 
(NDRI), and other antidepressant classes, such tetracyclic antidepressants (TeCA), reversible 
monoamine oxidase inhibitors (rMAO-A inhibitor) and noradrenergic and specific serotonergic 
antidepressants (NaSSA), and serotonin antagonist/reuptake inhibitor amongst others (Stahl, 2013;  
Zohar et al., 2014). 
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 In the paragraphs that ensue, the neural effects of SSRIs on negative emotional processing are 
discussed in detail as majority of the longitudinal neuroimaging treatment studies in depression have 
generally examined SSRIs compared to other antidepressant classes.  This may at least be partly due 
to SSRIs being recommended as first line treatment options for MDD patients who are indicated for 
antidepressant treatment (National Institute for Health and Clinical Excellence; NICE, 2015).  Drugs 
belonging to the SSRI class include fluoxetine, citalopram, escitalopram, sertraline, paroxetine and 
fluvoxamine.  They share a common feature, i.e. selective inhibition of serotonin reuptake or the 
serotonin transporter (Stahl, 2013).  However, each of these drugs also have distinguishing 
pharmacological features that make it distinctive from the others.  The longitudinal imaging studies in 
depression have examined the neural effects of  sertraline (Sheline et al., 2001; Anand et al., 2007; 
Victor et al., 2010), fluoxetine (Fu et al., 2004), citalopram (Arnone et al., 2012), paroxetine (Ruhe et 
al., 2012), and escitalopram (Jiang et al., 2012; Rosenblau et al., 2012) on negative emotional 
processing in depression.  Following treatment with SSRIs, normalisation of increased amygdala 
activation in patients has been widely observed (Sheline et al., 2001; Fu et al., 2004; Arnone et al., 
2012; Rosenblau et al., 2012).  This may be consistent with the density of serotonin receptors within 
the amygdala (Xu & Pandey, 2000) which are a target of action for SSRIs (Jiang et al., 2011).  
Although normalization of amygdala activity in patients could merely reflect improvements in 
depression severity, recent neuroimaging studies have provided evidence for effects of SSRI treatment 
on amygdala.  For instance, acute administration of citalopram in controls and remitted MDD patients 
decreased amygdala responses to fearful emotions (Anderson et al., 2011).  Furthermore, short term 
administration of SSRIs in both healthy volunteers (Harmer et al., 2006) and MDD patients 
(Godlewska et al., 2012) normalized amygdala responses to negative emotional stimuli and 
remediation of amygdala activity in patients occurred even before clinical improvements (Godlewska 
et al., 2012), suggesting a therapeutic mechanisms of SSRI treatment for depression.  It is important to 
note that the probability of amygdala activation in response to emotional stimuli is increased using a 
region of interest (ROI) approach (Sheline et al., 2001; Arnone et al., 2012; Rosenblau et al., 2012), 
indicating the need for such sensitive methods in addition to whole brain analyses to investigate 
amygdala activity (Costafreda et al., 2008). 
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In addition to attenuation of amygdalar activation, antidepressant treatment also normalizes activity in 
other limbic and subcortical regions that are dysregulated in patients.  For instance, MDD patients 
have shown increased activations in the anterior cingulate, insula (Fu et al., 2004), hippocampus 
(Victor et al., 2010), parahippocampal gyrus (Surguladze et al., 2005) and putamen (Fu et al., 2004; 
Surguladze et al., 2005) relative to healthy controls during implicit processing of sad faces which was 
attenuated with treatment (Anterior cingulate: Fu et al., 2004; Victor et al., 2013; Insula: Fu et al., 
2004; Wagner et al., 2010; Putamen: Fu et al., 2004).  Limbic regions such as hippocampus, 
parahippocampal gyrus, orbitofrontal and anterior cingulate cortices are highly responsive to 
emotional stimuli but are also engaged by other responses that are seen as dysfunctional in depression.  
For example, orbitofrontal cortex is involved in reward processing (Elliott et al., 2000; Rolls, 2000; 
Elliott et al., 2003), with greater responses in this region during the lowest and highest reward values 
relative to mid-values (Elliott et al., 2003), hippocampal gyrus in episodic memory (Burgess et al., 
2002) and anterior cingulate in conflict monitoring and cognitive control (Botvinick et al., 2001; 
Mitterschiffthaler et al., 2008).  In response to other affective stimuli, such as negative pictures, 
antidepressants regulate activity in the prefrontal regions including orbitofrontal and dorsolateral 
prefrontal cortices (Rosenblau et al., 2012), and subcortical regions including striatum (Anand et al., 
2007) which are seen to be highly activated in patients relative to the controls (Anand et al., 2005; 
Rosenblau et al., 2012).  Furthermore, a strong association between cortico-limbic activations and 
clinical improvements has been observed, such that the patients who showed the most improvement 
also had the greatest reductions in activation with treatment (Fu et al., 2004).   
Investigation of SNRI treatment effects on negative emotional processing in MDD have revealed 
similar normalization of limbic regions, particularly in the hippocampus, and in other subcortical 
regions including the fusiform gyrus, thalamus, precuneus and the cerebellum (Frodl et al., 2011) as 
well as some increases in the insula and anterior cingulate (Davidson et al., 2003) following venlafaxine 
treatment.  SNRI antidepressant drugs, as the name suggests inhibit the reuptake of both serotonin as 
well as norepinephrine neurotransmitters.  A study that examined the effects of duloxetine, another drug 
belonging to this class, in MDD in response to painful stimuli observed decreases in the insula, 
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pregenual-subgenual anterior cingulate and the dorsolateral prefrontal regions following treatment 
(López-Solà et al., 2010).  An extended release version of Bupropion, an atypical antidepressant whose 
mechanism of action is not fully understood, but is known to exert antidepressant effects through 
modulation of dopaminergic, or noradrenergic systems, or both (Robertson et al., 2007) was also 
associated with decreased activation in limbic regions, particularly in the amygdala/hippocampal area, 
anterior cingulate, in the prefrontal regions such as the inferior frontal gyrus and the dorsomedial 
prefrontal cortex, and in the fusiform gyrus and posterior cingulate cortex in response to negative 
emotional distractors (Robertson et al., 2007).  However, with Mirtazapine, an alpha 2 antagonists, 
distinct increases have been observed, particularly in the supplementary motor area and middle 
cingulum during implicit processing of negative facial expressions (Frodl et al., 2011).  
 The number of studies that have examined the effects of antidepressant drugs belonging to classes other 
than SSRIs are few, and therefore it is difficult to make accurate comparisons of the common and 
distinct neural mechanisms of actions of the different antidepressant classes.  This is compounded by 
the observation that there are a lot of variations with respect to the experimental paradigms, sample 
characteristics, analysis methods and threshold severity, especially amongst studies that examined the 
effects of drugs belonging to the SNRI class on the functional correlates of depression.  For instance, 
López-Solà  & colleagues (2010) administered painful heat stimulation, while Davidson et al. (2003), 
Schaefer et al. (2006) and Frodl et al. (2011) used classic emotional paradigms such as faces (Frodl et 
al., 2011) or pictures (Davidson et al., 2003; Schaefer et al., 2006).  The study by Robertson & 
colleagues (2007) used an emotional oddball task, a paradigm that investigated attentional processing 
and negative emotional processing.  In relation to sample characteristics, Schaefer and colleagues 
(2006) also included patients with primary diagnosis of dysthymia, and with other secondary diagnoses 
such as generalized anxiety disorder and binge eating disorder.  With respect to sample size, all studies 
except Frodl et al. (2011) had a small patient group of less than 15 participants.  The studies also used 
differing statistical thresholds to examine treatment related effects, with Robertson et al. (2007) 
particularly utilizing a very lenient threshold (p <0.05, uncorrected) compared to the other studies.  
None of these studies had a patient group arm receiving placebo, however López-Solà et al. (2010), 
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Davidson et al.  (2003)  and Schaefer et al. (2006) at least accounted for effects of time and repeated 
scans by having healthy controls undergo scans at the same time points as patients.   
Due to the lack of well-controlled placebo neuroimaging trials in depression, it is often difficult to 
separate the neural effects of clinical improvement from that of the drug.  However, a meta-analysis in 
healthy controls based on double-blind placebo controlled trials show some distinct effects of acute 
antidepressant treatment (Outhred et al., 2013).  Acute administration of SSRIs was found to reduce 
emotional reactivity by normalizing increased activations in the limbic regions, particularly the 
amygdala, while NRIs increased prefrontal and medial activations, suggesting increased emotion 
regulation (Outhred et al., 2013).  Moreover, amygdala modulation with SSRIs in MDD patients is 
evident even before patients reported any subjective improvements in clinical symptoms (Godlewska 
et al., 2012).  Similarly, treatment with SNRIs have also shown very early modulation of limbic and 
prefrtonal regions in MDD patients.  For instance, decreases with duloxetine in the insula, 
hippocampus, anterior cingulate, and additionally in the ventromedial prefrontal regions during 
painful stimuli (López-Solà et al., 2010) as well as increases with venlafaxine in the insula in response 
to negative pictures (Davidson et al., 2003) have been observed following one and two week 
treatment, although both studies also reported significant, albeit modest improvements in depression 
scores during this time.  Furthermore, decreases in the insula and hippocampus (López-Solà et al., 
2010) with duloxetine were also previously shown with fluoxetine, but not in placebo responders 
(Mayberg et al., 2002).  In summary, although evidence is not conclusive, there is some preliminary 
evidence to suggest that SSRI and SNRI classes of antidepressants show similar modulation of limbic 




1.5 Neural effects of antidepressant treatment during processing of positive emotional 
stimuli in MDD 
Implicit processing of happy facial expressions, on the other hand is associated with decreased 
activation in MDD patients relative to healthy controls in the amygdala and parahippocampal regions 
(Lawrence et al., 2004), as well as in the posterior cingulate, precuneus, lingual gyri, and cerebellum, 
which improved following antidepressant fluoxetine treatment (Fu et al., 2007).  Happy facial 
expressions have also been associated with  decreased activations in the fusiform gyrus in MDD  
patients (Surguladze et al., 2005) which increased following escistalopram treatment (Jiang et al., 
2012).  The fusiform gyrus is important in face processing (Adolphs, 2002) and it is usually engaged 
in explicit processing of emotional stimuli.  Fusiform responses are greater for attended faces 
(Pizzagalli et al., 2002), and MDD patients show greater fusiform activation than controls when 
attending to negative emotional stimuli (versus a neutral baseline) but decreased fusiform responses 
during attentional processing of positive emotions (meta-analysis: Groenewold et al., 2013).  These 
findings outline the functional network underlying the neurocognitive observations that MDD patients 
are more likely to attend to faces of increasing sadness in comparison to healthy controls (Gotlib et 
al., 2004;  Joormann & Gotlib, 2007), who in turn attend more to happy facial expressions (Joormann 
& Gotlib, 2007).  Normalisation in fusiform activity following treatment in MDD patients suggest 
parallels with limbic responses to initially impaired attentional processing of negative as well as 
positive emotional stimuli.   
 
1.6 Neural effects of antidepressant treatment on cognitive functioning in MDD  
Besides the role of antidepressants in normalizing regional brain activations involved in affective 
processing, they also regulate impaired brain activations associated with more cognitive demands.  
Tasks of cognitive processing have shown increases in rostral anterior cingulate gyrus (Wagner et al., 
2006; Mitterschiffthaler et al., 2008), dorsolateral prefrontal cortex (Wagner et al., 2006), as well as 
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decreases in the precuneus, cingulate, frontal, occipital regions and brain stem (Kikuchi et al., 2012) 
in patients relative to controls, during an acute episode.  All of these studies (Wagner et al., 2006; 
Mitterschiffthaler et al., 2008; Kikuchi et al., 2012) had applied variations of the Stroop task to 
investigate the neural correlates of cognitive control, perhaps as reflected in the variations in their 
regional responses.  Both Kikuchi et al. (2012) and Wagner et al. (2006) modified the Stroop task to 
include button press response instead of vocalization.  Furthermore, Wagner et al. (2006) also 
presented the response as options along with the target word to reduce memory demand, whilst 
Mitterschiffthaler et al. (2008) used a variant of the Stroop task that used affective words.  
Antidepressant treatment was associated with attenuation in the amygdala-hippocampus, prefrontal, 
and parietal regions in MDD patients (Wagner et al., 2010), providing further evidence that 
antidepressants modulate cortico-limbic activations that are impaired in depression. 
 
1.7 Antidepressant treatment effects on neural connectivity in MDD 
It has been theorised that depression results from abnormal connections between the limbic regions, 
such as the amygdala, and other parts of the brain.  Therefore, in order to examine the relationship 
between regions which may be excessively engaged, impaired or unaltered in depression, a 
connectivity analysis attempts to define the interaction between brain regions.  The amygdala has 
connections with the subgenual anterior cingulate cortex (ACC) and receives connections from dorsal 
cingulate cortex (Aggleton & Saunders, 2000).  Reduced frontocortical and limbic regional 
connectivity has been observed in MDD (Anand et al., 2005; Chen et al., 2008; Costafreda et al., 
2013) which may worsen with increasing severity of depression (Matthews et al., 2008; Friedel et al., 
2009).  Moreover, non-responders to antidepressants can be differentiated from responders based on 
their pre-treatment functional connectivity (Lisiecka et al., 2011).  The use of multimodal 
neuroimaging techniques, for instance, fMRI and PET in combination have rendered further support 
for dysfunctional connectivity between the limbic and frontocortical region in MDD patients during 
processing of emotional stimuli (Irwin et al., 2004).  The reduced frontocortical and limbic coupling 
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observed in acutely depressed patients tend to improve following successful antidepressant treatment 
(Chen et al., 2008). 
Interestingly, lateralization effect of antidepressants have been observed, such that the effect on 
amygdala coupling was predominant for the left amygdala compared to the right (Chen et al., 2008).  
Activation of the lateral prefrontal and dorsal cingulate cortices suppresses amygdala activation, part 
of the process of voluntary emotional down-regulation (Costafreda et al., 2008).  These findings 
indicate that depression is associated with impairments in the inhibitory influence of cortical regions 
on limbic regions, which may improve with treatment. 
 
1.8 Neural effects of psychological therapy  
Fewer studies to date have investigated the neural correlates of psychological therapy.  Increases in 
baseline activations in the amygdala-hippocampal regions in MDD patients relative to healthy 
controls have been followed by significant reductions following treatment with short term cognitive 
behavioural therapy (CBT) (Fu et al., 2008a) as well as with long term psychodynamic psychotherapy 
(Buchheim et al., 2012).  Increases within the prefrontal regions in MDD patients, such as the medial 
prefrontal (Buchheim et al., 2012; Yoshimura et al., 2014) and orbitofrontal (Dichter et al., 2010) 
cortex are also normalized following a variety of forms of psychological treatments, including CBT 
(Yoshimura et al., 2014), behavioural activation therapy (Dichter et al., 2010) and psychodynamic 
psychotherapy (Buchheim et al., 2012).  In the anterior cingulate, several studies have demonstrated 
increased activation (Fu et al., 2008a; Dichter et al., 2009) but there have also been reports of 
decreases (Buchheim et al., 2012) in activation following psychological therapy.  There is a growing 
evidence to suggest that the medial prefrontal cortex plays an important role in self-referential 
processing of negative stimuli (Kelley et al., 2002), which is common in rumination and depression 
(Nolen-Hoeksema et al., 2008).  It has been proposed that treatment with psychotherapy significantly 
impacts on the brain regions involved in emotion processing disturbances in MDD patients.  The 
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studies though have been limited to date along with variations with respect to treatment, treatment 
duration, and task processing which require further study. 
The differential effects of pharmacological and psychological therapies on regional brain activity have 
been investigated using resting state positron emission tomography (PET) (Brody et al., 2001; 
Goldapple et al., 2004; Kennedy et al., 2007) and single-photon emission computed tomography 
(SPECT) (Martin et al., 2001).  These studies have generally compared cognitive behavioural therapy 
(Goldapple et al., 2004; Kennedy et al., 2007) or interpersonal psychotherapy (Brody et al., 2001; 
Martin et al., 2001) with antidepressant drugs such as paroxetine (Brody et al., 2001; Goldapple et al., 
2004) or venlafaxine (Martin et al., 2001; Kennedy et al., 2007).  MDD patients in an acute episode 
were assigned randomly to either psychological therapy or pharmacological intervention (Martin et 
al., 2001; Kennedy et al., 2007), although few studies have used a nonrandomized design, in which 
treatment type was guided by patient preference (Martin et al., 2001) or CBT treatment group were 
compared post-hoc to an independent group of paroxetine responders (Goldapple et al., 2004).  Both 
antidepressant treatment and psychotherapy were associated with reductions in the prefrontal cortex, 
including the middle frontal gyrus (Brody et al., 2001), lateral orbital, dorsomedial (Kennedy et al., 
2007) and ventral (Goldapple et al., 2004) prefrontal cortex, as well as increases in the basal ganglia 
(Martin et al., 2001) and the temporal lobe (Brody et al., 2001).  Antidepressants were specifically 
associated with decreases in the limbic regions such as the insula (Goldapple et al., 2004), posterior 
(Kennedy et al., 2007) and ventral (Goldapple et al., 2004) subgenual cingulate regions.  In addition, 
widespread increases in the posterior temporal lobe (Martin et al., 2001), brainstem and the 
cerebellum (Goldapple et al., 2004) were also observed.  Psychological therapies, on the other hand 
were associated with decreases in the thalamus (Kennedy et al., 2007), orbitofrontal, medial and 
ventrolateral prefrontal cortices (Goldapple et al., 2004), as well as increases in the subgenual 
(Kennedy et al., 2007) and dorsal (Goldapple et al., 2004) cingulate regions.  In the posterior cingulate 
region, however, some inconsistencies have been noted with reports of both decreases (Goldapple et 
al., 2004) as well as increases (Martin et al., 2001) in activations with psychological therapy.   
37 
  
It has been proposed that cognitive therapy shows a cortical “top-down” mechanism of action, as it 
focuses on altering memory and attention processes that are involved in the mediation of cognitive 
biases and maladaptive processing of information (DeRubeis et al., 2008).  Antidepressants, may also 
show a similar mechanism of action to cognitive therapy whereby antidepressant modulate the 
negative biases and memory impairments in depression very early on in the course of treatment, even 
before patients report any change in their mood or anxiety (Harmer et al., 2009a, 2009b).  The 
common neural mechanisms of action of antidepressants and cognitive therapy may reflect their 
targeting similar underlying processes that lead to improvements in depressive symptoms. 
 
1.9 Functional neuroimaging predictors of clinical response 
In addition to examining treatment effects in major depression, identifying biomarkers of responses to 
treatment is crucial as it could lead to the development of novel strategies to augment existing 
treatment methods.  Meta-analysis of pharmacological and psychotherapeutic treatment studies 
showed that increased baseline activity in the anterior cingulate, medial prefrontal and orbitofrontal 
regions was predictive of a better response to treatment, whilst activity in the right striatum and 
anterior insula was predictive of a poorer prognosis (Fu et al., 2013).  Specific sub-regions of the 
anterior cingulate cortex, namely the pregenual and the subgenual ACC are important targets for 
antidepressant action, and could be good predictors of clinical response (Chen et al., 2007).   
Increased anterior cingulate activity as being predictive of response to antidepressant medications, 
prior to the initiation of treatment, has been highly replicated, while the evidence for CBT has been 
more mixed (Fu et al., 2013).  The predictive function of the anterior cingulate has been observed 
with numerous tasks, including resting state PET studies (Mayberg et al., 1997; Kennedy et al., 2007) 
and with both cognitive (Marquand et al., 2008; Roy et al., 2010) and emotional processing (Davidson 
et al., 2003; Chen et al., 2007; Costafreda et al., 2009a; Keedwell et al., 2010) MRI tasks.  However, 
findings of potential biomarkers from these studies were obtained from group comparisons; and in 
order for a biomarker to have a clinical impact, it is important that the measure is able to provide a 
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classification with high level of accuracy for an individual (Fu et al., 2008b).  Moreover, there have 
also been some inconsistencies in results as some studies showed that greater anterior cingulate 
activity was predictive of a poorer clinical response to pharmacotherapy (Brody et al., 1999; Konarski 
et al., 2009) as well as to CBT (Siegle et al., 2006; Konarski et al., 2009).  Elicitation of anterior 
cingulate in response prediction is usually seen in response to negative emotional stimuli (Davidson et 
al., 2003; Chen et al., 2007; Keedwell et al., 2010) rather than towards positive ones.  The anterior 
cingulate plays a key role in emotion processing, and specific sub-regions, namely the pregenual and 
subgenual anterior cingulate can be good predictors of clinical response as they are important targets 
of antidepressant action (Chen et al., 2007).  There is evidence that the anterior cingulate is more 
likely to get activated during tasks of cognitive demand (Duncan & Owen, 2000) and therefore it may 
be a more reliable functional marker of treatment response during specific task processing rather than 
during resting state.  The insula is engaged by negative emotional stimuli (Anand et al., 2005; Van 
Dillen et al., 2009) in particular the anterior region for social stimuli, with interoceptive integration of 
internal and external stimuli of emotional pain recognition (Singer et al., 2004).  More recently, 
hypometabolic activity in the insula was associated with remission to CBT and poor response to 
escitalopram, whilst the opposite effect was seen with insula hypermetabolism, suggesting that pre-
treatment metabolic activity in the insula can be used to inform initial choice of treatment in 
depression (McGrath et al., 2013).  
 
1.10 Neuroimaging biomarkers of diagnosis and treatment response  
At the present time, the diagnosis of depression is based solely on clinical signs and symptoms, and 
there are no biological tests that are used to diagnose the disorder or to predict clinical response.  
Methods of analysis based on machine learning algorithms, such as Support Vector Machines (SVM) 
have been applied to neuroimaging measures to predict diagnosis, course of illness and treatment 
prognosis as they facilitate individual level classification (Nouretdinov et al., 2011; review: Wise et 
al., 2014).  SVM uses a classification algorithm that allows categorization of unseen individual data 
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into specific groups (for instance, either patients or controls) based on a training data set (Orrù et al., 
2012).  Such biomarkers can be identified with high predictive accuracy at the individual level even 
before the initiation of treatment or very early on during the course of treatment.  For instance, 
baseline neural activity during sad facial processing predicted remission to CBT with a sensitivity of 
71 % and a specificity of 86% (Costafreda et al., 2009a), while remission to antidepressants showed a 
trend towards significance (Fu et al., 2008b).  Evidence from structural data, on the other hand 
revealed that grey matter density predicted clinical response to antidepressant, in particular in the 
anterior cingulate (Costafreda et al., 2009b; Nouretdinov et al., 2011).  For diagnostic prediction, the 
pattern of baseline neural activity during sad facial expression accurately classified 84% of the 
patients and 89% of controls (Fu et al., 2008b), while neural correlates of verbal working memory 
showed reduced accuracy (Marquand et al., 2008).  Further investigations of neuroimaging as well as 
other biological measures are required to develop clinically useful biomarkers of clinical response.  
Future research should also aim to investigate whether integration of neuroimaging biomarkers based 
on multiple neural processes associated with depression (ex. affective and emotional processing and 
structural neuroimaging) would achieve more accurate classification.  This would be of particular 
benefit to patients whose may be less likely to improve solely with conventional treatment methods 
and would benefit from an earlier initiation of alternative or combination therapies. 
 
1.11 Conclusions 
In summary, research has begun to elucidate the function of antidepressants and psychotherapy in 
modulating the regions involved in the emotional, cognitive and behavioural disturbances that 
underlie major depression.  Limited number of PET studies have examined the functional correlates of 
placebo effect in depression (ex.  Mayberg et al., 1999, 2000) and none of the fMRI studies, to my 
knowledge, had included a patient group receiving a placebo treatment.  Future placebo-controlled 
longitudinal fMRI studies would assist in distinguishing between the effects of treatment and changes 
associated with depressive state and to control for effects of time and test-retest with particular 
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neuroimaging paradigms.  Additional investigations are also required to determine the common and 
distinct mechanisms of action of antidepressants and psychological therapies.  Pattern classification 
based analysis of neuroimaging data is beginning to delineate potential biomarkers for both diagnosis 
and prognosis with high predictive accuracy at the individual level which will aid in the development 
of clinically useful measures.   
 
1.12 Aims and Objectives 
The main objective of this thesis is to examine the neuropsychological abnormalities associated with 
emotional and cognitive processing and how they change with treatment.  These processes were 
especially chosen, since there is a sizeable body of evidence associating affective biases and cognitive 
impairments to the aetiology and maintenance of depression, as detailed in this chapter.  Owing to the 
scarcity in the literature in longitudinal studies examining treatment strategies other than SSRIs, it is 
unclear whether the regional changes seen after treatment is specific to a class of pharmacotherapy; or 
whether such changes are common across different classes of antidepressant drugs and even across 
different treatment modalities.  Three chapters in this work attempt to bridge this gap in the literature.  
In Chapter 2, the neural correlates of Cognitive Behavioural Therapy (CBT) on dysfunctional 
attitudes are examined.  A paradigm termed the ‘modified dysfunctional attitude scale’ (mDAS; 
Sankar et al., 2014) was developed to examine negative thinking, a common feature associated with 
depression.  The neural effects of CBT are especially examined as one of the aims of CBT is to 
address dysfunctional attitudes which contribute to the persistence of depressive symptoms (Dobson 
& Dozois, 2001).  
The effects of a dual acting SNRI, duloxetine, on affective and cognitive impairments in depression 
are investigated here in two separate branches of their own (Chapters 3 & 4).  First, affective biases 
were studied using a series of sad and happy facial expressions adapted from the standardized Ekman 
and Freisen’s Pictures of Facial affect (Ekman & Friesen, 1976).  Secondly, a modified Sternberg task 
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was used to examine cognitive biases, specifically impairments in working memory, in patients with 
depression.  
In order for neuroimaging findings to have tangible clinical applications, it is important that we are 
able to develop biomarkers that can predict therapeutic response in MDD with high accuracy at the 
individual level.  Therefore, another key focus in the thesis is to examine the potential of structural 
neuroimaging data to identify depression and predict clinical outcome using machine learning 
algorithms (Chapter 5).  This is significant as it helps optimize treatment strategies at an early stage.  
In particular, this means we can provide alternate treatment options early on for those who are less 
likely to benefit from conventional methods. 
 
1.13 Hypothesis 
Explicit hypotheses and background literature are detailed in the individual chapters contained herein. 
Overall, it is hypothesised that MDD patients would show increased activations in the limbic regions, 
especially in the amygdala during processing of negative emotional stimuli, such as sad facial 
expressions and negative dysfunctional attitudes, which would attenuate with duloxetine and CBT 
respectively.  It is also expected that during the Sternberg paradigm, MDD patients would show 
increased activations in regions associated with working memory, such as the inferior frontal and the 
dorsolateral prefrontal regions, in comparison with controls, which would normalise with duloxetine 
treatment. 
In the examination of biomarkers of diagnosis, it is hypothesised that the structural correlates of 
prefrontal, parietal and temporo-occipital regions would show significant predictive power for MDD 
diagnosis.  For prognostic markers, in line with the literature, it is expected that the anterior cingulate 












2 Neural effects of cognitive behavioural therapy on dysfunctional 
attitudes in major depressive disorder 
 
The important findings from the chapter are included in the paper listed below: 
Sankar, A., Scott, J., Paszkiewicz, A., Giampietro, V., Steiner, H., & Fu, C. (2014). Neural Effects of 
Cognitive–Behavioural Therapy on Dysfunctional Attitudes in Depression. Psychological Medicine, 
1-9. 
 
The preliminary neuroimaging analyses presented in this chapter were performed as part of my MSc 
project titled “Dysfunctional thinking in major depressive disorder: Neural mapping and analysis 
following cognitive behavioural therapy”.  However, more complex second level analyses for the 
contrast DAS-cDAS, including examining main effect of group at baseline, main effect of group at 
week 16 for extreme attributions, main effect of group at baseline, main effects of group at week 16 
for regular attributions, main effect of task (DAS< cDAS & cDAS>DAS) for baseline, and then again 
at week 16, correlation between baseline activations and  improvements in depression scores, 
correlations of change in baseline activations with reduction in HAMD scores; preparation of the 
manuscript for publication, revisions and re-submissions were done during my PhD studies.  This 
chapter has been added to the PhD thesis due to its relevance to the thesis topic and the volume of 




Beck (1967) postulated that negative life incidents, especially those very early on in life can lead to 
the development of negative “schemas” which involve themes of loss, failure and abandonment.  
Dysfunctional attitudes, such as “If I fail partly, it is as good as being a complete failure”, are 
activated during stressful life events and are characteristic of a depressive episode (Haaga et al., 
1991).  Negative or dysfunctional patterns of thinking are typically measured using the Dysfunctional 
Attitude Scale (DAS) (Weissman & Beck, 1978), which is a self-report inventory in which individuals 
indicate the extent to which they agree or disagree with a series of functional and dysfunctional 
attitude statements.  It has been proposed that depressive symptoms are promoted by dysfunctional 
attitudes (Sheppard & Teasdale, 2000).  According to the circular causality hypothesis, dysfunctional 
attitudes and negative emotions have a reciprocal causal effect (Burns & Spangler, 2001).  In support, 
positive associations between depression severity and dysfunctional attitudes have been observed 
(Beevers et al., 2003), which revert to normal during remission (Haaga et al., 1991), and the 
magnitude of dysfunctional thinking during a dysphoric mood state is predictive of a subsequent 
depressive relapse (Segal et al., 2006).   
High levels of dysfunctional thinking during a depressive episode have been associated with greater 
5HT2 receptor binding potential in the anterior cingulate, prefrontal regions, thalamus, caudate and 
putamen (Meyer et al., 2004).  Administration of the serotonin agonist d-fenfluramine led to a 
reduction in dysfunctional attitudes, suggesting that serotonin agonism can reduce dysfunctional 
attitudes by inducing neuronal release of serotonin in depression (Meyer et al., 2003).  Although a 
correlation with receptor binding potential and negative attributions has been observed, subjects were 
not actively engaged in a dysfunctional attitudes task during the brain scan.  In the present fMRI 
study, the DAS task was administered whilst patients were in the scanner to provide a more accurate 
measure of regional brain activations associated with dysfunctional thinking.  
An aim of CBT is to address dysfunctional attitudes which contribute to the persistence of depressive 
symptoms (Dobson & Dozois, 2001).  Functional imaging studies of patients with major depressive 
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disorder during an acute episode and following treatment with CBT have revealed modulation of 
amygdala and anterior cingulate activity with therapy.  For instance, amygdala hyperactivity to 
negative emotional stimuli in depressed patients has been widely reported (Fu et al., 2004, Surguladze 
et al., 2005, Fu et al., 2008a) with some evidence of normalization following CBT (Fu et al., 2008a).  
Furthermore, following treatment with CBT, increased activity has been observed in the anterior 
cingulate during a resting state (Goldapple et al., 2004), in response to sad faces (Fu et al., 2008a), 
and with self-referential processing to positive stimuli though not to negative stimuli (Yoshimura et 
al., 2014).  The role of anterior cingulate as a predictor of treatment response has been consistently 
observed (meta-analysis: Fu et al., 2013).  Additional neural correlates of CBT in depression include 
increases in ventromedial cortical activity (Ritchey et al., 2011), decreases in dorsal frontal cortical 
activity (Kennedy et al., 2007), and increases in hippocampal activity during a resting state 
(Goldapple et al., 2004).  The changes in prefrontal, limbic and subcortical activity are generally 
consistent with models of neurocognitive circuits in depression and the effects of CBT (DeRubeis et 
al., 2008). 
However, the brain regions engaged by dysfunctional thinking in depression and the effects of CBT 
have not been examined.  The present study sought to investigate the neural correlates of 
dysfunctional attitudes in patients with depression during an acute depressive episode and following 
treatment with CBT.  It is hypothesised that patients would show greater endorsement of 
dysfunctional attitudes during an acute depressive episode, which would improve following treatment 
with CBT.  It is also hypothesized that MDD patients would show greater activation in the anterior 
cingulate and other regions associated with attention and self-referential processing with extreme 
attributions relative to healthy controls.  It is also expected that regions associated with attentional 
processing of negative stimuli would show increased activity in patients during an acute depressive 
episode which would resolve following CBT.  In particular, it is hypothesised that patients would 






Depressed Group:  Sixteen participants (13 women, age 40.00, [SD 9.27]) who met criteria for MDD 
by Structured Clinical Interview for DSM-IV (SCID) (Fu et al., 2008a) and a clinical interview with a 
psychiatrist were recruited through local newspaper advertisements. 
The inclusion criteria were an acute episode of major depressive disorder, unipolar subtype and a 
score of at least 18 on the 17- item Hamilton Rating Scale for Depression (HRSD) (Fu et al., 2008a).  
The exclusion criteria were a current neurological disorder, history of neurological trauma resulting in 
a loss of consciousness, history of diabetes or medical disorder, other Axis I disorders including 
anxiety disorder or history of substance abuse within 2 months of participation in the study.  All 
patients were free of psychotropic medications for a minimum of 4 weeks at the time of recruitment (8 
weeks for fluoxetine) and remained medication free throughout the treatment. 
Control Group:  Sixteen age, gender and IQ matched healthy controls with HSRD scores less than 8 
(13 women, age 39.94 years [SD= 9.48]) and no history of previous psychiatric illness, neurological 
disorder or head injury resulting in a loss of consciousness were recruited through local newspaper 
advertisements. 
All participants provided written, informed consent.  The study was approved by the Institute of 
Psychiatry and South London and Maudsley (SLaM) NHS Ethics Research Committee.  The HRSD 
(Hamilton, 1960) and the Beck Depression Inventory (BDI) (Beck, 1961) were measured at baseline 
and following the course of CBT at the end of 16 weeks.   
2.2.2 Dysfunctional attitude scale (DAS) 
The DAS measures pervasive negative attitudes towards the self, the world and the future.  The 
widely used DAS consists of 66 statements reflecting dysfunctional attitudes (“I should be upset if I 
make a mistake”) and 34 statements reflecting functional attitudes (“I do not need the approval of 
other people in order to be happy”).  Participants respond to each statements using a 7 point Likert 
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scale, ranging from totally agree to totally disagree (reverse scoring is applied to functional statements 
such that the highest score on any item represents the most dysfunctional response); the maximum 
score is 700. 
In the present study, the DAS 24 (Power et al., 1994) was used, which is a shortened version of the 
DAS (Weissman & Beck 1978) consisting of 24 statements.  24 neutral statements were included as a 
control task for the present study, which the authors of the study called the control DAS (cDAS).  The 
resulting 48 item scale was termed as the ‘modified Dysfunctional Attitude Scale’ (mDAS -48).  
During the fMRI scan, participants were presented with the mDAS-48 task consisting of statements 
alternating from the DAS and cDAS.  There were a total of 48 statements (24 cDAS and 24 DAS 
statements).  After 6 statements of alternating DAS and control DAS statements, a thirty second rest 
period was given to each subject before proceeding with the next set of six statements.  Total duration 
of the task was 1645 seconds.  
Subjects were asked to respond to each statement using a 7 point Likert scale, ranging from totally 
agree to totally disagree.  Extreme responses are a reflection of the endorsement of dysfunctional 
attitudes (Power et al., 1994).  The fMRI task began with either a DAS or cDAS statement which was 
presented in a counterbalanced order for consecutive participants, and the same version was used for 
the same participant.  fMRI scans were acquired at baseline (week 0) and upon study completion 
(week 16).  Each MRI scan was up to 1.5 hours in duration consisting of fMRI tasks and structural 
MRI scans, and data from an affective facial processing task have been published in Fu et al. (2008a).  
All behavioural data were recorded during the fMRI scans and analysed using SPSS (Version: PASW 
Statistics 18).  Repeated measures ANOVA was used to analyse main effect of group (patients vs 
controls), main effect of statement (DAS vs cDAS), main effect of time (week 0 vs week 16) and 
group by time interactions (i.e. changes in response between baseline and final trials).  Percentage 
change in extreme attributions (total number of extreme DAS scores at week 16 – total number of 
extreme DAS scores at baseline / total number of extreme DAS scores at baseline * 100) was also 
calculated for each subject. 
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2.2.3 CBT treatment 
Patients received 16 sessions of CBT with experienced therapists (Fu et al., 2008a).  The standard 
CBT procedures as described by Beck et al. (1979) were followed, and all therapists met the required 
level of training and proficiency (Paykel et al., 1999).  The CBT sessions were audiotaped and 
reviewed to ensure adherence and competence.  HRSD scores were obtained from patients at baseline 
and after 16 weeks of CBT.  Treatment response was defined as a minimum reduction of 50% in 
HRSD score from baseline. 
fMRI image acquisition 
Gradient echo echoplanar Imaging (EPI) data were acquired on a GE Sigma 1.5 T system (General 
Electric, Milwaukee, USA), at the Maudsley Hospital, London.  A total of 441 T2 – weighted images 
depicting blood – oxygen- level – dependent (BOLD) contrast were acquired over 27 minutes (for 
each run) at each of 22 near- axial noncontigious 3 mm planes parallel to the inter commissural (AC 
PC) line: time to echo (TE) = 40 msec, repetition time TR =3.74 secs, in - plane resolution = (3.75) 
mm, interslice gap 0.3 mm and matrix size 64 x 64 voxels.  This EPI dataset provided almost 
complete brain coverage.  Four dummy acquisitions were made at the beginning of each scan to allow 
magnetization to reach equilibrium amplitude. 
2.2.4 fMRI data analysis 
2.2.4.1 Individual analysis 
 
Images were first realigned to minimise subject head motion (Bullmore et al., 1999) and then 
smoothed using a Gaussian filter (full width at half maximum = 7.2 mm).  Responses to the 
experimental paradigm were detected by carrying out time series analysis using two gamma variate 
functions (peak responses at 4s and 8s respectively) to model the BOLD response.  The best fit 
between the weighted sum of these functions (convolved with each component of the experimental 
design) and the time series at each voxel was computed using the constrained BOLD effect model 
developed by Friman et al. (2003).  Following this, a goodness of fit statistic was computed at each 
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voxel, and for each experimental condition.  This consisted of the ratio of the sum of squares of 
deviations from the mean image intensity due to the model (over the whole time series) to the sum of 
squares of deviations due to the residuals, termed the SSQ ratio.  The data were then permuted using a 
wavelet-based method calculating the null distribution of SSQ ratios under the assumption of no 
experimentally determined response (Bullmore et al., 2003).  This distribution can then be used to 
compute critical SSQ ratio values and then find the associated statistical threshold yielding less than 
one Type I error voxel/cluster per map.  The detection of activated regions was extended from voxel 
to cluster level (Bullmore et al., 2003).  In order to minimise the potential confounding effects of 
between-group and between-condition variation in task performance, the analysis of the BOLD 
response data of each subject was modelled using trials associated with correct responses only.  In 
addition to the SSQ ratio, the percentage BOLD change at each voxel was also calculated from the 
model fit.   
2.2.4.2 Group analysis 
 
The SSQ ratio data for each individual were transformed into the standard space of Talairach and 
Tournoux (Talairach & Tournoux, 1988), using a two stage warping procedure.  Group activation 
maps were then computed contrasting the median SSQ ratio at each voxel in the observed and 
permuted maps (Brammer et al., 1997).  Permutation methods and median statistics were used to 
obtain the null distribution of SSQ ratios, and the statistical thresholds were set in such a way as to 
obtain less than one Type I error 3D cluster per brain.  For the present group analysis, less than 1 false 
positive clusters were expected at p < 0.05 for voxel level and p < 0.01 at cluster level.  Only those 
voxels at which all subjects contributed data were included for analysis (Fu et al., 2008a).  
In order to examine the neural correlates of dysfunctional attributions, the fMRI time series 
corresponding to attributions which corresponded to endorsements of 1, 2, 6, or 7 on the Likert scale 
were encoded.  The fMRI time series associated with regular attributions were encoded by Likert 
scale responses of 3, 4 or 5.  A 2 X 2 ANOVA was employed to examine the main effect of group 
(patients vs healthy controls across both time points), main effect of time (week 0 vs week 16) and the 
group by time interaction.  The analyses were examined for regular attributions made to DAS relative 
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to control DAS statements. For the extreme attributions, predictors of clinical response were 
examined by correlating baseline activity with change in HAMD scores.  Additionally, correlation 
between change in BOLD response and reduction in HAMD scores were also performed.  
 
2.3 Results 
2.3.1 Demographic results 
There were no significant group differences in mean age, full IQ, verbal IQ and performance IQ (all p 
> 0.05) (Table 2.1).  All patients completed a full course of 16 weeks CBT.  There was an expected 
significant difference in HRSD scores between the groups at week 0 (F1, 30 = 1765.21, p < 0.001) and 
at week 16 (F1, 30 = 18.96, p < 0.001).  Patients showed a significant reduction in mean HRSD scores 
from baseline to week 16 (F1, 15 = 118.45, p < 0.001). 
Table 2.1: Demographic and clinical characteristics 
                               Healthy Controls MDD Patients 
Number of participants 16 16 
Male/Female 3/13 3/13 
Age 40.00 (9.27) 39.94 (9.48) 
Full IQ 123.44 (10.63) 120.03 (14.02) 
Verbal  IQ 120.44 (11.98) 118.09 (15.95) 
Performance IQ 122.31 (11.74) 118.34 (13.37) 
Age of onset NA 33.8 years (range: 18-53 years) 
Number of previous episodes NA 0.63 (range: 0-2) 
Duration of current episode NA 1.64 years (range: 0.2-4 years) 
Number of treatment trials for present episode NA 0.13 (range: 0-1 trials) 
HRSD scores at baseline 0.19 (0.05) 20.88 (1.89) 
HRSD scores at week 16 0.56 (1.15)   6.37 (5.21) 
Mean values are presented with standard deviations in parenthesis, unless otherwise specified.  
50 
  
2.3.2 Behavioural data 
The extreme responses to the DAS statements showed a significant group by time interaction effect 
(F1, 30 = 7.434, p = 0.011), in which patients showed a significant reduction in mean number of 
extreme responses following a course of CBT (t = 2.938, df = 15, p = 0.010), while healthy controls 
did not have a change in extreme scores at the follow up scan as compared to baseline (t = -0.659, df = 
15, p = 0.520) (Table 2.2).  There was also a trend towards a significant effect of time (F1, 30 = 3.681, p 
= 0.065) as participants showed a reduction in extreme responses at the follow up scan.  There was no 
significant main effect of group in extreme responses (F1, 30 = 0.016, p = 0.900) (Table 2.2, 
Supplementary material 1a). 
In the control DAS statements, there were no significant main effects of time (F1, 30 = 2.054, p = 
0.162), group (F1, 30 = 0.140, p = 0.711), or group by time interaction effects (F1, 30 = 3.343, p = 0.077) 
(Supplementary material 2a).  
There were no significant correlations between the change in HRSD scores and the change in the 
number of extreme responses made to the DAS statements in MDD patients (r = 0.465, p > 0.05, 1-
tailed test).  I was also interested in examining the relationship between changes in DAS scores and 
response to treatment (a minimum reduction of 50% in HRSD score from baseline).  However, the 
number of patients who did not respond to treatment (n = 3) was insufficient to compare with those 
who responded (n = 13).  Hence, I report the mean percentage change in extreme DAS scores in 








Table 2.2: Behavioural performance on DAS task 





Extreme attributions 13.94 (4.11) 15.82 (5.45) 
Regular attributions 10.06 (4.10)   8.18 (5.62) 
Week 16 
  
Extreme attributions 14.44 (3.67) 12.94 (4.46) 
Regular attributions   9.56 (3.67) 11.06 (4.46) 




Extreme attributions 13.88 (4.44) 15.88 (3.84) 
Regular attributions 10.12 (4.44)   8.12 (3.61) 
Week 16 
  
Extreme attributions 14.12 (3.91) 13.43 (3.85) 
Regular attributions   9.88 (3.91) 10.57 (3.85) 
Mean values are presented and standard deviations in parenthesis 
 
2.3.3 fMRI results 
2.3.3.1  Neural responses to extreme attributions in DAS 
 
2.3.3.1.1 Group by time interaction effect 
A significant group by time interaction effect for extreme attributions to DAS statements was found in 
the left parahippocampal gyrus (BA 37) (Talairach coordinates: x, y, z = -36, -41, -7; cluster size = 41 
voxels, corrected p = 0.0027).  The parahippocampal gyrus showed less attenuated activation in MDD 







Figure 2.1: Group by time interactions in the left parahippocampal gyrus 
 
(a)  There was a significant group by time interaction effect in the left parahippocampal region for extreme 
attributions to DAS statements (corrected p = 0.0027).  Both depressed patients and healthy controls showed a 
decrease in activation in the left parahippocampal gyrus at the follow up scans but to a lesser extent in patients.  
Transverse sections of the brain are presented with the Talairach z-coordinates indicated.   
 
 
(b)  The graph presents the group by time interaction effect in the left parahippocampal region. The boxes 
indicate interquartile range.  The horizontal lines in the boxes represent medians.  The limit lines indicate ranges 
excluding outliers, and the circles represent outliers which are defined as points greater than 1.5 times the 
interquartile range from the limits of the interquartile range.  The y-axis SSQ (sum of squares) values represent 
normalised statistic of the brain response. 
 
2.3.3.1.2 Main effect of group 
There was a significant main effect of group in which patients showed greater activation in the left 
hippocampal region (coordinates: x, y, z = -11, -33, -3; cluster size = 27 voxels, corrected p = 0.0016), 
left inferior parietal lobe (BA40) (coordinates: x, y, z = -36, -33, 40; cluster size = 55 voxels, 
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corrected p = 0.0013) and left precuneus (BA 7) (coordinates: x, y, z = -14, -67, 33; cluster size = 109 
voxels, corrected p = 0.00006) relative to healthy controls.  The left cerebellum, on the other hand 
showed greater activation in healthy controls as compared to MDD patients (coordinates: x, y, z = -11, 
-44, -23; cluster size = 45 voxels, corrected p = 0.0016) (Figure 2.2). 
Figure 2.2: Main effect of group 
 
 
In the main effect of group, MDD patients showed significantly greater activation in the left hippocampus 
(corrected p = 0.0016), left inferior parietal lobe (corrected p = 0.0013) and left precuneus (corrected p = 
0.0006), relative to healthy controls.  Healthy controls showed a greater activation in left cerebellum (corrected 
p = 0.0016) compared to depressed patients. Transverse sections of the brain are presented with the Talairach z-
coordinates indicated. 
 
2.3.3.1.3 Main effect of time in MDD patients 
In patients, the right posterior cingulate gyrus (BA 30) (coordinates x, y, z = 11, -44, 23; cluster size = 
73 voxels, corrected p = 0.006) (Talairach coordinates x, y, z = 11, -44, 23; cluster size = 73 voxels, 
corrected p = 0.006) showed decreased activation from week 0 to week 16, while no regions showed 
greater activation at week 16 relative to week 0.  
2.3.3.1.4 Main effect of time in healthy volunteers 
In healthy controls, no regions showed decreased activation from week 0 to week 16, but there was a 
significant main effect of time in the left cuneus (BA 18) (coordinates  x, y, z = -18, -78, 17; cluster 
size = 53 voxels, corrected p = 0.005) which showed increased activation from the initial to the final 
scan. 
2.3.3.1.5 Correlation with change in HRSD score 
Patients showed a significant positive relationship between changes in HRSD score and overall 
activity in the left precentral gyrus (BA 6) (coordinates x, y, z = -43, -4, 40; cluster size = 28 voxels, r 
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= 0.739, corrected p = 0.004), in which patients with the greatest improvement in HRSD scores 
following CBT treatment had the greatest increase in precentral gyrus activity (Figure 2.3). 
Figure 2.3:  Correlation with change in HRSD score 
 
A significant correlation was found between the change in the severity of depression as measured by the HRSD 
scores and activity in the left precentral gyrus.  Patients who had the greatest change in HRSD score following 
CBT showed the greatest increase in activity in the left precentral gyrus during processing of dysfunctional 





2.3.3.2 Neural responses to regular attributions in DAS 
 
There was no significant main effect of group or any group by time interaction effects in the neural 
responses to regular attributions to the DAS statements.  
2.3.3.2.1 Main effect of time in MDD patients 
In patients, no regions showed decreased activation from the initial to final scan, but there was main 
effect of time in the left cerebellum (Talairach coordinates x, y, z = -11, -74, -17; cluster size = 26 
voxels, corrected p = 0.0025) which showed increased activation from weeks 0 to 16.   
2.3.3.2.2 Main effect of time in healthy controls 
In healthy controls, main effects of time were observed in the left lingual gyrus (BA 18), left 
parahippocampal gyrus, and bilateral precuneus (BA 7) (corrected p < 0.006) which showed reduced 
activation from the initial to final scans, and in the left inferior frontal gyrus (BA 10) (coordinates x, 
y, z = -36, 44, 3; cluster size = 36 voxels, corrected p = 0.003) which showed increased activation 
from the initial to final scans. 
Main effects of the DAS task and group are presented in Supplementary material 1b. 
 
2.4 Discussion 
In the present study, the effects of dysfunctional thinking on regional brain activations in MDD 
patients as compared to healthy volunteers were examined.  In addition, the neural effects of cognitive 
behavioural therapy on dysfunctional attitudes were also investigated.  
2.4.1 Behavioural responses to DAS  
The present study supports a modifying effect of CBT on dysfunctional attitudes (Haaga et al., 1991; 
Furlong & Oei, 2002) as patients endorsed a greater number of extreme responses to DAS statements 
during an acute depressive episode which normalised following CBT.  Dysfunctional attitudes are 
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also seen to reduce following antidepressant treatment (Shankman et al., 2012), suggesting that they 
may be a state feature of depression.  There is considerable evidence for a parallel decrease in levels 
of dysfunctional attitudes and depression during CBT (Persons & Burns, 1985), although 
dysfunctional attitudes have also been observed as a trait feature of depression (Roberts & Gamble, 
2001).  However, a correlation between improvements in depression severity with a reduction in 
extreme DAS attributions was not observed. 
2.4.2 Neural responses to extreme attributions in DAS 
Extreme attributions to statements showed a group by time interaction effect in the left 
parahippocampal gyrus.  The neural correlates revealed that endorsement of dysfunctional attitudes 
was associated with left parahippocampal activation in both depressed patients and healthy controls, 
which decreased at the follow up scans in both groups but to a lesser extent in patients.  The 
parahippocampal region along with the hippocampus and association areas of the cerebral cortex form 
the medial temporal lobe (MTL) system (Eichenbaum & Lipton, 2008).  The flow of information from 
the association areas of cortex to the hippocampus is in the form of a bidirectional hierarchy of 
connections (Eichenbaum & Lipton, 2008).  The output from the hippocampus is then returned to the 
parahippocampal region and to the cortical regions where the input originated (Eichenbaum & Lipton, 
2008).   
Depressed individuals have shown greater activation in the left parahippocampal gyrus relative to 
controls, during encoding of an associative learning paradigm (Werner et al., 2009) and in processing 
negative pictures (Sheline et al., 2009).  MDD patients also show reductions in parahippocampal 
activation following treatment with antidepressant medication (Kennedy et al., 2001; meta-analysis: 
Delaveau et al., 2011).  Behavioural studies of dysfunctional attitudes show higher endorsement of 
dysfunctional attitudes by patients relative to controls during negative mood induction (Lau et al., 
2012) and significant improvement in dysfunctional thinking in patients following CBT (Warmerdam 
et al., 2010).  To date, there has been no fMRI study that has investigated the neural correlates of 
dysfunctional attitudes in depression, and therefore one cannot make direct comparisons to confirm 
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the role of parahippocampal gyrus in dysfunctional attitudes.  However, the left parahippocampal 
activation seems to be especially associated with negative stimuli (Iidaka et al., 2002; Surguladze et 
al., 2005), and activation in this region in both patients and in controls during presentation of DAS 
statements supports the role of the left parahippocampal gyrus in processing negative information 
contained in the DAS statements.  The circular causality hypothesis (Burns & Spangler, 2001) 
proposes that dysfunctional attitudes and negative emotions have a reciprocal causal effect, which was 
likely induced by the DAS statements.   
The parahippocampal region is also associated with contextual associations or episodic memory and 
shows a familiarity effect during repetition of tasks with greater activation during novel as compared 
to familiar tasks (O’Kane et al., 2005).  The reduction in parahippocampal activation at the follow up 
scan for both groups is consistent with increased familiarity with repetition of the task, although 
patients did not demonstrate the same extent in the reduction in activation.  This may perhaps reflect 
patients’ inability to recall the task in the same manner as controls, likely due to persistent 
engagement and contextual associations to the DAS statements.  
The main effect of group across both time points revealed greater activation in the left hippocampal 
gyrus, inferior parietal lobe and precuneus in patients relative to healthy controls.  The inferior 
parietal lobe plays a prominent role in attentional processing of emotional stimuli (Pessoa et al., 
2002), processing of written language (Eckert, 2004), working memory of emotional stimuli (Rämä et 
al., 2001), and during episodic memory retrieval (Maddock et al., 2001).  The increased activation 
observed in MDD patients relative to controls in the inferior parietal lobe may have reflected their 
greater attention in the processing of DAS statements along with the retrieval of memories associated 
with statements presented in the DAS.  The precuneus is associated with visual processing of 
information including the retrieval of episodic memory which is modulated by attention (Cavanna & 
Trimble, 2006).  In depression,  greater activation in left precuneus has been found in patients during 
presentation of sad relative to happy stimuli (Keedwell et al., 2005b), and during visual presentation 
of negative stimuli (Phillips et al., 2004).  The increased activity in the precuneus in MDD patients 
likely reflects increased attention during visual processing of DAS statements.   
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Furthermore, improvement in the severity of depressive symptoms showed a significant positive 
correlation with left precentral activity.  The precentral gyrus plays an important role in successful 
response inhibition, and patients in an acute depressive episode tend to show impaired response 
inhibition (Schmid et al., 2011).  Increased activity in the left precentral gyrus has been reported in 
patients following treatment with psychotherapy (Dichter et al., 2009).  Larisch et al. (1997) found 
significant positive correlations between dopamine (D2) binding changes in the left precentral gyrus 
and an improvement in depression scores following antidepressant treatment, and the left precentral 
gyrus shows increased functional connectivity with the orbitofrontal cortex at baseline in subsequent 
responders to antidepressant treatment relative to non-responders (Lisiecka et al., 2011).  The positive 
association between precentral activity and depression scores in the present study could reflect the 
improvements in inhibitory control in patients as they recovered from an acute depressive episode. 
It was notable that the group differences in neural responses to extreme attributions to the DAS 
statements were not found with the regular attributions to DAS statements, reflecting the specificity of 
the neural effects to extreme attributions.  However, contrary to the hypothesis, there was no evidence 
for increased amygdala activity in MDD patients.  The probability of amygdala activation is greater 
during passive processing of emotional stimuli rather than tasks involving any form of attentional 
effort, and language is associated with a significant reduction in amygdala activity (Costafreda et al., 
2008).  In the present study, DAS statements were presented as sentences and participants were 
required to make an active judgement in response, which likely contributed to the low elicitation of 
amygdala responsivity with the DAS statements.  Furthermore, the present study was limited by the 
lack of a patient group who received a placebo treatment.  Therefore it is not possible to conclude 
with certainty that the significant difference in brain activation in patients is as a result of treatment 
with CBT.  Future research also needs to investigate whether a reduction in dysfunctional thinking is 
evident with antidepressant treatment. 
In summary, the present study supports findings that dysfunctional thinking is characteristic of major 
depression.  Extreme attributions made to DAS statements are indicative of dysfunctional thinking, 
and depressed patients showed a significant decrease in extreme attributions, following CBT.  The 
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main effect of group for extreme attributions showed greater activation in patients relative to controls 
in the left hippocampal gyrus, left inferior parietal lobule and the left precuneus.  This suggests that 
when the DAS statements are presented, depressed patients, compared to controls, engage more in 
attentional processing of the statements, along with retrieval of memory associated with them.  The 
group by time interactions for extreme attributions showed significant reductions in the 
parahippocampal gyrus in both groups at follow up scan, though to a lesser extent in MDD patients, 












3 Neural effects of duloxetine treatment on sad and happy facial 
processing in major depressive disorder 
 
 
The important findings from the chapter are included in the paper listed below: 
Fu, C.H., Costafreda, S.G., Sankar, A., Adams, T.M., Rasenick, M.M., Liu, P., . . . Marangell, L.B. 
(2015). Multimodal Functional and Structural Neuroimaging Investigation of Major Depressive 











Affective processing biases in depression have been extensively studied, especially in relation to 
emotional facial expressions (see review: Elliott et al., 2011).  Acutely depressed MDD patients show 
impaired recognition of affective facial expressions (Surguladze et al., 2004), whereby they tend to 
misinterpret happy, neutral or ambiguous facial expression as being sad or less happy (Bourke et al., 
2010).  The affective bias is evident in several neurocognitive domains, especially in memory and 
attention (ex. review: Roiser et al., 2012).  In particular, MDD patients show a greater recollection of 
negative facial expressions and decreased recall for happy facial expressions compared to neutral ones 
(Ridout et al., 2003).  In tasks of gender recognition of negative affective stimuli, evidence suggests that 
MDD patients respond less accurately (Surguladze et al., 2004) and less rapidly (Fu et al., 2004, 2008a; 
Arnone et al., 2012) than healthy controls do.  There have been few inconsistencies however, with 
studies showing acutely depressed MDD patients also performing as well as controls in these tasks 
(Sheline et al., 2001; Lawrence et al., 2004).  Findings for recognition impairment for positive stimuli in 
depression have also been inconclusive.  For instance, some behavioural studies have shown impaired 
performance in patients relative to healthy controls during processing of happy facial expressions 
(Sheline et al., 2001; Fu et al., 2007), while others have not found any group differences in either 
accuracy (Surguladze et al., 2005; Arnone et al., 2012) or latency (Surguladze et al., 2005).  In MDD 
patients, impairments in processing facial expressions may be more evident when the target stimuli are 
presented over a long duration of time, permitting extensive processing (Mogg & Bradley, 2005). 
Pharmacological treatments have been shown to improve emotional processing bias in MDD patients.  
A 2-week antidepressant treatment enhanced recognition of both negative as well as positive emotions 
in MDD patients (Tranter et al., 2009).  A single dosage of reboxetine in patients also improved 
recognition of happy facial expressions compared to those who received placebo (Harmer et al., 2009a), 
while acute administration of citalopram normalised the bias towards fearful faces in recovered MDD 
patients (Bhagwagar et al., 2004).  Even in healthy controls, a single dose of citalopram had improved 
their attention towards positive words though it had also increased their recognition of fearful faces 
(Browning et al., 2007).  Furthermore, enhancement of the recognition of happy faces following 
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antidepressant treatment in MDD patients was linked with improvements in depressive symptoms 
(Tranter et al., 2009), suggesting that these emotional processing biases may be a state rather than a 
persistent trait-related feature of depression.   
Facial processing biases in depression have been well examined with fMRI studies using standardised 
experimental paradigms, such as faces (Ekman & Friesen, 1976) (ex. Sheline et al., 2001; Fu et al., 
2004; Keedwell et al., 2005a; Fu et al., 2007, 2008a; Suslow et al., 2010; see review: Stuhrmann et al., 
2011).  The affective processing tasks are typically implicit or explicit in nature.  For instance, the 
gender decision facial task is an implicit affective processing task where the explicit instruction is to 
identify the gender of the face; such that the emotional expression is processed implicitly (ex. Sheline et 
al., 2001; Lawrence et al., 2004; Fu et al., 2004; Gotlib et al., 2005; Surguladze et al., 2005; Fu et al., 
2007, 2008a; see review: Stuhrmann et al., 2011).  On the other hand, in the explicit affective 
processing tasks, explicit instruction is to identify the emotion of the presented face which allows 
explicit processing of the emotion (ex. Peluso et al., 2009; Almeida et al., 2010, Scheuerecker et al., 
2010; Frodl et al., 2011; see review: Stuhrmann et al., 2011).  Neuroimaging studies most often use 
implicit affective processing tasks as they are associated with greater activations in key limbic regions 
within the MDD network, in particular the amygdala (Costafreda et al., 2008).   
Limbic regions, especially the amygdala, are associated with emotional processing, in which the 
probability of amygdala activation is greater for negative rather than positive stimuli (Costafreda et al., 
2008).  Cross-sectional fMRI studies comparing patients and healthy control subjects have shown 
elevated amygdala activation in acutely depressed MDD patients, relative to healthy controls, in 
response to sad (Fu et al., 2004, 2007; Victor et al., 2010; Arnone et al., 2012) and fearful faces (Sheline 
et al., 2001), and negative pictures (Anand et al., 2007), although some studies have also found no 
group differences in amygdalar activity in response to negative emotional stimuli (Davidson et al., 
2003; Frodl et al., 2011).  Evidence suggests that emotional faces are more likely to show initial 
amygdala hyperactivity in patients, compared to other emotional tasks (Costafreda et al., 2008).  
Processing of happy facial expressions on the other hand was also associated with attenuated amygdala 
activation in patients compared to control subjects (Lawrence et al., 2004), providing further support for 
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the negative bias in depression (Surguladze et al., 2005).  fMRI studies have also examined amygdala 
activity in at-risk individuals and in MDD patients in remission to delineate whether they are state or 
trait markers of depression.  In response to fearful faces, high-risk individuals showed greater bilateral 
amygdala activation in comparison with low-risk individuals (Monk et al., 2008).  Similarly, remitted 
MDD patients relative to controls showed elevated amygdala activity during masked sad facial 
processing, with a pattern of activations similar to acutely depressed patients (Victor et al., 2010).  
However, there is also evidence that amygdala activation in MDD patients is specific to mood state, 
suggesting that increased amygdala actviation may be a state marker in depression (Fu et al., 2008a; 
Arnone et al., 2012). 
In addition to amygdala activation, the fusiform gyrus is also engaged by face processing tasks 
(Adolphs, 2002).  A model proposed by Haxby and colleagues (2000) outlines the core face processing 
network that comprises of bilateral occipital regions, a face responsive region in the fusiform gyrus, and 
superior temporal sulcus regions.  Along with this core network, facial processing is also associated 
with additional neural systems, such as the frontal eye regions and intraparietal sulcus for focusing 
attention, affective regions like the amygdala and the insula for processing emotions, and the anterior 
temporal lobe for retrieving semantic information associated with the face (Haxby et al., 2000).  Greater 
fusiform activity is seen in MDD patients relative to controls during processing of negative emotional 
stimuli, whereas decreased fusiform gyrus activations are seen in response to positive emotional stimuli 
in patients (Surguladze et al., 2005; Suslow et al., 2010; meta-analysis: Groenewold et al., 2013).  This 
supports behavioural evidence which show that patients are more likely to attend to faces of increasing 
sadness compared to healthy controls who in turn attend more to happy facial expressions (Joorman & 
Gotlib, 2007; Victor et al., 2010).  In addition to amygdalar and fusiform activations, sad facial 
processing is also associated with activations in other limbic-subcortical structures in MDD patients, 
relative to controls, in particular the anterior cingulate, insula (Fu et al., 2004), hippocampus (Victor et 
al., 2010) and parahippocampal gyrus (Fu et al., 2004; Surguladze et al., 2005).  As expected, reverse 
pattern of neural responses in limbic–subcortical regions is observed in response to implicit processing 
of happy faces, whereby MDD patients show attenuated activations in the posterior cingulate gyrus (Fu 
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et al., 2007), putamen (Surguladze et al., 2005), thalamus and parahippocampal region (Lawrence et al., 
2004) compared to healthy control subjects.  
Longitudinal fMRI studies have shown normalisation of abnormal neural responses in MDD patients in 
response to facial processing following treatment.  Majority of these studies have focussed on the neural 
changes following antidepressant treatment specifically selective serotonin reuptake inhibitors (SSRI; 
ex. Sheline et al., 2001; Fu et al., 2004, 2007; Victor et al., 2010; Arnone et al., 2012) and relatively few 
studies have focussed on changes following other antidepressant classes like serotonin-norepinephrine 
reuptake inhibitors (ex. SNRI; Frodl et al., 2011) and psychological therapies (ex. Fu et al., 2008a).  
Following SSRI treatment, attenuation in activity in the amygdala (Sheline et al., 2001; Fu et al., 2004; 
Arnone et al., 2012), anterior cingulate (Fu et al., 2004, Victor et al., 2013), insula and putamen (Fu et 
al., 2004) have been observed in MDD patients.  Treatment with SSRIs also seemed to improve the 
abnormal brain activations observed in response to positive facial stimuli in the cortico-limbic regions 
in MDD patients, particularly in the fusiform gyrus (Jiang et al., 2012), posterior cingulate, lingual 
gyrus, precuneus and the cerebellum (Fu et al., 2007).  
Investigation of SNRI treatment effects on negative emotional processing in MDD have revealed 
similar normalization of limbic regions, particularly in the hippocampus and in other subcortical regions 
including the fusiform gyrus, thalamus, precuneus and the cerebellum (Frodl et al., 2011) as well as 
some distinct increases in the insula and anterior cingulate (Davidson et al., 2003) following 
venlafaxine treatment.  To my knowledge, this is the first study that has examined neural responses to 
sad and happy facial stimuli following treatment with the SNRI, duloxetine.  A study that examined 
duloxetine effects in MDD in response to painful stimuli observed decreases in the insula, pregenual-
subgenual anterior cingulate and the dorsolateral prefrontal regions following treatment (López-Solà et 
al., 2010).  Together, these findings suggest that SSRI and SNRI classes of antidepressants have some 
similar as well as distinct effects on brain activity in MDD patients. 
A longitudinal fMRI study was conducted to examine the effects of duloxetine on processing sad and 
happy facial expressions.  The main hypothesis was that treatment would be associated with 
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normalization of anterior cingulate cortex and amygdala activation to sad faces in patients with MDD as 
compared with healthy participants (Sheline et al., 2001; Fu et al., 2004; meta-analyses: Delaveau et al., 
2011; Ma, 2015).  It is also predicted that patients would show attenuated amygdala activity in response 
to happy facial expressions as compared with controls (Lawrence et al., 2004; Victor et al., 2010), 
which would improve with treatment (Victor et al., 2010; meta-analysis: Ma, 2015).  
 
3.2 Methods 
3.2.1 Participants  
30 patients with Major Depressive Disorder and 27 healthy controls matched for age, gender and IQ 
were recruited through local newspaper advertisements.  MDD patients were assessed with the 
Structured Clinical Interview for DSM-IV Axis I disorders (SCID; First et al., 2012), meeting criteria 
for single or repeated episodes of MDD without psychotic features as defined by Diagnostic 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR; American 
Psychiatric Association, 2000).  All patients had a minimum score of 18 on the 17-item Hamilton 
Depression Rating Scale (HAMD-17; Hamilton, 1960) at the time of study entry and were free of 
antidepressant medication for a minimum of 4 weeks before start of the study (6 weeks for 
fluoxetine).  Exclusion criteria were any DSM-IV-TR comorbid Axis I or II disorder including a 
history of substance abuse or dependence within the prior 6 months, known Alzheimer’s disease or 
mental retardation; serious suicidal risk or risk of self-harm (Columbia-Suicide Severity Rating Scale; 
Posner et al., 2011); history of electroconvulsive therapy, transcranial magnetic stimulation, or vagus 
nerve stimulation within the past year; abnormal thyroid stimulating hormone concentration; or 
medical disorders known to affect central nervous system structures or function  (eg. diabetes, high 
blood pressure, HIV and glaucoma).  MDD patients were administered duloxetine 60 mg once daily 
for 12 weeks.  At week 8, MDD patients who met criteria for remission continued on 60 mg dose, 
while the others could opt for an increase in dose up to 120 mg once daily.   
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Healthy controls with a HAMD-17 score of ≤ 7 at baseline were screened to ensure that they did not 
meet criteria for any psychiatric illness, neurological disorder, or heady injury resulting in a loss of 
consciousness.  Anxiety scores of all participants were measured using the Hamilton Anxiety Rating 
Scale (HAMA; Hamilton, 1959).  Medical reports were acquired from the General Practitioners for all 
participants and they were extensively examined to obtain information on antidepressant use, 
medication history, concomitant medications, and previous history of psychiatric illness other than 
major depressive disorder, previous treatment for depression or other psychiatric conditions, and any 
other medical or physical condition that met exclusion criteria for the study.  The study was funded by 
Eli Lilly and company and was approved by the Cambridgeshire 4 Research Ethics Committee.  The 
study was conducted in conformity with the Declaration of Helsinki and its amendments.  
Functional MRI scans were obtained from all participants at baseline (week 0), week 1, week 8 and 
upon study completion (week 12).  30 MDD patients and 27 healthy volunteers (HV) were enrolled.  
Data from 3 healthy controls were excluded as medical reports from 2 controls revealed previous 
history of antidepressant use and another healthy control was diagnosed with depression one month 
after study completion.  23 MDD patients and 22 healthy controls completed the 12 week study.  Of 
the 7 patients who dropped out, 4 patients discontinued as they were unable to tolerate the side effects 
of the drug, 1 patient suffered a serious adverse event of retinal pigment epitheliopathy which was not 
judged to be related to the study drug, and 2 patients did not comply with study procedures.  2 healthy 
volunteers dropped out of the study as they could not tolerate the scanner.  Longitudinal analyses were 
performed with all participants who completed the study, i.e., 23 MDD patients and 22 healthy 
controls. 
3.2.2 fMRI data acquisition 
Gradient echo T2*-weighted echoplanar images were acquired depicting blood oxygenation level-
dependent (BOLD) contrast.  A total of 180 volumes were acquired for each for the happy and sad 
facial affect tasks.  For each volume, 39 oblique axial slices parallel to the intercommissural plane 
were collected with the following parameters: slice thickness: 3 mm, slice gap: 0.3 mm, echo time 
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(TE): 30 milliseconds, repetition time (TR): 2000 milliseconds, flip angle: 75°, field of view: 240 mm, 
and matrix size: 64 x 64. 
3.2.3 Experimental design 
The event-related fMRI paradigm consisted of facial expressions and baseline trials presented in a 
pseudo-randomise order.  The happy and sad faces tasks were presented as separate tasks with the sad 
faces following the happy faces task.  Participants were shown a series of ten human faces (5 females) 
adapted from Ekman and Friesen’s Pictures of Facial affect (Ekman & Friesen, 1976) morphed to 
represent faces of varying intensities: low, medium and high.  The facial stimuli were presented twice 
at each intensity (60 faces in total), along with 12 baseline trials consisting of a crosshair visual 
fixation point, for a total of 72 presentations.  Each stimulus was presented for duration of 3 seconds, 
and the interval between trials varied randomly according to a Poisson distribution, with a mean 
intertrial interval of 5 seconds, for a total duration of 360 seconds (6 minutes).  fMRI data were 
acquired at weeks 0, 1, 8 and 12 (sample response file is available in Supplementary material 2).  
During each trial, subjects were instructed to specify the gender of the face.  Responses were made by 
pressing a button in the scanner (right button to indicate a male face and left to indicate a female face) 
with their forefinger and third finger.  Latency (response time) and accuracy of gender decision were 
recorded for each trial.   
3.2.4 fMRI data analysis 
Statistical Parametric Mapping (SPM8, Wellcome Department of Imaging Neuroscience, London, 
UK; Ashburner et al., 2012) was used to pre-process and analyse the task-related fMRI data using 
default settings.  The images were realigned to correct for motion artefacts, spatially normalized to the 
Montreal Neurological Institute (MNI) template, and smoothed using an 8mm full-width at half 
maximum (FWHM) Gaussian kernel filter.  First-level analysis was performed using the general 
linear model, accounting for serial autocorrelations by applying an autoregressive model.  Stimuli 
presentation was modelled as individual events and the first level analysis produced contrast images 
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relevant to the main contrast of interest (sad faces or happy faces vs crosshair baseline).  Second-level 
analysis employed a random-effects model to examine the main effect of group (MDD vs HV across 
all time points), main effect of time (linear changes over weeks 0, 1, 8, 12) and the group x time 
interaction.  Independent samples t-tests were also used to compare scanning data at a particular time 
point between groups.  Paired t-tests was also performed in patients and controls separately to 
compare changes between two specified time points.  To identify brain regions associated with 
clinical improvement, percentage change in HAMD-17 scores after 12 weeks of treatment was 
regressed on change in BOLD response, estimated by subtracting the t map for bold response at week 
0 from the corresponding map at week 12.  Inference on whole-brain statistical images was conducted 
using the general linear model (GLM) and cluster-wise family-wise error rate (FWER) with p < 0.05 
corrected for multiple comparisons.  In addition to the whole brain approach, a region-of-interest 
analysis was also performed by other investigators of this study to examine mean percentage signal 
change in BOLD response, by comparing patients and controls, from baseline to week 12 in bilateral 
amygdala in response to sad facial expressions (Fu et al., 2015).  
 
3.3 Results 
3.3.1 Demographic results 
Age, gender and IQ were not significantly different between patients and controls (all p > 0.4) (Table 
3.1).  Patients had significantly higher HAMD scores compared to controls (p < 0.001) which 
decreased following treatment (p < 0.05).  Upon study completion, 18 patients met criteria for a 
clinical response to treatment defined by a minimum of 50% reduction in HAMD-17 score and 16 
patients met criteria for clinical remission defined as a HAMD-17 score of 7 or less at the end of 
treatment.  Information on other clinical characteristics of patients such as illness onset, course, and 
duration, and treatment history were unavailable. 
Table 3.1: Demographic and clinical characteristics 
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Characteristic                        Patients with Depression (N=23)         Healthy Volunteers (N=22) 
                                                          Mean           SD                               Mean             SD  
 
Age (years)                                      39.83            11.21                            39.09            10.29 
Full IQ                                           107.83            10.71                           108.18           13.75 
Verbal IQ                                       110.00              9.86                           108.45           12.56 
Performance IQ                              103.17            14.43                           106.36           15.31 
HAMD (baseline)                             21.96             2.85                                0.32            1.09 
HAMD (week 12)                               6.87             4.62                                0.59            1.22 
HAMA (baseline)                             20.74             5.39                                  *                  * 
HAMA (week 12)                              7.52              4.41                                0.50            1.01 
* HAMA not done for healthy volunteers at baseline 
 
3.3.2 Behavioural results 
3.3.2.1 Behavioural results for sad facial affect processing 
 
ANOVA showed a main effect of intensity on latency (F2, 86 = 14.96, p < 0.001): all participants were 
slower at the high intensity of sad facial expressions.  There were no other main effects of group, time 
or any significant second or third order interaction effects on latency (Table 3.2).  
For accuracy of explicit gender recognition, there was a significant main effect of time on accuracy 
(F3, 129 = 3.54, p = 0.017) in which all subjects made more errors with the successive scans over time.  
There was also a main effect of intensity on accuracy (F2, 86 = 3.74, p = 0.028) in which participants 
made most incorrect responses while responding to facial stimuli portraying intense degrees of 
sadness compared to neutral ones.  There were no main effects of group, nor any significant second or 







Table 3.2: Behavioural performance on sad facial expression task 
Intensity of             MDD Patients   Healthy Controls 




   Low intensity            958.02 (221.77)  
958.44 (299.48) 
Medium intensity            986.25 (211.70) 
 
955.54 (250.73) 





   
Low intensity               17.30 (1.10)  
17.77 (0.86) 
Medium intensity               17.65 (1.02) 
 
17.81 (0.39) 





Reaction Time    
Low intensity           970.39 (283.65)  934.20 (277.43) 
Medium intensity           958.98 (260.96)  935.67 (267.81) 
High intensity         1015.36 (290.47)  959.64 (272.21) 
Accuracy     
Low intensity              15.91 (3.32) 
 
17.36 (1.76) 
Medium intensity              16.26 (3.00)  17.40 (1.76) 
High intensity              16.04 (3.57)  17.04 (1.78) 
    
Mean values are presented with standard deviation in parenthesis 
 
3.3.2.2 Behavioural results for happy facial affect processing 
 
ANOVA showed a main effect of time on latency (F3, 123 = 3.3, p = 0.023), with all participants 
responding at a faster rate over time (Table 3.3).  There were no other significant main effects of 
group, intensity, or group by time interactions on latency.  
Accuracy of gender recognition showed significant intensity by group interaction (F2, 82 = 3.85, p = 
0.025), as MDD participants showed the greatest errors for the medium intensity of expression while 
healthy participants had greater errors for the lowest intensity.  There was also a significant 
interaction effect of intensity by time (F6, 246 = 2.86, p = 0.01) in which all participants made the most 
errors for the medium and highest intensities at the final (week 12) scan while there were few changes 
in accuracy for the lowest intensity with successive scans over time.  There were no other significant 
main effects of group, time, or any other second or third order effects on accuracy (Table 3.3).  
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 Table 3.3: Behavioural performance on happy facial expression task 
Intensity of          MDD Patients 
 
Healthy Controls 






   Low intensity                   1086.76 (381.10)  
 975.88 (192.34) 
Medium intensity                   1122.31 (413.32) 
 
1006.35 (189.69) 
High intensity                   1117.18 (420.35) 
 
 981.45 (171.85) 
 
Accuracy  
   
Low intensity                       17.52 (1.16)  
   17.29 (1.27) 
Medium intensity                       17.17 (0.83) 
 
   17.62 (0.92) 
High intensity  N                  17.65 (0.77) 
 
   17.71 (1.05) 
 
Week 12 
Reaction Time    
Low intensity                  1000.69 (291.11)  893.88 (155.87) 
Medium intensity                    953.73 (212.64)  884.76 (142.69) 
High intensity                    974.08 (244.75)  935.35 (140.24) 
 
Accuracy     
Low intensity                       17.35 (1.02) 
 
   17.33 (1.90) 
Medium intensity                       16.57 (1.92)     17.19 (1.77) 
High intensity                       16.87 (2.18)     17.33 (1.79) 
    
Mean values are presented with standard deviation in parenthesis. * Behavioural response only available 
 for 21 healthy controls.  
 
3.3.3 Functional MRI results  
3.3.3.1 Functional MRI results for sad facial affect processing 
 
Contrary to the hypothesis, the whole brain results did not reveal any significant group by time 
interaction effects nor any main effect of group.  In MDD patients, there was a main effect of time 
with a significant increase in the BOLD contrast response to the mean of the medium and high 
intensity of expressions in the posterior cingulate (x = -3, y = -43, z = 19; 221 voxels; peak T = 4.50; 
p(FWE corrected) = 0.010) (Figure 3.1), while healthy participants showed a trend towards a decrease in the 
orbitofrontal region (x = 45, y = 29, z = -11; 118 voxels, T = 4.61, p(FWE corrected) = 0.068).  When 
medium and high intensity faces were considered separately, there was a main effect of time in MDD 
patients with a significant increase in the BOLD response to the medium intensity facial expression in 
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the posterior cingulate (x= -3, y = -43, z = 22; 298 voxels; peak T = 4.77; p(FWE corrected) = 0.002), while 
healthy volunteers showed a decrease in the fusiform gyrus in response to high intensity of 
expressions (x = -36, y = -82, z = -17; 138 voxels; peak T = 4.39; p(FWE corrected) = 0.050).  
The region-of-interest analysis did not reveal any significant difference between groups in the change 
in BOLD response from baseline to week 12 in the bilateral amygdala in response to sad facial 
expressions (Fu et al., 2015). 
Figure 3.1: Main effect of time in MDD patients in the posterior cingulate gyrus 
 
 
MDD patients showed a significant increase with time in the BOLD contrast response to the mean of the 
medium and high intensity of expressions in the posterior cingulate (x = -3, y = -43, z = 19; 221 voxels; peak T 
= 4.50; p(FWE corrected) = 0.010).  Transverse sections are depicted from z co-ordinates 15 to 23. 
 
3.3.3.2 Functional MRI results for happy facial affect processing 
 
There were neither group by time interaction effects nor main effects of group.  There were no main 
effects of time among patients with MDD, but healthy participants showed a significant decrease with 
time in response to the mean of medium and high intensity expressions in the mid cingulate gyrus (x = 
9, y = 29, z = 40; 315 voxels, peak T = 4.27; p(FWE corrected) = 0.002) and precentral region (x = -51, y = 
11, z = 34; 190 voxels; peak T = 4.08; p(FWE corrected) = 0.018) (Figure 3.2), as well as approaching 
significance in the thalamus (x = 3, y = -13, z = 10; 118 voxels; T = 4.12; p(FWE corrected) = 0.070).  
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Figure 3.2: Main effect of time in controls in the mid cingulate and precentral regions 
 
Healthy participants showed a significant decrease with time in the BOLD contrast response to the mean of the 
medium and high intensity of expressions in the mid cingulate gyrus gyrus (x = 9, y = 29, z = 40; 315 voxels, 
peak T = 4.27; p(FWE corrected) = 0.002)  and precentral region (x = -51, y = 11, z = 34; 190 voxels; peak T = 4.08; 
p(FWE corrected) = 0.018).  Transverse sections are depicted from z co-ordinates 33 to 41. 
 
3.3.3.3 Functional MRI results for exploratory analysis on happy facial affect processing 
 
Exploratory analyses (paired t-tests) were also performed in MDD patients to examine changes in 
brain activity at different time points (week 1, week 8 and week 12) from baseline.  Findings showed 
decreases in BOLD responses in the inferior frontal gyrus after both 1 and 8 weeks of treatment.  
Additional changes were observed in the insula and the angular gyrus after 1 week of treatment.  
However, compared with baseline, no regions showed significant changes in activity following 12 
weeks of treatment (Table 3.4).    
 Table 3.4:  Longitudinal analysis in MDD patients following 1 and 8 weeks of treatment 
Brain Region   MNI coordinates      Voxels Z value P value 
    x       y z       
Week1 < Baseline 
       
Neutral vs cross        
L Angular Gyrus 
 
-48 -52 34 140 6.60 0.028 
R Insula 
 
 39  26 -2 263 6.37 0.002 
L Inferior Frontal Gyrus (Orbital Part) -39  41 -11 118 6.33 0.047 
Week 8 <  Baseline 
       
Neutral vs cross        
L Inferior Frontal Gyrus (Orbital Part)  33  20 -20 261 6.78 0.003 
R Inferior Frontal Gyrus (Orbital Part) -33  20 -23 192 6.28 0.010 





The present study investigated the behavioural and neural correlates of facial processing bias in 
medication-free depressed patients and following treatment with the SNRI duloxetine.  Behavioural 
responses showed limited differences between the groups, especially for sad facial processing.  
3.4.1 Neural correlates of treatment during processing of sad facial expressions 
Contrary to the hypothesis, the neural correlates did not reveal a significant group by time interaction 
in response to sad facial expressions.  A meta-analysis of the neural effects of antidepressant 
treatment revealed a consistent normalisation of limbic activity particularly in the amygdala, 
hippocampus, parahippocampal region and the anterior cingulate gyrus in MDD patients during 
negative emotional processing (Delaveau et al., 2011), however these responses were typically 
observed following treatment with selective serotonin reuptake inhibitors (Sankar & Fu, in press).  In 
MDD patients, attenuation of amygdala activity following SSRI treatment is consistent with the 
density of serotonin receptors within the amygdala (Xu and Pandey, 2000) which are a target of action 
for SSRIs (Jiang et al., 2011).  Moreover, in MDD patients, normalization of amygdala activity has 
been reported even before clinical improvements (Godlewska et al., 2012), reflecting a therapeutic 
mechanism of action of SSRIs.  On the other hand, very few functional imaging studies have 
investigated the effects of SNRI on emotional processing; therefore our understanding of whether the 
neural correlates of different antidepressant classes is comparable remains unclear.  Preliminary 
investigations on healthy controls revealed that a single dose of SSRI led to decreased amygdala 
responses to emotional faces, while acute administration of the Norepinephrine Reuptake Inhibitor 
(NRI) medication increased activation in medial and frontal areas (Outhred et al., 2013).  In patients, 
treatment with the SNRI venlafaxine was associated with increases in the limbic regions, particularly 
the insular and anterior cingulate regions (Davidson et al., 2003), as well as decreases in the 
subcortical and cortical regions (Frodl et al., 2011) in response to negative affective paradigms.  It is 
postulated that SSRI may have early attenuating effects on emotional reactivity, while NRI is 
associated more with emotional regulation (Outhred et al., 2013).   
75 
  
The present study showed significant increases in the posterior cingulate in MDD patients with time 
during sad facial processing.  The posterior cingulate is an important part of the default mode network 
(Fransson & Marrelec, 2008; Leech et al., 2011) and has functional connections with the limbic 
system (review Leech & Sharp, 2014).  It is also associated with episodic memory (Wagner et al., 
2005), shows activation in response to affective stimuli, both negative and positive, (Maddock et al., 
2003) and plays a key role in regulating attention (Hahn et al., 2007; review: Leech & Sharp, 2014).  
Resting state studies using PET have revealed increases in the posterior cingulate with venlafaxine 
(Kennedy et al., 2007).  Moreover, in MDD patients who received either mirtazapine or venlafaxine, 
increased pre-treatment activity in the posterior cingulate during sad facial processing was associated 
with better response to treatment (Samson et al., 2011).  Even in healthy controls, acute administration 
of NRI was associated with increased posterior cingulate activity during processing of emotional 
pictures (Outhred et al., 2013).  A comparison of SSRI and NRI classes of antidepressants in healthy 
controls showed that acute administration of reboxetine (NRI) led to increases in the posterior 
cingulate, a finding not seen with citalopram (SSRI) which was more associated with prefrontal 
modulations (Brühl et al., 2010).  However, there have been concerns over the clinical efficacy of 
reboxetine in alleviating depressive symptoms.  A study that analysed 13 published and unpublished 
acute placebo controlled and/or SSRI controlled treatment trials concluded that reboxetine was 
ineffective as an antidepressant (Eyding et al., 2010).  This was contrary to findings from two earlier 
analyses of merely placebo-controlled studies that found greater efficacy of the drug compared with 
placebo (Ferguson et al., 2002; Montogomery et al., 2003).  In MDD patients, SSRI treatment was 
specifically associated with decreases in the posterior cingulate region (meta-analysis: Delaveau et al., 
2011).  Thus, dual acting antidepressants that modulate noradrenergic and serotonergic systems have 
differential neural effects to SSRI that modulate specifically the serotonergic system.  Increase in 
posterior cingulate activity following treatment with duloxetine in the present study may reflect a 
specific treatment effect of antidepressants that modulate noradrenergic systems. 
76 
  
3.4.2 Neural correlates of treatment during processing of happy facial expressions 
The present study did not reveal a significant group by time interaction effect in the amygdala for 
happy facial expressions, contrary to the hypothesis.  A meta-analysis of functional neuroimaging 
studies in healthy controls found greater probability of amygdala activation for negative stimuli, such 
as those that evoke fear and disgust relative to happiness (Costafreda et al., 2008).  Even in MDD 
patients, abnormal amygdala activity in response to sad stimuli has been widely reported, while for 
happy faces, differences in amygdalar activity have been less replicated (review: Stuhrmann et al., 
2011).  In particular, previous neuroimaging studies that examined neural correlates of positive 
emotional stimuli have failed to observe significant group differences (Fu et al., 2007; Arnone et al., 
2012; Rosenblau et al., 2012) or any group by time interaction effects (Davidson et al., 2003; Fu et al., 
2007) in the amygdala.  
Additional exploratory analysis in MDD patients examining changes in brain activity following 1, 8 
and 12 weeks of duloxetine treatment showed that compared with baseline scans, inferior frontal 
gyrus activity reduced after both 1 and 8 weeks of treatment in response to neutral faces (Table 3.4).  
The right inferior frontal gyrus is especially activated during assessment of facial expressions 
(Nakamura et al., 1999) and in healthy controls, activation of inferior frontal gyrus is seen in response 
to neutral faces in comparison with non-facial stimuli (ex. scrambled images) (Kesler et al., 2001).  In 
MDD patients, a meta-analysis of emotional processing studies found significant decreases in the 
right inferior frontal gyrus with antidepressant treatment (Delaveau et al., 2011).  This is consistent 
with findings from the present study, although potential confounding effects of time and repeated 
neuroimaging scans must be considered.  I expected to find greater change in regional brain activity in 
MDD patients following study completion (week 12), however paired-t-test did not reveal any 
significant difference in brain activity in patients between week 12 and baseline scans.  It is proposed 
that antidepressants that potentiate the noradrenergic systems seem to have earlier effects on 
emotional processing and less consistent long term effects on negative emotional processing which is 
usually seen with SSRI treatment (Pringle et al., 2013).  
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Limitations of the present study include the small sample size, which may have led to insufficient 
power to detect all group differences at the neural level.  Also, the high response rate in this study 
limited the power to detect differences between treatment responders and patients with a more 
treatment resistant form of depression, which may be associated with distinct neural correlates (Anand 
et al., 2005; Fu et al., 2015).  Finally, the absence of a treatment group receiving placebo limits our 
attribution of effects to the antidepressant medication as opposed to changes associated with clinical 
improvement, although the potential effects of time were accounted for by having HV participants 
undergo scans at the same time points as MDD patients. 
In summary, the functional neuroimaging correlates showed increases in the posterior cingulate gyrus 
in MDD patients with treatment.  This is consistent with findings that show increases in this region 
with antidepressants that potentiate the noradrenergic systems (Kennedy et al., 2007; Brühl et al., 
2010; Outhred et al., 2013).  Results from this study reflect some distinct effects of the SNRI class of 
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4.1  Introduction 
Major depression is often associated with cognitive deficits which are evident across numerous 
neuropsychological domains.  Patients with MDD show impairments in attention (Trichard et al., 
1995; Austin et al., 1999; Ravnkilde et al., 2002; Porter et al., 2003; Donaldson et al., 2007; Iverson et 
al., 2009), memory, both immediate (Brand et al., 1992; Ravnkilde et al., 2002; Porter et al., 2003; 
Walter et al., 2007; Iverson et al., 2009) as well as delayed (autobiographical memory: Young et al., 
2012), and other executive functions such as decision making (Murphy et al., 2001).  Cognitive 
impairments are seen in MDD patients, very early in the course of the disorder, even in their first 
episode (meta-analysis: Lee et al., 2012).  Furthermore, these may be present in individuals at familial 
risk (Christensen et al., 2006), and have enduring effects in recovered patients (Weiland-Fiedler et al., 
2004; Paelecke-Habermann et al., 2005; Smith et al., 2006; Reppermund et al., 2009).  A recent meta-
analysis, investigating a single neuropsychological test battery, the Cambridge Neuropsychological 
Test Automated Battery, (CANTAB), found impairments in memory and attention in acutely 
depressed as well as remitted MDD patients (Rock et al., 2014), suggesting that cognitive deficits may 
be present in patients independent of  their mood state.  Impairments were also evident in euthymic 
MDD patients in a range of cognitive domains that included inhibitory control, executive functions, 
memory and processing speed (Bora et al., 2013).  However, both studies included elderly populations 
with MDD and age is likely to have a significant effect on cognitive functioning in MDD patients 
(Porter et al., 2007).  Moreover, both Rock et al. (2014) and Bora et al. (2013) included patients with 
late-onset depression in their analyses and the magnitude of deficits in attention and memory in 
euthymic patents were generally modest when late onset depression was excluded (Bora et al., 2013).  
Presence of comorbid disorders may also influence the extent of cognitive impairments in major 
depression.  For instance, psychiatric comorbidity was found to be a strong predictor of impaired 
cognitive function (Baune et al., 2009), and the presence of psychotic symptoms was associated with 
poorer attentional performance in MDD patients (Nelson et al., 1998; Schatzberg et al., 2000).  Other 
clinical factors that may be linked to the magnitude of cognitive impairments in MDD patients include 
illness severity and number of depressive episodes, although they require further investigation.  For 
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example, while some studies have found negative associations between illness severity and cognitive 
functioning, such as with executive functions (Paelecke-Habermann et al., 2005; Sheline et al., 2006; 
McDermott & Ebmeier, 2009), language processing (Sheline et al., 2006; McDermott & Ebmeier, 
2009), working and episodic memory (Sheline et al., 2006; McDermott & Ebmeier, 2009), others 
have found no significant associations between working memory performance (Gruber et al., 2011), 
or executive functions (Porter et al., 2003; Schmid & Hammar et al., 2013) and severity of depression.  
It has also been suggested that increase in number of episodes may be associated with further decline 
in cognitive control (Vanderhasselt & De Raedt, 2009), however findings have been inconsistent with 
results showing no such relationship with working memory (Lyche et al., 2010; Schmid & Hammar et 
al., 2013).  
Apart from patient characteristics, pharmacological effects on cognitive functions needs to be 
considered when examining MDD patients (ex. Kyte et al., 2005; Boeker et al., 2012).  In general, 
cognitive impairments are seen to improve following successful treatment with SSRIs (Koetsier et al., 
2002; Herrera-Guzman et al., 2009), SNRIs (Herrera-Guzman et al., 2009) or tricyclic antidepressants 
(Koetsier et al., 2002), although some persistent residual impairments are also found in recovered 
individuals (Paelecke-Habermann et al., 2005; Reppermund et al., 2009 ).  
It has been postulated that some of the cognitive deficits seen in MDD patients are due to 
dysfunctions in the central executive component of working memory (Channon et al., 1996).  
Working memory is a brain system which permits transient holding and manipulation of information, 
important for higher level processing such as comprehension, learning and memory (Baddeley, 1992).  
Functional magnetic resonance imaging (fMRI) studies of working memory in healthy controls have 
shown involvement of the lateral prefrontal cortex (PFC), especially the ventrolateral prefrontal cortex 
(VLPFC)/inferior frontal gyrus (IFG) and the dorsolateral prefrontal cortex (DLPFC), and also the 
posterior parietal cortex (Owen et al., 2005).  The subregions of the PFC are involved in specific 
working memory related functions, for instance, the VLPFC is thought to be involved in the simpler 
processes, such as encoding and retrieval of information (Petrides, 2000) whereas active monitoring 
and manipulation of information recruits the DLPFC (D’Esposito et al., 1998; Petrides 2000).  
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Moreover, the prefrontal regions show load dependent activations, with greater engagement of these 
regions with increasing task difficulty (IFG: Braver et al., 1997; DL PFC: Braver et al., 1997; 
Manoach et al., 1997).   
Typically neuroimaging studies have used the n-back task to investigate working memory processes 
in healthy subjects (Nystrom et al., 2000; Rämä et al., 2001; Hautzel et al., 2002; Ragland et al., 2002; 
Zurowski et al., 2002).  In the n-back task, subjects indicate whether a given verbal or nonverbal 
stimulus in a sequence matches the one presented n trials previously.  The n-back tasks require ‘on-
line’ monitoring and manipulation of information held in working memory (Owen et al., 2005), 
however such designs do not differentiate maintenance dependent load activation from other working 
memory processes such as encoding and probe related effects (Narayanan et al., 2005).  In the present 
study, a modified version of the Sternberg Item Recognition Task (Sternberg, 1966) was used in 
which subjects, after maintaining a sequence of letters across a delay period are asked to judge 
whether the probe letter belonged to the original sequence of letters.  
 It is argued that the Sternberg task may be more similar to a visuospatial recognition memory task 
rather than a working memory task especially when the task does not require participants to recall the 
sequence of digits in the order of their presentation (Corbin & Marquer, 2013).  Unlike the classic 
Sternberg paradigm used in the Corbin & Marquer (2013) study, in which subjects are shown the 
probe digit shortly after a brief delay (typically 1-2 seconds), the present study used a modified 
version of the task that incorporated a variable maintenance period lasting between 5 and 15 seconds. 
Thus, in this study, the stimuli needed to be actively maintained over a minimum duration of 5 
seconds, not merely recognised, and working memory load was manipulated as a function of the 
duration of the delay phase (5 seconds vs 15 seconds).  Moreover, to prevent direct visual match or 
recognition with the encoded stimuli,  items were presented as uppercase letters (eg: A Q B J H E) 
while the probe stimuli were in lower case, a method also employed in other Sternberg-type working 
memory studies (ex. Bunge et al., 2001; Schneider-Garces et al., 2010).  The Sternberg task is seen as 
a good measure of the ability to search and maintain information in the working memory (Barch et al., 
2011) and engages more in stimulus maintenance, compared to the n-back which emphasizes 
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manipulation of information.  Modifications to the Sternberg task for fMRI compatibility have 
consistently activated regions associated with working memory maintenance such as the ventrolateral 
prefrontal and posterior parietal regions (Veltman et al., 2003; Narayanan et al., 2005), and also 
activates the DLPFC, which is thought to be involved in manipulations of information, at higher loads 
(Manoach et al., 1997).  Preliminary findings from neuroimaging studies (ex Veltman et al., 2003 and 
Narayanan et al., 2005) have also revealed that maintenance and manipulation tasks activate very 
similar distributed area of the working memory network.  In the present study, the modified Sternberg 
paradigm was used to measure working memory, as opposed to the n-back task, as it permitted the 
delineation of neural responses during encoding, maintenance and retrieval of information (see 
Narayanan et al., 2005).  In line with previous findings, it is expected that the Sternberg task used here 
would engage a network of working memory regions, such the inferior frontal and DLPFC, similar to 
what is seen with the n-back tasks.  However, large scale neuroimaging studies that compare the n-
back with the modified Sternberg task, such as the one used here, are required to examine whether 
maintenance and manipulation working memory tasks reliably engage the same network of regions.  
Novel paradigms of working memory that allow investigation of both maintenance and manipulation 
related brain activations, yet permit dissociation from other working memory processes such as 
encoding and retrieval would help understand the neuropsychological underpinnings of working 
memory impairments in depression more accurately.  Moreover, the neural correlates of another 
feature of depression, i.e. autobiographical memory impairments, whereby MDD patients show 
deficits in recalling specific personal memories,  have biased recollection of negative memories,  or 
tend to avoid or supress painful personal memories (review: Dalgleish & Werner-Seidler, 2014), have 
been hardly explored (Young et al., 2012) and calls for further investigation.  
Few cross-sectional neuroimaging studies have examined the neural correlates of working memory in 
MDD patients, including patients taking medication (ex. Harvey et al., 2005; Rose et al., 2006; Walter 
et al., 2007; Fitzgerald et al., 2008), and patients with comorbid illnesses (ex. Matsuo et al., 2007).  
fMRI investigations of group differences in neural activity revealed greater recruitment of regions 
associated with working memory in acutely depressed MDD patients relative to healthy controls.  For 
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instance, processing of working memory using n-back tasks was associated with increased activity in 
patients relative to healthy controls in the DLPFC/middle frontal gyrus (Harvey et al., 2005; Matsuo 
et al., 2007; Walter et al., 2007; Fitzgerald et al., 2008), inferior frontal gyrus (Harvey et al., 2005; 
Walsh et al., 2007; Fitzgerald et al., 2008) and temporo-parietal regions (Walsh et al., 2007; 
Fitzgerald et al., 2008).  In the anterior cingulate, however, there has been evidence of increased 
activity bilaterally in MDD patients (Fitzgerald et al., 2008), no significant mean group differences 
(Matsuo et al., 2007), as well as decreases in both groups, but with significantly greater deactivation 
in controls compared to patients in the rostral part (Rose et al., 2006).  The neurobiological 
differences between patients and controls during working memory were evident in the absence of 
behavioural differences (Harvey et al., 2005; Rose et al., 2006; Matsuo et al., 2007; Fitzgerald et al., 
2008).  These findings suggest that MDD patients show greater prefrontal engagement compared with 
healthy controls, to maintain performance on working memory tasks. 
Majority of the studies on working memory in MDD have used the n-back task (ex. Harvey et al., 
2005; Rose et al., 2006; Matsuo et al., 2007; Walsh et al., 2007; Fitzgerald et al., 2008), and relatively 
few studies have used paradigms that allow dissociation of encoding and probe related effects.  
Preliminary investigations of PET and fMRI studies have revealed encoding and retrieval related 
increases in the inferior frontal gyrus (encoding: Bremner et al., 2004; recognition: Dietsche et al., 
2014), as well as decreases in the anterior cingulate regions (encoding: Bremner et al., 2004; Kelley et 
al., 2013; retrieval: Kelley et al., 2013) in MDD patients relative to healthy controls.  There have also 
been some inconsistencies, for instance, the middle frontal gyrus has shown increases (Bremner et al., 
2004; Dietsche et al., 2014), as well as decreases (Kelley et al., 2013), while the parietal regions have 
shown both increases (Bremner et al., 2004), decreases (Werner et al., 2009) or no regional 
differences (Kelley et al., 2013) in MDD patients compared with controls during encoding.  The 
hippocampus is usually associated with memory retrieval, and studies have shown dysfunctional 
activations (Fairhall et al., 2010) in MDD patients as well as no significant group differences (Kelley 
et al., 2013; Werner et al., 2009).  The differences in the neural responses in these studies may be in 
part due to the variations in sample characteristics, neuroimaging paradigm as well as the analysis 
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methods.  For instance, Bremner et al. (2004) used PET imaging to examine functional correlates of 
working memory impairments in depression, while all other studies (ex. Werner et al., 2009; Fairhall 
et al., 2010; Kelley et al., 2013; Dietsche et al., 2014) employed fMRI methods.  Moreover, except for 
Bremner et al. (2004), all other studies included patients already on antidepressant medication 
(Werner et al., 2009; Fairhall et al., 2010; Kelley et al., 2013; Dietsche et al., 2014).  Additionally, 
Dietsche et al. (2014) and Kelley et al. (2013) also included patients with comorbid disorders.  With 
respect to paradigms, both Kelley et al. (2013) and Bremner et al. (2004) used verbal tasks, while 
Dietsche et al. (2014), Werner et al. (2009) and Fairhall et al. (2010) presented the items as faces.  
Furthermore, Kelley et al. (2013) and Fairhall et al. (2010) used a region-of-interest approach, which 
provides greater power to detect a difference compared to whole brain approaches (Costafreda et al., 
2008), but may not detect all possible neural effects. 
In order to study neural responses that are state specific from trait related features, fMRI studies have 
also investigated working memory impairments in remitted patients (Schoening et al., 2009; Kerestes 
et al., 2012; Norbury et al., 2014) and in people at familial risk for developing depression (Mannie et 
al., 2010).  Although, at-risk individuals (Mannie et al., 2010) and remitted patients (Schoening et al., 
2009; Kerestes et al., 2012; Norbury et al., 2014) did not differ from healthy controls in their 
behavioural responses on a verbal (Schoening et al., 2009; Mannie et al., 2010; Norbury et al., 2014) 
or an affective (Kerestes et al., 2012) memory task, changes in neural responses were observed.  For 
example, in response to verbal working memory, at risk individuals showed increased load-response 
activity in the lateral occipital, superior temporo-parietal regions (Mannie et al., 2010), while remitted 
patients showed increased activity in the hippocampal region (Norbury et al., 2014) and in anterior 
and posterior cingulate cortex (Schoening et al., 2009) in comparison with control subjects.  
Incorporation of an emotional distractor in a working memory task was associated with increased 
DLPFC activity in remitted patients compared to controls in response to negative stimuli, while the 
opposite effect was observed in response to positive ones (Kerestes et al., 2012).  Together, these 
findings suggest that the neural responses to working memory may be trait markers for depression that 
are present independent of task performance.   
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Treatment related changes on the neural correlates of working memory have not been widely 
examined.  Much of the research performed to date is focussed on the effects of antidepressant 
medication on affective stimuli (see meta-analysis: Delaveau et al., 2011), and the neural correlates of 
treatment on cognitive processes in MDD patients remains unclear.  In MDD patients, examination 
with PET imaging showed that antidepressant treatment was associated with increased ACC activity 
for both neutral and emotional declarative memory (Bremner et al., 2007).  Moreover, investigations 
using functional MRI revealed that lower load response activity in the ACC at baseline on a verbal 
working memory task was associated with better response to fluoxetine (Walsh et al., 2007).  The 
anterior cingulate is an important part of the limbic system, but specific subdivisions of the ACC, 
specifically the dorsal division is activated by cognitively challenging tasks such as the Stroop, 
divided-attention and many working memory tasks (Bush et al., 2000).  Increase in anterior cingulate 
activity following antidepressant treatment is perhaps indicative of improvement in cognition in MDD 
patients.  In addition to modulation in the anterior cingulate, antidepressant treatment is also 
associated with increased load response activity in the caudate and thalamus in response to verbal 
working memory (Walsh et al., 2007).  Even in healthy individuals who underwent a sad mood 
induction, immediate administration of duloxetine led to increased activity in the amygdala during 
mood incongruent memory retrieval, as well as decreased activity in the putamen, middle frontal and 
cingulate gyri during formation of congruent and incongruent memory (Tendolkar et al., 2011), 
suggesting improvement in mood congruent biases with antidepressant treatment.  Changes in neural 
activation with treatment were evident even in the absence of improvement in behavioural 
performance (Walsh et al., 2007; Tendolkar et al., 2011).   
Although evidence from cross-sectional studies show modulations in the prefrontal and anterior 
cingulate regions in MDD patients relative to controls during working memory, it is unclear whether 
such changes are evident across the different working memory processes (i.e. encoding, rehearsal and 
retrieval stages).  Moreover, the effects of antidepressants on the neural correlates of working memory 
have not been extensively studied.  Thus, based on the limited findings,  it is hypothesised that 
patients would show increased activity in the prefrontal regions, primarily the inferior frontal gyrus 
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and the middle frontal gyrus/dorsolateral prefrontal cortex in comparison to controls during encoding, 
maintenance and retrieval that normalised following antidepressant treatment.  In addition, patients 




Participants who took part in the happy and sad facial expression tasks (Chapter 3) also responded to 
the working memory paradigm, the neural correlates of which is examined in this chapter.  As 
described in Chapter 3, 30 patients with MDD and 27 healthy controls matched for age, gender and IQ 
were recruited through local newspaper advertisements.  Patients with MDD assessed with the 
Structured Clinical Interview for DSM-IV Axis I disorders (SCID-IV; First et al., 2012) met criteria 
for single or repeated episode MDD without psychotic features as defined by Diagnostic Statistical 
Manual of Mental Disorders, Fourth edition, text revision (DSM-IV-TR; American Psychiatric 
Association, 2000).  All patients had a minimum score of 18 on the 17-item Hamilton Depression 
Rating Scale (HAMD-17; Hamilton, 1960) at the time of study entry and were free of antidepressant 
medication for a minimum of 4 weeks before start of the study (6 weeks for fluoxetine).  Exclusion 
criteria were any DSM-IV-TR comorbid Axis I or II disorder including a history of substance abuse 
or dependence within the prior 6 months, excluding nicotine and caffeine; known Alzheimer’s disease 
or mental retardation; serious suicidal risk or risk of self-harm (Columbia-Suicide Severity Rating 
Scale; Posner et al., 2011); history of electroconvulsive therapy, transcranial magnetic stimulation, or 
vagus nerve stimulation within the past year; abnormal thyroid stimulating hormone concentration; or 
medical disorders known to affect central nervous system structures or function.  MDD patients were 
administered duloxetine, a serotonin norepinephrine reuptake inhibitor (60 mg once daily) for 12 
weeks.  At week 8, patients with MDD who met criteria for remission continued on 60 mg dose, while 
the others could opt for an increase in dose (up to 120 mg, once daily) (Fu et al., 2015).  
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Healthy controls with a HAMD-17 score of ≤7 at baseline were screened to ensure that they did not 
meet criteria for any psychiatric illness, neurological disorder, or heady injury resulting in a loss of 
consciousness (Fu et al., 2015).  Medical reports were acquired from the General Practitioners for all 
participants and they were extensively examined to obtain information on antidepressant use, 
medication history, concomitant medications, previous history of psychiatric illness other than major 
depressive disorder, previous treatment for depression or other psychiatric conditions, and any other 
medical or physical condition that met exclusion criteria for the study.  The study was funded by Eli 
Lilly and company and was approved by the Cambridgeshire 4 Research Ethics Committee.  The 
study was conducted in conformity with the Declaration of Helsinki and its amendments.  Functional 
MRI scans were obtained from participants at baseline (week 0), week 1, week 8 and upon study 
completion (week 12).  23 patients with MDD (13 Males, 10 Females) and 22 healthy volunteers (12 
Males, 10 Females) completed the study (Fu et al., 2015). 
4.2.2 Experimental design 
The Sternberg item recognition task was used to assess working memory in participants.  During the 
encoding phase, subjects viewed a set of six letters that was presented for duration of 3 seconds.  
Following this, a blank screen appeared (rehearsal phase) that lasted either 5 seconds (short 
maintenance) or 15 seconds (long maintenance).  The participants were then presented with a single 
letter for 2 seconds and they were required to indicate with a button press whether the target letter was 
part of the initial set of letters.  The target letter was contained in the cue letter set in 50 % of the 
trials.  There were a total of 32 trials with alternating durations of short and long maintenance 
sessions.  Each trial was followed by a rest phase lasting 5 seconds and the total duration of the task 
was 640 seconds.  The participants performed the task at baseline (week 0), week 1, week 8 and upon 
study completion (Week 12).  They were instructed to respond as accurately and quickly as possible 
and reaction time and accuracy was recorded for each trial (sample response file is available in 
Supplementary material 3; Table S3.1).   
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4.2.3 fMRI acquisition 
Gradient echo echoplanar images (EPI) were used to acquire 320 T2*-weighted image volumes 
depicting BOLD contrast on a 3 Tesla GE Signa HDx MRI scanner at the Centre for Neuroimaging 
Sciences, King’s College London.  For each volume, 39 oblique axial slices parallel to the 
intercommissural plane were collected with the following parameters: slice thickness: 3 mm, slice 
gap: 3.3 mm, echo time (TE): 30 milliseconds, repetition time (TR): 2000 milliseconds, flip angle: 
75°, field of view: 240 mm, and matrix size: 64 x64. 
4.2.4 fMRI data analysis 
Statistical Parametric Mapping (SPM8, Wellcome Department of Imaging Neuroscience, London, 
UK; Ashburner et al., 2012) was used to pre-process and analyse the task-related fMRI data using 
default settings.  The images were realigned to correct for motion artefacts, spatially normalized to the 
Montreal Neurological Institute template, and smoothed using an 8mm full-width at half maximum 
Gaussian kernel filter.  First-level analysis was performed using the general linear model, accounting 
for serial autocorrelations by applying an autoregressive model.  The images corresponding to correct 
responses were used in the first level analysis to produce contrast images relevant to the main contrast 
of interest (encoding vs rest, short rehearsal vs rest, long rehearsal vs rest, short retrieval vs rest, long 
retrieval vs rest).  Second-level analysis employed a random-effects model to examine the main effect 
of group (MDD vs HV) at baseline (week 0) and upon study completion (week 12), main effect of 
time (linear changes over weeks 0, 1, 8, 12) and the group x time interaction over the series of scans 
(linear effects).   
Functional magnetic resonance imaging studies of working memory in depression that examined 
encoding and retrieval related effects separately have used less stringent thresholds than FWE 
corrected p < 0.05.  For instance, Kelley & colleagues (2013) used a height threshold of p < 0.001 and 
extent threshold of 10 voxels to identify group differences (psychotic MDD, non-psychotic MDD and 
healthy volunteers).  A recent study on episodic memory used a threshold of p < 0.001, corrected by 
Monte Carlo cluster simulation; cluster extent threshold of 43 voxels (Dietsche et al., 2014).  Werner 
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et al. (2009) used a threshold of p FDR < 0.05, while Fairhall et al. (2010) used height threshold at p < 
0.001 and further corrected for multiple comparison at the cluster level.   
In the present study, a voxel-wise threshold corrected for multiple comparisons (p (FWE corrected) < 0.05) 
was used.  As per recent recommendations (Woo et al., 2014), additional regions that survived a 
height threshold of p uncorrected < 0.001, and further corrected for multiple comparison at the cluster 
level (cluster level p FWE < 0.05) as showing trends for significance were also reported.  A voxel-level 
uncorrected p < 0.001 was used, as lower thresholds (ex.  p < 0.01 or p < 0.005) are likely to lead to 
inaccurate FWE corrections (Woo et al., 2014). 
To my knowledge, the only other study that examined antidepressant effects on encoding and retrieval 
separately has been a PET investigation by Bremner & colleagues (2007) that compared pre-treatment 
activations in MDD patients with changes after therapy, rather than examining changes over time.  
Therefore, in the present study, in addition to examining changes in brain activation across different 
time points (i.e.  weeks 0,1, 8 and 12), a comparative analysis of baseline activations with changes 
after 12 weeks in MDD patients and in controls (paired t-test: week 0 vs week 12) was also 
performed.  Additionally, a group by time interaction from the week 0 and week 12 scans was also 
done.   
 
4.3 Results 
4.3.1 Demographic results 
Age, gender and IQ were not significantly different between patients and controls (all p > 0.4) (Table 
4.1).  Patients had significantly higher HAMD scores compared to patients (p < 0.001) which 
decreased following treatment (p < 0.05).  Upon study completion, 18 patients met criteria for a 
clinical response to treatment defined by a minimum of 50% reduction in HAMD-17 score and 16 
patients met criteria for clinical remission defined as a HAMD-17 score of 7 or less at the end of 
90 
  
treatment.  Information on other clinical characteristics of patients such as illness onset, course, and 
duration, and treatment history were unavailable. 
Table 4.1: Demographic and clinical characteristics 
Characteristic                        Patients with Depression (N=23)         Healthy Volunteers (N=22) 
                                                          Mean           SD                               Mean             SD  
 
Age (years)                                      39.83            11.21                            39.09            10.29 
Full IQ                                           107.83            10.71                           108.18           13.75 
Verbal IQ                                       110.00              9.86                           108.45           12.56 
Performance IQ                              103.17            14.43                           106.36           15.31 
HAMD (baseline)                             21.96             2.85                                0.32            1.09 
HAMD (week 12)                               6.87             4.62                                0.59            1.22 
HAMA (baseline)                             20.74             5.39                                  *                  *  
HAMA (week 12)                              7.52              4.41                                0.50            1.01 
 * HAMA not done for healthy volunteers at baseline 
 
4.3.2 Behavioural analysis 
In the immediate (5 second) recall condition, there was a main effect of time (F3, 126 = 13.83, p < 
0.001) with all participants responding faster with time.  There were no main effects of group or group 
by time interaction effects.  For accuracy, there were neither main effects of group or time nor any 
significant group by time interaction effect (Table 4.2).   
In the delayed (15 second) recall condition, there was again a main effect of time (F3, 126 = 12.90, p < 
0.001) as all participants made faster responses with time.  There were no main effects of group or 
group by time interaction effects.  For accuracy, there were neither main effects of group or time nor 









Table 4.2: Behavioural performance on the Sternberg task 
  MDD Patients   Healthy Controls 
P value 
  N=23   N=22 
Baseline  
    Immediate Recall 
    Reaction Time 1577.64 (477.18)  
1505.09 (281.75) 0.54 
Percentage Accuracy     91.88 (7.96) 
 
    89.37 (9.50) 0.34 
 
 
Delayed Recall  
  
 
 Reaction Time 1635.48 (458.90)  
1499.68 (368.51) 0.28 
Percentage Accuracy     86.55 (9.18) 
 
    82.57 (10.00) 0.17 
     Week 12 
    Immediate Recall 
    Reaction Time 1368.12 (256.58) 
 
1273.68 (166.42) 0.15 
Percentage Accuracy     88.88 (12.33) 
 
    89.75 (8.73) 0.76 
Delayed Recall  




Reaction Time 1374.88 (250.32) 
 
1327.87 (183.85) 0.47 
Percentage Accuracy     85.70 (17.27) 
 
    87.63 (10.52) 0.65 
          
 
4.3.3 fMRI results 
4.3.3.1 Encoding 
 
4.3.3.1.1 Main effect of group 
No significant main effects of group were observed at the baseline (week 0) or at the final scan (week 
12).   
4.3.3.1.2 Main effect of time 
There were no significant linear effects of time over both groups, or within each group.   
However, comparisons of baseline with final scan (week 0 vs week 12) showed main effect of time 
within each group.  In MDD patients, there was a significant reduction in activation in the right 
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precentral gyrus (x = 24, y = -16, z = 50; k = 14, T = 6.50, p(FWE corrected) = 0.009) and left middle 
temporal gyrus (BA 37) (x = -38, y = -56, z = 10; k = 6, T = 6.34, p(FWE corrected) = 0.019) after 12 weeks 
compared with baseline scan.  Additional regions showed a trend towards a decrease from weeks 0 to 
12 in regions extending from the inferior frontal gyrus, through the middle and inferior temporal, to 
the inferior parietal regions (cluster level p FWE < 0.05) (Table 4.3).   
In healthy controls, there were no significant differences in regional brain activations from weeks 0 to 
12.  A trend towards a significant reduction in activation was found in a cluster comprising of the 
cerebellar vermis (x = 6, y = -58, z = -8; k = 1007, T = 5.02, cluster level p FWE < 0.001) and 
additionally the left  parahippocampal gyrus (subordinate peak: x = -18, y = -26, z = -16; T = 4.66, 
cluster level p FWE < 0.001) and the right lingual gyrus (subordinate peak: x = 12, y = 32, z = -8; T = 
4.65 cluster level p FWE < 0.001) (Table 4.3).   
4.3.3.1.3 Interaction effects 
There were no significant linear group by time interaction effects, nor any significant group by time 
interaction effects from the week 0 and week 12 scans. 
93 
  
Table 4.3: Changes in regional brain activation in MDD patients and healthy controls at week 
12 in comparison with baseline scans 
  
  MNI coordinates 
 Voxels T  value P value Brain Region 
  x y     z       
 
MDD Patients 
   
  
 Right Precentral Gyrus  40 -18  52 564 4.04 0.005 
Left Middle Temporal Gyrus -42 -42    8 382 4.21 0.023 
Left Inferior Temporal Gyrus -60 -50 -10 557 5.95 0.005 
 
-60 -28 -14 
 
5.77 0.005 
Right Inferior Parietal Gyrus  54 -38  48 424 5.45 0.016 
Right Inferior Frontal Gyrus   44  38    6 905 5.34 0.001 
Right Middle Frontal Gyrus  34  52    4 
 
4.82 0.001 
Right Superior Frontal Gyrus  28  54  12 
 
4.46 0.001 
Left Supplementary Motor Area -12 -20  50 643 5.21 0.003 
Left Middle Cingulum -14    0  46 
 
4.56 0.003 
Left Inferior Parietal Gyrus -50 -48  44 461 4.88 0.011 
       
Healthy Controls 
      
Vermis   6 -58   -8 1007 5.02 <0.001 
Left Parahippocampal Gyrus -18 -26 -16 
 
4.66 <0.001 
Right Lingual Gyrus  12  32   -8 
 
 4.65 <0.001 
In all these regions, there was a reduction in activation at week 12 compared with baseline (all cluster p FWE 
<0.05) 
 
4.3.3.2 Short rehearsal  
 
4.3.3.2.1 Main effect of group 
There were no significant main effects of group at baseline or at the end of 12 weeks.   
4.3.3.2.2 Main effect of time 
No significant linear effects of time were observed over both groups, or within each group.  In 
addition, the comparison of baseline with week 12 activations did not show a main effect of time in 
either of the groups. 
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4.3.3.2.3 Interaction effects 
There were no significant linear group by time interaction effects, nor any significant group by time 
interaction effects from the week 0 and week 12 scans. 
4.3.3.3 Long rehearsal 
 
4.3.3.3.1 Main effect of group 
No significant main effects of group were observed at baseline.  At week 12, however, patients 
showed significant reduction compared to controls in the left inferior frontal gyrus (x = -48, y = 12, z 
= 26; k = 8, T = 5.08, p(FWE corrected) = 0.027) (Figure 4.1). 
Figure 4.1:  Main effect of group at week 12 during long rehearsal 
 
Patients showed significant reduction at week 12 in the left inferior frontal gyrus relative to controls (p(FWE 
corrected) < 0.05) 
 
4.3.3.3.2 Main effect of time 
No linear effects of time were observed over both groups, or within each group.  Comparison of 
baseline with week 12 scans did not reveal a main effect of time in patients.  However, in controls, 
there was a trend for decrease at week 12 compared to baseline in the cerebellum (x = 8, y = -48, z = -
12; k = 296, T = 4.82, cluster level p FWE = 0.047) and cerebellar vermis (x = 4, y = -54, z = -8; k = 
296, T = 4.94, cluster level p FWE = 0.047). 
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4.3.3.3.3 Interaction effects 
No significant linear effects of time over both groups, or within each group were observed.  However, 
comparison of baseline with week 12 scans revealed a significant group by time interaction, such that 
there was a tendency for reductions in brain activations at week 12 relative to week 0 in controls in 
the bilateral caudate, left middle frontal gyrus, middle temporal gyrus, right mid cingulate gyrus, 
superior temporal pole and vermis, while no change was observed in patients (Table 4.4, Figure 4.2, 
Supplementary material 3, Table S3.2, Figure S3.1).  There was also a group by time interaction in the 
left superior temporal gyrus, and this effect was due to patients showing a tendency for decreased 
activation in the final scan.   
 
Table 4.4:  Group by time interaction during long rehearsal  
  
        MNI coordinates 
 Voxels T  value P value Brain Region 
  x        y     z       
    
  
 Left Middle Frontal Gyrus -20 46 16 50 5.35 0.001 
Right Middle Cingulum 10 -26 34 40 5.31 0.001 
Left Superior Temporal Gyrus -58 -50 -12 28 5.19 0.002 
 
-58 -40 18 1 4.51 0.041 
Right Superior Temporal Pole 46 16 -22 136 5.7 <0.001 
 
50 10 -18 
 
5.48 0.001 
Left Middle Temporal Gyrus -48 -2 -14 66 5.15 0.003 
Right Caudate 8 0 12 202 5.58 0.001 
Left Caudate -8 -4 18 83 5.42 0.001 
Right Thalamus 12 -22 10 12 4.59 0.03 
 
16 -28 6 
 
4.57 0.032 
Vermis 4 -52 -8 40 5.06 0.004 








 Figure 4.2: Group by time interaction during long rehearsal 
  
  (a)   Regions showing group by time interaction effect (p(FWE corrected) < 0.05) 
 
 
(b)  The graphs represent group by time interaction in the bilateral caudate, cerebellar vermis, and the right 
superior temporal pole.  Effect sizes (β-weights) for the group by time interaction in the right caudate (x,y,z,= 
8,0,12; p(FWE corrected)  = 0.001), left caudate (x,y,z, = -8,-4,18; p(FWE corrected)  = 0.001), vermis (x,y,z,= 4, -52, -8; 
p(FWE corrected) = 0.004) and right superior temporal pole (x,y,z = 46,16, -22; p(FWE corrected) < 0.001). 
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4.3.3.4 Short retrieval 
 
4.3.3.4.1 Main effect of group 
There were no main effects of group neither at baseline, nor at week 12 following treatment with 
duloxetine. 
4.3.3.4.2 Main effect of time 
No significant linear effects of time over both groups, or within each group were observed.  However, 
comparison of baseline scans with final week 12 scan revealed significant reduction in MDD patients 
in the left inferior parietal gyrus (x = -34, y = -32, z = 40; k = 1, t = 5.98, p(FWE corrected) = 0.038) (Figure 
4.3) and a trend for significance in the left postcentral gyrus (x = -32, y = -24, z = 46; k = 580, t=5.17, 
cluster level p FWE = 0.005) at week 12 relative to baseline.  In healthy controls, the right insula (x = 
42, y = 6, z = -10; k = 1, t = 6.43, p(FWE corrected) = 0.035) and the right inferior frontal gyrus (x = 50, y = 
28, z = -4; k = 2, t = 6.75, p(FWE corrected) = 0.028) showed significant reduction at week 12 compared to 
week 0 scans. 
Figure 4.3:  Pre-treatment vs post-treatment differences in MDD during short retrieval 
 
Patients showed significant reduction in the left inferior parietal gyrus at week 12 relative to baseline (p(FWE 
corrected)  < 0.05) 
 
4.3.3.4.3 Interaction effects 
There were neither linear group by time interaction effects, nor any significant interaction effects from 




4.3.3.5 Long retrieval 
 
4.3.3.5.1 Main effect of group 
No significant main effects of group were observed at the baseline or at the final scan.   
4.3.3.5.2 Main effect of time 
No significant linear effects of time were observed for both groups or within each group over the 
series of scans.  In MDD patients, there was a significant reduction at week 12 compared with 
baseline in the right precentral gyrus (x = 40, y = 4, z = 52; k = 3, t = 6.22, p(FWE corrected) = 0.029) and 
the cerebellum (x = 32, y = -44, z = -32; k = 4, t = 6.17, p(FWE corrected) = 0.025).  Additional regions 
showed a trend towards a decrease from weeks 0 to 12 in regions extending from the inferior and 
superior frontal gyri, to the middle temporal and occipital regions (Table 4.5).  No regions in controls 
showed a significant change at the final scan compared with baseline scan. 
Table 4.5: Changes in regional brain activations during long retrieval in MDD patients at week 
12 in comparison with baseline scans. 
  
        MNI coordinates 
 Voxels T  value P value Brain Region 
  x y z       
    
  
 Right Middle Temporal Gyrus 48 -58 14 3173 4.36 <0.001 
Left Middle Occipital Gyrus -34 -72 24 446 3.53 0.017 
 
-30 -72 32 
 
3.35 0.017 
Left Mid Cingulum -8 -2 48 1401 3.92 <0.001 
Left Superior Frontal Gyrus -22 -8 54 
 
3.88 <0.001 
Left Inferior Frontal Gyrus -34 -36 44   3.79 <0.001 
In all these regions, patients showed reduction in activation after 12 weeks of treatment compared to baseline 
(all cluster p FWE < 0.05) 
 
4.3.3.5.3 Interaction effects 
There were no significant linear group by time interaction effects, or any significant group by time 
interaction effects from the week 0 and week 12 scans. 
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4.4 Discussion  
The study examined the behavioural responses and the neural correlates of working memory in 
acutely depressed MDD patients and following 12 weeks of treatment with a dual acting serotonin 
norepinephrine reuptake inhibitor, Duloxetine.   
4.4.1 Behavioural results 
The behavioural responses did not reveal any significant difference between the groups in working 
memory, consistent with findings from previous studies using the n-back (Harvey et al., 2005; Rose et 
al., 2006; Matsuo et al., 2007) and Sternberg (Siegle et al., 2002) tasks.  Moreover, a study that 
examined various cognitive functions in MDD patients revealed no marked decline in patients during 
immediate, implicit, semantic, and recognition memory (Ilsley et al., 1995).  In fact, a meta-analysis 
of first-episode MDD patients did not find significant impairments in verbal memory in patients 
relative to healthy controls (effect size =0.13, p=0.40) (Lee et al., 2012).  Memory impairments may 
be more likely in severely depressed patients who need hospitalization (ex. Sternberg et al., 1976), or 
those with comorbid illnesses such as anxiety (Kizilbash et al., 2002; DeLuca et al., 2005).  The 
sample used in this study comprises patients with a less severe form of depression without psychiatric 
comorbidity, and are representative of patients found in the community.  Memory impairments in 
depression are also more evident in response to cognitively challenging tasks.  For instance, 
performance inaccuracies were more likely in MDD patients when the memory load on the working 
memory task was high (ex. Vasic et al., 2009), a distractor element was introduced in the task (ex. 
Porter et al., 2003), or when the task required recognition of a previously encoded stimuli from a 
group of very similar stimuli after a delayed period (ex. Porter et al., 2003).  It is likely that MDD 
patients in the current study sample may show impairments in working memory if they are assigned a 




4.4.2 fMRI results 
4.4.2.1 Encoding 
 
The neural correlates did not reveal any significant group differences at baseline or upon study 
completion, any linear group by time interaction effects or any other interaction effects from the week 
0 and week 12 scans.  However, MDD patients showed a significant reduction in activations in the 
precentral gyrus and the middle temporal gyrus at week 12 relative to baseline scans.  Additionally, 
the right prefrontal regions, left inferior temporal, cingulate regions and the bilateral inferior parietal 
gyrus showed a trend for reduction after 12 weeks.  The precentral gyrus is associated with motor 
control (Sanes et al., 1995) and engaged by both working memory and visuospatial attention tasks 
(LaBar et al., 1999).  In healthy controls, precentral gyrus (specifically Brodmann area 6) activations 
are seen in response to both non-verbal and verbal encoding (Kelley et al., 1998; Wagner et al., 1998).  
The middle temporal gyrus is also involved in the encoding of words (Anderson et al., 2000; Jackson 
& Schacter, 2004) and activation in this region during encoding is associated with successful 
recognition (Jackson & Schacter, 2004).  Comparison of MDD patients and controls in tasks of 
working memory showed increased activations in the precentral gyrus (Harvey et al., 2005) and 
decreased activations in the middle temporal gyrus (Werner et al., 2009) in patients.  In the present 
study, there were no significant baseline differences in neural activations between the groups. 
However, the results of the present study are consistent with previous PET findings that showed 
reductions in MDD patients after treatment in the middle/superior frontal, inferior temporal gyrus, and 
parietal regions during encoding (Bremner et al., 2007).  Although the findings from this study only 
showed a trend for significance in these regions, variation in the functional imaging technique 
employed and the use of what may be perceived as a more liberal threshold (p < 0.005 with extent 
threshold of 40 voxels) in Bremner et al. (2007) may have contributed to some of the differences in 
effect size.  The decreased engagement of the prefrontal and parietal areas after duloxetine treatment 
in MDD patients in the present study may indicate less reliance on these regions during working 





The neural correlates did not reveal any group by time interaction effects or main effects of group or 
time for the short rehearsal phase.  However, a significant interaction effect during the long rehearsal 
phase in the left superior temporal gyrus was observed, and this effect was due to patients showing a 
tendency for decreased activation with time.  Additional group by time interaction effects in a 
network of regions extending from the middle frontal, caudate/thalamus, mid cingulate, down to the 
superior temporal pole and the cerebellar vermis were also observed.  In healthy controls, there was a 
tendency for reductions in activations in these regions from week 0 to week 12, while no change was 
observed in patients.  The neural correlates of n-back working memory in healthy controls constitute a 
network of regions comprising the dorsal cingulate, medial and inferior frontal regions, premotor 
cortex, frontal poles and posterior parietal regions (Owen et al., 2005).  The present study found 
significant group by time interaction within this network.  Walsh et al. (2007) also found a group by 
time interaction in the caudate and thalamus with fluoxetine in response to a verbal working memory 
task, whereby controls showed a decrease in activation with time, while the opposite effect was seen 
in patients.  In the current study, tendency for decreased activations in controls in the follow up scan 
is perhaps indicative of less recruitment of these regions with increased familiarity with the task, 
while no change in activation in patients may reflect persistent recruitment of regions associated with 
working memory to maintain task performance. 
The results in the present study must be considered preliminary and further investigations with a 
larger sample size are required to confirm obtained findings.  Previous longitudinal studies in 
depression have predominantly used affective stimuli (see meta-analysis Delaveau et al., 2011; Ma, 
2015) and only few imaging studies have examined treatment effects on the neural correlates of 
working memory (ex. Bremner et al., 2007; Walsh et al., 2007).  These studies have either not 
examined the effects of treatment on maintenance related activations (Bremner et al., 2007) or used 
the n-back task that did not permit delineation of maintenance related brain activations from encoding 
or retrieval related activations (Walsh et al., 2007).   
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In addition to examining changes in regional brain activations in MDD patients with treatment, neural 
changes in healthy volunteers were also examined to account for effects of time or effects of repeated 
scans.  In healthy controls, both the encoding and the long maintenance phase showed a trend towards 
reduction in the cerebellum at week 12 compared with baseline trial.  Cerebellum is frequently 
engaged by working memory tasks, learning and reading paradigms, as well as other tasks of 
executive function (Stoodley, 2012).  In healthy controls, practice induced deactivation in the 
cerebellum is evident in tasks of visual attention (Tomasi et al., 2004) verbal production (Peterson et 
al., 1998) and non-motor learning (Raichle et al., 1994).  Previous research has shown main effects of 
time in the cerebellum, with decreased activation in MDD patients and controls in response to sad (Fu 
et al., 2004, Fu et al., 2008a) and happy (Fu et al., 2007) facial processing, and verbal working 
memory (Walsh et al., 2007).  The reduction in cerebellum activations after 12 weeks in the present 
study perhaps reflects effects of repeated scanning in healthy volunteers. 
4.4.2.3 Retrieval 
 
The findings did not reveal any significant linear group by time interaction effects or any group by 
time interaction effects from the week 0 and week 12 scans during the short and long retrieval phases.  
The main effect of group also failed to showed significant differences either at baseline or upon study 
completion during the retrieval phases.  
Retrieval related activations are usually associated with ventrolateral prefrontal regions (Narayanan et 
al., 2005; meta-analysis: Cona et al., 2015).  However, brain activation specifically associated with 
retrieval in MDD patients has been examined in very few fMRI studies (ex. Werner et al., 2009; 
Kelley et al., 2013; Dietsche et al., 2014).  Findings from these studies however have been 
inconsistent, with evidence of retrieval related increases in the inferior frontal gyrus (Dietsche et al., 
2014), and in superior frontal gyrus (Werner et al., 2009), as well as decreases in the anterior 
cingulate gyrus (Werner et al., 2009; Kelley et al., 2013) in MDD patients relative to controls.  The 
differences in the brain activations may reflect variations in the fMRI paradigms used in these studies.  
For instance, Dietsche et al. (2014) and Werner et al. (2009) presented items as faces.  The former 
study used neutral faces, while the latter used a face-profession task that was not limited to neural 
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faces.  Kelley et al. (2013) on the other hand used a verbal declarative memory task, although 
different from the task used here.  In this study, each trial was associated with an encoding, rehearsal 
and retrieval stage, unlike Kelley et al. (2013) where encoding and retrieval tasks were individual 
scans, separated by a five minute scan to minimise the possibility of rehearsal (Kelley et al., 2013).   
 The  neural effects of antidepressants on retrieval or recognition have been previously examined in 
healthy volunteers (ex. Miskowiak et al., 2007; Norbury et al., 2008; Tendolkar et al., 2011) and less 
extensively in MDD patients (ex. Bremner et al., 2007).  Decreased activations in the precentral gryus 
and cerebellum following treatment were observed in the present study, and additional trends in the 
middle temporal gyrus, inferior and superior frontal gyrus and the mid cingulate gyrus during the long 
retrieval stage.  Interestingly, decreased baseline activations in all these regions during verbal working 
memory were associated with better clinical response (Walsh et al., 2007).  Decreases in mid 
cingulate activations reported in this study were also evident in healthy controls after seven days of 
treatment with reboxetine (Norbury et al., 2008).  Acute or short term antidepressant treatment in 
healthy controls were also associated with increases in the amygdala during mood-incongruent 
memory retrieval (Tendolkar et al., 2011) as well as decreases in the fronto-parietal network during 
successful recognition of positive personality-trait words (Miskowiak et al., 2007; Norbury et al., 
2008).  In MDD patients, consistent with results from the present study, PET investigations found 
retrieval related decreases after SSRI treatment in the superior frontal gyrus (Bremner et al., 2007).  
There were also some inconsistencies, for instance, the inferior frontal gyrus showed decreases with 
treatment in the present study, while the opposite effect was observed in Bremner et al. (2007).  It is 
important note that unlike the present study, previous studies (Bremner et al., 2007; Miskowiak et al., 
2007; Norbury et al., 2008; Tendolkar et al., 2011) used affective paradigms, and processing of 
affective material may be associated with distinct neural correlates (Bourke et al., 2010).  Moreover, 
Tendolkar et al. (2011) used an initial height threshold of p < 0.005 and according to a recent study, 
lowering thresholds beyond p < 0.001, may lead to incorrect FWER corrections and are undesirable in 
neuroimaging research (Woo et al., 2014).  Future investigations on the effects of antidepressants on 




Limitations of the present study include the small sample size, which may have led to insufficient 
power to detect all group differences at the neural level.  Also, the high response rate in this study 
limited the power to detect differences between treatment responders and patients with a more 
treatment resistant form of depression, which may be associated with distinct neural correlates (Fu et 
al., 2008a).  Finally, the absence of a treatment group receiving placebo limits our attribution of 
effects to the antidepressant medication as opposed to changes associated with clinical improvement, 
although the potential effects of time were accounted for by having HV participants undergo scans at 
the same time points as MDD patients.   
In summary, the functional neuroimaging correlates failed to show any baseline group differences or 
group by time interaction effects during the encoding and retrieval phases of working memory.  There 
was however a significant group by time interaction during the long rehearsal phase, such that there 
was a tendency for reductions in brain activations at week 12 relative to week 0 in controls in a 
network of brain areas extending from the prefrontal, to the cingulate, temporal and cerebellar 
regions, while no change was observed in patients.  The tendency for decreased activations in controls 
in the follow up scan is perhaps indicative of less recruitment of these regions with increased 
familiarity with the task, while no change in activation in patients may reflect persistent recruitment 
of regions associated with working memory to maintain task performance.  Further placebo-controlled 
investigations with larger sample are required to confirm the present findings and delineate 























5 Diagnostic and prognostic potential of structural neuroimaging 














At the present time, the diagnosis of MDD is determined by clinical signs and symptoms, and there 
are no biological measures for the diagnosis.  Neuroimaging offers the potential to develop 
biomarkers for diagnosis as well as in the prediction of clinical response and course of illness (Fu & 
Costafreda, 2013). 
Structural neuroimaging studies of MDD have revealed widespread cortico-limbic regional deficits in 
grey matter (reviewed in: Atkinson et al., 2014) as well as in white matter (Korgaonkar et al., 2011; 
Cole et al., 2012).  There is evidence that some regional atrophy in the hippocampus may already be 
present in the first episode of MDD (Cole et al., 2011) and may worsen with recurrent episodes, in 
particular in patients with a more treatment-resistant form of MDD (MacQueen & Frodl, 2011), 
although an earlier study found no significant difference in hippocampal volume between controls and 
patients with early onset depression (Lloyd et al., 2004).  In order for a potential clinical application, it 
is important that biological markers be established with high predictive accuracy at the individual 
level.  Methods of analysis, for instance, those based on machine learning algorithms such as Support 
Vector Machine (SVM) provide an opportunity to develop classification measures which may be 
applied to an individual subject (Fu et al., 2008b). 
Multivariate pattern analysis using SVM has demonstrated the potential of structural neuroanatomy in 
classifying MDD.  For example, one of the earliest studies performed on 37 MDD patients and an 
equal number of healthy controls revealed that grey matter volume could distinguish acutely 
depressed patients from healthy controls with an accuracy of 67.6% (Costafreda et al., 2009b).  Since 
then, different pattern classification techniques have investigated the predictive power of grey matter 
volume in the diagnosis of MDD (Table 5.1) using first episode (Qiu et al., 2014) treatment-naïve 
MDD patients (Liu et al., 2012; Qiu et al., 2014), medication free MDD patients in an acute 
depressive episode (Costafreda et al., 2009b), MDD patients on antidepressant medication (Mwangi et 
al., 2012) and psychotic MDD patients (Serpa et al., 2014).  Furthermore, as MDD patients show a 
substantial variation in how they respond to treatment, and because non-response to pharmacotherapy 
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may represent a more chronic form of the disorder, predictors of illness have been studied in treatment 
sensitive and treatment resistant patients separately.  For instance, Gong & colleagues (2011) found 
that grey matter volume was better at discriminating treatment sensitive (76.09 %, p < 0.001) when 
compared to treatment resistant (67.39 %, p < 0.01) MDD patients from healthy volunteers, whilst a 
newer study based on a slightly smaller size revealed similar accuracy rates (82.4 %  and 85.7 % 
respectively) (Liu et al., 2012).  Grey matter regions of the frontal temporal, parietal, occipital regions 
(Costafreda et al., 2009b; Gong et al., 2011; Liu et al., 2012), including the superior frontal, angular 
and middle temporal gyri (Gong et al., 2011; Liu et al., 2012), and cerebellum (Costafreda et al., 
2009b; Liu et al., 2012),  have consistently showed potential for diagnosis prediction.  Although 
studies typically investigated regional volumetric features in MDD patients, geometric features, such 
as Jacobian metric distortion also showed potential for diagnosis (Qiu et al., 2014).   
Building on evidence from structural MRI (Janssen et al., 2007; Amico et al., 2011) and Diffusor 
Tensor Imaging (DTI) (Li et al., 2007; Kieseppa et al., 2010; Korgaonkar et al., 2011; Cole et al., 
2012) data suggesting white matter abnormalities in acutely depressed patients, studies have sought to 
investigate the predictive potential of white matter volume in the diagnosis of MDD (Table 5.1).  It 
has been proposed that the structural and functional cortical grey matter changes in depression may be 
communicated through underlying subcortical white matter changes (Korgaonkar et al., 2011).  
Alterations in white matter integrity is evident in depression (Cole et al., 2012), including in the first 
episode of MDD (Zhu et al., 2011) and in adolescents with familial risk, even before they manifest 
any clinical symptoms of the illness (Huang et al., 2011).  White matter distinguished treatment 
sensitive patients from healthy controls with an accuracy of 84.65 % (Gong et al., 2011) and 91.2 % 
(Liu et al., 2012), which was better than that with grey matter (76.09 % and 82.4 % respectively).  
These findings outline the underlying neural mechanisms associated with the pathophysiology of 
depression and suggest the need to investigate multiple neuroanatomical features in classification.   
In addition, investigation of biological markers of clinical response in MDD has been of particular 
interest (Table 5.2) as they help optimize treatment strategies at an early stage especially for those 
patients who are less likely to benefit from the usual first line treatment options.  Using neuroimaging 
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measures, it has been possible to identify markers of prognosis even before the initiation of treatment 
or early in the course of treatment (Fu et al., 2013).  Notably, grey matter density predicted response 
to antidepressants (Costafreda et al., 2009b: 88.9 %; Gong et al., 2011: 69.57 %; Liu et al., 2012: 82.9 
%) better than to cognitive behavioural therapy (Costafreda et al., 2009b: non-significant finding).  
Additionally, a study that employed feature selection and feature based morphometry to the 
classification algorithm obtained a prognostic accuracy as high as 90 % with antidepressants (Mwangi 
et al., 2012).  One of the most widely replicated biomarker of clinical response is the anterior 
cingulate, which has been reported across different structural (Costafreda et al., 2009b; Liu et al., 
2012) and functional (see meta-analysis: Fu et al., 2013) neuroimaging studies.   
However, these studies that examined the potential of structural data to predict diagnosis and 
prognosis have several limitations: homogenous ethnic group (Chinese: Gong et al., 2011; Liu et al., 
2012; Qiu et al., 2014; Caucasian: Costafreda et al., 2009b; Mwangi et al., 2012) limiting the 
generalizability of the findings to other races; restriction to treatment-naïve MDD patients (Liu et al., 
2012; Qiu et al., 2014) reducing the translational value of the results in patients with a more chronic 
form of the disorder, inclusion of medicated MDD patients (Mwangi et al., 2012) eliciting 
confounding drug effects on brain structure, heterogeneous antidepressant treatment (Gong et 
al.,2011; Liu et al., 2012) and inclusion of grey matter only (Costafreda et al., 2009b).  These 
limitations have been addressed in the present study by including medication-free patients of white, 
Asian and African descent, incorporating both first episode MDD patients as well as those at a later 
stage of the disorder, administering a stable dose of a single drug duloxetine belonging to the SNRI 
class and investigating the potential of both grey and white matter in predicting diagnosis and 
prognosis.   
The present study examined whether MDD patients could be distinguished from healthy controls 
based on their structural neuroanatomy using SVM.  In addition to examining grey and white matter 
volumes individually, a combined analysis of both features was also performed to examine its 
influence on accuracy rates.  In line with previous findings (Costafreda et al., 2009b; Gong et al., 
2011; Liu et al., 2012), it is hypothesized the structural correlates of prefrontal, parietal and temporo-
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occipital regions to show significant predictive power for diagnosis.  Consistent with the literature, it 
is also expected that white matter would show higher predictive accuracy than grey matter.    
 The potential of grey matter and white matter to predict clinical remission with duloxetine was also 
investigated.  To my knowledge, this is the first study that has examined the potential of structural 
data to predict prognosis with duloxetine, as previous studies used SSRIs (Costafreda et al., 2009b) 
and non-specific antidepressants (Gong et al., 2011; Liu et al., 2012).  It is expected that the anterior 














This study was funded by Eli Lilly and company, and approved by the Cambridgeshire 4 Research 
Ethics Committee.  The study was conducted in conformity with the Declaration of Helsinki and its 
amendments.  
The structural data was obtained from the same participants who took part in the longitudinal study 
that examined the effects of duloxetine on the functional correlates of depression (Chapters 3 & 4).  
All participants were right-handed adults who provided informed written consent (Fu et al., 2015).  
Participants were patients with major depressive disorder (n = 23) and healthy controls (n = 20) 
matched for age, gender and IQ (all p > 0.3) (Table 5.3).  A diagnosis of MDD, single or repeated 
episode without psychotic features, was made as defined by Diagnostic Statistical Manual of Mental 
Disorders, Fourth edition, text revision (DSM-IV-TR; American Psychiatric Association, 2000) and 
assessed with the Structured Clinical Interview for DSM-IV Axis I disorders (SCID-IV; First et al., 
2012) without any comorbid disorders.  All MDD patients had a minimum score of 18 on the 17-
item Hamilton Depression Rating Scale (HAMD-17) (Hamilton, 1960) at the time of study entry 
and were free of antidepressant medication for a minimum of 4 weeks before start of the study (or 6 
weeks for fluoxetine).  Medical reports were acquired from the General Practitioners for all 
participants and they were extensively examined to obtain information on antidepressant use, 
medication history, concomitant medications, and previous history of psychiatric illness other than 
major depressive disorder, previous treatment for depression or other psychiatric conditions, and 
any other medical or physical condition that met exclusion criteria for the study.  Healthy controls 
had no history of psychiatric disorders, interviewed with SCID-IV (First et al., 2012), and had a 
HAMD score of ≤ 7.  MDD patients received treatment with the serotonin norepinephrine reuptake 
inhibitor class of antidepressant, duloxetine, following the initial neuroimaging scan starting at a 
dosage of 60 mg once daily for 12 weeks.  As expected, patients had significantly higher HAMD 
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scores at baseline (p < 0.001), which improved following treatment (p < 0.001).  Upon study 
completion, 18 MDD patients met criteria for a clinical response, as defined by > 50 % reduction in 
HAMD score, and 16 MDD patients met criteria for clinical remission, as defined by a HAMD-17 
score of ≤ 7.  Information on other clinical characteristics of patients such as illness onset, course, 
and duration, and treatment history were unavailable.  
Table 5.3: Demographic and clinical characteristics 
 
 
Mean values and standard deviations are presented in parentheses. Age is presented in years.   
 
Neuroimaging scans were acquired at baseline (week 0), weeks 1, 8 and upon study completion 
(week 12).  Baseline scans were obtained from 29 MDD patients and 22 healthy controls and 
structural neuroimaging data are presented from the baseline scan.  Data from 2 healthy volunteers 
had to be excluded due to excessive moment during the structural scan.  Since, the use of SVM 
requires approximately equal number of participants, data from the participants who completed the 
study (i.e. 23 MDD and 20 HV) were used.  Of these, 18 patients responded to treatment and 16 
patients achieved full clinical remission at the end of treatment. 
 
 
MDD Patients Healthy Controls P value 
Number 23 20 
 
Age  39.8 (11.2) 38.8 (9.9) 0.84 
Male, n (%) 13 (56.5) 12 (60.0) 0.82 
Baseline 
   
HAMD  22.0 (2.9) 0.5 (1.1) <0.001 
HAMA  20.7 (5.4) n/a 
 
Week 12 
   
HAMD 6.9 (4.6) 0.6 (1.3) <0.001 
HAMA  7.5 (4.4) 0.6 (1.1) <0.001 
Full IQ  107.8 (10.7) 109.2 (14.6) 0.63 
Performance IQ 103.2 (14.4) 107.9 (15.2) 0.30 
Verbal IQ  110.0 (9.9) 109.8 (12.4) 0.95 
114 
  
5.2.2 Data acquisition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Structural MRI scans were acquired on a 3.0 T GE SIGNA HDx (Milwaukee, USA) at King’s 
College London.  A structural image was acquired at each session: Magnetization Prepared 
Gradient Echo, resolution 1mm3, acquisition parameters: TE: 30 ms, flip angle: 90°, slice thickness: 
3 mm, interslice gap: 0.3 mm, number of slices, matrix size: 64 x 64. 
5.2.3 Image preprocessing 
Pre-processing of the structural MRI T1 weight images included bias correction, skull stripping and 
tissue segmentation.  Bias correction was performed using N41TK, which is an improved MNI_N3 
bias correction software package available at: http://www.insight-
journal.org/browse/publication/640package.  Skull stripping was completed using Multi- Atlas 
Skull Stripping software (MASS, version 1.0), which is based on a multi-atlas registration 
framework and uses a set of templates from the study data set which best represent the anatomical 
variations (Doshi et al., 2013).  The images were then segmented into grey matter (GM), white 
matter (WM) and cerebrospinal fluid (CSF) using the automated algorithm Multiplicative Intrinsic 
Component Optimization (MICO) (Li et al., 2014).  The quality of the processed images was 
ensured by automated quality control measures and manual review. 
Spatial registration of all the skull stripped images to the Jakob template was performed using the 
Deformable Registration via Attribute Matching and Mutual-saliencing Matching registration 
package (DRAMMS, version 1.1.0) (Ou et al., 2011).  The deformation field from the resulting 
registration was used to obtain the Regional Analysis of Volumes Examined in Normalized Space 
(RAVENS) maps or regional volumetric maps for grey matter, white matter and cerebrospinal fluid.  
The maps were corrected for individual intracranial volume, down sampled to 2x2x2 mm, and 
smoothed using an 8mm full width at half maximum (FWHM) Gaussian filter.  
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5.2.4 Analysis of structural neuroanatomy: grey and white matter  
Regional differences in grey and white matter between MDD patients and healthy controls were 
performed using the Optimally Discriminative Voxel Based Analysis (ODVBA, version 2.0) 
software package (Zhang & Davatzikos, 2011) using the RAVENS maps.  In the ODVBA 
approach, the optimal size and shape of the spatial smoothing is estimated from the data set prior to 
the statistical analysis.  ODVBA applies a form of matched filtering using machine learning 
techniques to optimally detect group differences.  It uses a spatially adaptive scheme which is 
designed to detect group differences with maximum sensitivity (Zhang & Davatzikos, 2011) and to 
improve identification of group differences (Zhang & Davatzikos, 2013).  Finally, the statistical 
significances are obtained by using permutation tests.  In the present study, 2,000 permutations 
were used to derive the significances, and significance was assigned as p (uncorrected) < 0.001 due 
to the relatively small sample size.  ODVBA has shown greater sensitivity to detect subtle structural 
abnormities and improved delineation of the region of abnormality as compared to conventional 
GLM methods (Zhang & Davatzikos, 2011; 2013) in numerous clinical studies (Chaim et al., 2014; 
Erus et al., 2015; Zhang et al., 2015). 
5.2.5 Classification using support vector machine 
The grey matter and white matter RAVENS maps were concatenated into a single feature vector for 
each subject.  Classification was then performed using SVM (Vapnik & Cortes, 1995), a 
multivariate classification technique that can optimally use high dimensional information such as 
neuroimaging data (Fu et al., 2008b; Costafreda et al., 2009b).  SVM identifies the optimal linear 
decision boundary, or hyperplane, that has the maximum margin separating the two training groups 
(in the present study: MDD patients and healthy controls; MDD remission and MDD non-
remission).  SVM treats individual images as points located in high dimensional space.  In SVM, 
both the hyperplane as well as the margin are important in classification accuracy, and usually the 
wider the margin the better the classification accuracy (Gaonkar et al., 2015).   
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SVM also extracts weight vectors as images, known as SVM discrimination maps, which represent 
the direction in which the two groups differs the most; however, these maps do not specify the 
statistical significance associated with the voxel or region (Gaonkar & Davatzikos, 2013).  In order 
to sufficiently explore the small p-value regime, it would be necessary to perform millions of 
permutation tests which require tremendous computational overhead in terms of data storage and 
time.  Instead, the necessary p-values may be estimated using analytical permutation testing 
(Gaonkar & Davatzikos, 2013).  An advanced version of the approximation which accounted for the 
SVM margins in addition to the SVM weights was used in this study (Gaonkar et al., 2015).  The 
SVM analysis was performed using five-fold cross validation strategy.   
The classification scores derived from the SVM analysis was evaluated using a receiver operating 
characteristic (ROC) curve to illustrate the diagnostic accuracy of the classifier.  The ROC curve 
was obtained by plotting the true positive rates (y axis: corresponding to sensitivity values) against 
false positive rates (x axis: corresponding to 1-specificity values) using individual z scores 
generated by the SVM classifier (Metz et al., 2006).  The area under the curve (AUC) was 
calculated from the ROC curve, which is a measure of the discriminative power of the classifier and 
is independent of the chosen p value or sample size. 
5.2.6 Classification using COMPARE analysis 
The grey and white matter RAVENS maps were also analysed using the SVM-based classification 
technique Classification of Morphological Patterns using Adaptive Regional Elements 
(COMPARE) (Fan et al., 2007).  The first step in this method is feature selection wherein regions 
that show high correlation between RAVENS maps and participant groups are extracted using a 
watershed algorithm.  A further volume-increment algorithm is then applied to these regions to 
extract regional volumetric features, from which a feature selection method based on SVM 
classification criteria is used to identify the most relevant features for classification (Fan et al., 
2007).  The feature selection procedure produces a small number of volumetric measurements for 
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more effective classification.  The SVM classification technique with the most distinguishing 
features is then used to predict group differences using the leave one out cross validation strategy 
(Fan et al., 2007).   
 
5.3 Results  
5.3.1 Structural neuroanatomy (ODVBA analysis) 
In grey matter density, reductions were revealed in the right superior frontal and superior temporal 
regions in MDD patients relative to healthy controls (p < 0.001, uncorrected) (Table 5.4, Figure 
5.1).  In white matter density, reductions were also evident in the right postcentral, superior parietal, 
middle temporal and left inferior occipital regions in MDD patients relative to healthy controls (p < 
0.001, uncorrected) (Table 5.4, Figure 5.1).   
Figure 5.1:  Grey and white matter regions showing atrophy in MDD relative to controls 
 
Grey matter regions showing atrophy in MDD patients relative to healthy controls.  (b) White matter regions 
showing atrophy in MDD patients relative to healthy controls.  Green indicates significant regions at p 
<0.001, uncorrected.  The area of hot colour (threshold p < 0.05) indicates the trend towards significance 






Table 5.4:  Regions showing atrophy in MDD patients relative to healthy controls 
Anatomical Region Mass size Talairach Coordinates 
 
  x y z 
Grey Matter 
 
Right superior frontal  74 17.82 31.54 48.16 
Right superior medial frontal  14 11.88 31.73 51.83 




Right superior parietal  212 21.78 -57.30 58.13 
Right middle temporal  46 49.50 -51.57 17.31 
Right postcentral  14 25.74 -41.80 57.36 
Left inferior occipital  10 -37.62 -75.81 -1.25 
There were no regions which showed greater volume in MDD patients relative to controls 
 
5.3.2 Diagnostic and prognostic classification using SVM  
For diagnosis, the combination of grey and white matter density was able to correctly identify 78.3 
% of MDD patients (sensitivity: 18 of 23 patients) and 55.0 % of healthy controls (specificity: 11 of 
20 healthy controls) for an overall accuracy of 67.4 % (AUC = 0.73, p = 0.02) (Figure 5.2).  Based 
on grey matter only, the accuracy of diagnosis was 60.47 %, but this did not reach statistical 
significance (AUC = 0.55, p = 0.2), while with white matter density alone, the accuracy was 65.1 % 
(AUC = 0.73, p = 0.05).  Several white matter regions in the superior and medial frontal gyri, 
superior parietal, inferior occipital gyri and the cerebellum contributed towards the identification of 
MDD patients (Figure 5.3). 
In predicting clinical remission, the accuracy was 51.40 % from combined grey and white matter 
densities (AUC = 0.42), which did not reach statistical significance.  Similarly, the accuracy for 
grey matter (57.0 %; AUC = 0.40) and white matter (57.3 %, AUC = 0.44) did not reach statistical 
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significance.  Structural biomarkers of clinical response were not examined as the majority (82.6%) 
of patients fulfilled criteria for clinical response following treatment. 
Figure 5.2:  ROC Curve for the comparison between MDD patients and healthy volunteers 
 
 Area under Curve (AUC) = 0.73 
 
Figure 5.3:  p map for diagnostic classification  
 
p map showing white matter regions that contributed towards diagnostic classification of depression at p < 
0.05, uncorrected.  Blue indicates regions showing atrophy in MDD patients relative to controls, while yellow 




5.3.3 Diagnostic classification from COMPARE analysis  
With the inclusion of feature selection in the COMPARE analysis (Fan et al., 2007), the best 
classification rate obtained was 81 % with 47 features.  A relatively stable pattern with an accuracy 
of around 70 % was achieved with 50 - 70 features (Figure 5.4).   




In the present study, potential of structural data to predict diagnosis of depression as well as predict 
clinical remission to duloxetine, an antidepressant of the SNRI class, were examined.  The results 
revealed that white matter was better at predicting diagnosis (accuracy 65.12 %: AUC = 0.73, p = 
0.05), and yielded statistically significant results compared to grey matter (accuracy of 60.46 %, 
AUC = 0.55, p = 0.2).  However, combined evaluation of grey and white matter did not 
significantly improve classification rates (accuracy 67.44 %, p = 0.02).  In contrast, the present 
study revealed that the whole brain structural correlates of depression showed limited potential as a 
prognostic marker.   
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It was notable that the highest accuracy was achieved from combining grey and white matter 
features in the structural MRI scans.  A widespread network of the superior and medial frontal gyri, 
superior parietal and inferior occipital regions was found to contribute towards diagnostic 
classification.  The present findings are in line with recent studies that confirm the potential of 
combined grey and white matter in diagnostic classification (Gong et al., 2011; Liu et al., 2012).  
Univariate VBM studies have consistently reported grey matter deficits in MDD in the frontal 
regions, including the dorsolateral prefrontal cortex, inferior and medial frontal gyrus (see meta-
analyses: Bora et al., 2012; Atkinson et al., 2014).  Other regions include the anterior cingulate, 
insula, (Bora et al., 2012; Atkinson et al., 2014), putamen, precentral gyrus (Bora et al., 2012), post 
central gyrus, parahippocampal gyrus and the thalamus (Atkinson et al., 2014).  More recently, 
investigations of white matter abnormalities in MDD patients have also reported volume reductions 
as well as reduced fractional anisotropy (FA), a measure of brain connectivity derived from DTI 
studies, in the frontal (Volume: Steingard et al., 2002; FA: Ma et al., 2007; Wu et al., 2011; also see 
meta-analysis: Liao et al., 2012), parietal (Volume: Zeng et al., 2012; FA: Ma et al., 2007; Wu et 
al., 2011) and occipito- temporal (FA: Ma et al., 2007) white matter regions.  Moreover, greater 
deficits in white matter integrity was also associated with more severe symptoms (Cole et al., 2012).  
These findings suggest widespread white matter abnormalities in MDD patients in addition to grey 
matter atrophy, which may worsen with depression severity. 
Both Gong et al. (2011) and Liu & colleagues (2012) showed that white matter could distinguish 
treatment sensitive patients (85 % and 91 % respectively), better than treatment resistant ones (59 % 
and 86 % respectively) from healthy controls.  Consistent with the results obtained here, white 
matter regions in the frontal, parietal, and occipital lobes differentiated treatment sensitive patients 
from controls (Gong et al., 2011; Liu et al., 2012).  These included the middle frontal, inferior 
parietal, supramarginal and lingual gyri (Gong et al., 2011; Liu et al., 2012) as well as the anterior 
and posterior cingulate, precuneus and inferior occipital regions (Liu et al., 2012).  Further research 
is required to confirm the finding of improved diagnostic accuracy with treatment sensitive patients 
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as one would expect greater structural differences between treatment resistant patients and controls, 
than between treatment sensitive ones and controls.    
The results also revealed that white matter regions in the bilateral cerebellum contributed towards 
diagnostic classification.  There is increasing evidence to suggest that the role of the cerebellum 
may not be limited to motor control and coordination, but may also involve other cognitive 
functions including emotional processing and regulation of emotional responses (Schmahmann & 
Caplan, 2006; Baumann & Matingley, 2012).  Neuroanatomical studies have rendered further 
support for the involvement of cerebellum in emotional processing with different regions of the 
cerebellum, especially the vermis and the fastigial nucleus, showing connections with the limbic 
system including the amygdala, hippocampus and the cingulate cortices (Blatt et al., 2013).  
Findings from multivariate pattern analysis studies suggest that grey matter regions in the 
cerebellum differentiated patients from controls (Costafreda et al., 2009b; Liu et al., 2012), while 
the predictive power of cerebellar white matter was limited to differentiating treatment resistant 
patients from controls (Liu et al., 2012).  Additionally, resting state cerebellar-cerebral connectivity 
(Ma et al., 2013), especially connections between the cerebellum and regions of the affective and 
default mode networks (Zeng et al., 2014) also showed high discriminative power for diagnosis.  It 
is important to note that some pattern recognition studies in depression have excluded the 
cerebellum for investigation (ex. Kipli et al., 2013; Qiu et al., 2014; Serpa et al., 2014), which may 
have contributed to this region being underreported, and therefore requires further examination.   
In addition to pattern classification using SVM, analysis of regional group differences in grey and 
white matter between MDD patients and controls was also performed.  Results from the ODVBA 
analysis showed grey matter atrophy in the right superior frontal gyrus in acutely depressed MDD 
patients relative to controls.  Studies based on VBM analysis have also showed decreased grey 
matter volume in this region in patients with sub-threshold depression (Taki et al., 2005), in patients 
in an acute episode (meta-analysis: Atkinson et al., 2014), and in remission (Li et al., 2010), relative 
to healthy control subjects.  The superior frontal gyrus is thought to be involved in a variety of 
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cognitive functions, especially in working memory (du Boisgueheneuc et al., 2006).  Grey matter 
loss in the superior frontal gyrus in MDD patients in an acute episode is consistent with results that 
show working memory deficits in this group (Rose & Ebmeier, 2006).  In addition, results also 
showed reduced grey matter volume in the superior temporal region (p < 0.001, uncorrected), in line 
with studies that showed grey matter loss in this region in both acutely depressed MDD patients 
(Takahashi et al., 2010) and in chronically depressed treatment-resistant group (Shah et al., 1998).  
Moreover, specific sub regions of the superior temporal gyrus, such as the temporal pole were 
negatively associated with depression scores (Takahashi et al., 2010).  
 In addition to grey matter loss, MDD patients also showed significant reductions in white matter 
volume in the right postcentral gyrus, superior parietal, middle temporal and left inferior occipital 
regions (p < 0.001, uncorrected).  Majority of the studies in major depression examining white 
matter have used DTI to investigate microstructural changes (ex. Alexopoulos et al., 2002; Taylor et 
al., 2004; Bae et al., 2006; Nobuhara et al., 2006; Ma et al., 2007; Wu et al., 2011) and a 
considerable number of these studies have focussed on geriatric depression (ex. Alexopoulos et al., 
2002; Taylor et al., 2004; Bae et al., 2006; Nobuhara et al., 2006).  Fewer studies have examined 
volumetric abnormalities in white matter in major depression and evidence has shown increases in 
the dorsolateral prefrontal cortex and putamen (Zeng et al., 2012), deceases in the frontal (Steingard 
et al., 2002), cerebellar and inferior parietal regions (Zeng et al., 2012), as well as no volumetric 
differences in white matter (Kim et al., 2008; Abe et al., 2010) in MDD patients relative to healthy 
controls.  Further investigations of white matter volume in different depressive states (ex. acute 
episode, in recovery or in remission) and alterations with treatment are required.  
Interestingly, temporal regions have also shown the potential to discriminate treatment sensitive 
(Liu et al., 2012) and treatment resistant (Gong et al., 2011; Liu et al., 2012) patients from control 
subjects using multivariate pattern recognition, though this finding could not be replicated in the 
SVM analysis.  While the SVM analysis in this study was unable to detect findings in the temporal 
regions for diagnostic prediction, the voxel-based analysis between patients and controls using 
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ODVBA showed significant reductions in grey and white matter in temporal regions in patients 
relative to controls.  It is likely that the small sample size may have led to insufficient power to 
detect all findings that contributed towards diagnosis prediction.   
A limitation of the present study is the relatively small sample size, although comparable to 
previous studies (Gong et al., 2011; Liu et al., 2012; Mwangi et al., 2012).  Advantages of the 
current sample include their medication-free status while in an acute depressive episode as all 
patients had not been taking any medications for a minimum of 4 weeks, while one of the highest 
classification accuracy was observed in patients who were already on antidepressant medications 
(Mwangi et al., 2012); inclusion of patients in their first episode as well as having recurrent 
episodes; and their wide ethnicity which included Asian, African and Caucasian participants. 
In summary, the whole brain structural correlates showed limited potential for prognosis.  
Nevertheless, the present study showed that structural neuroanatomy combining white and grey 
matter distinguished patients from controls at the highest accuracy of 81% with the most stable 
pattern being at around 70%.  A widespread network encompassing frontal, parietal, occipital and 
cerebellar regions contributed towards diagnostic classification.  These findings provide an 

































This chapter opens with a review of the aims and objectives of this work.  Next, a brief treatment of 
the contextual situation of this research in relation to previous work is attempted.  Then, the chapter 
provides a summary of the key findings from the individual studies presented; these findings are 
also compared with and discussed in view of other existing work.  Lastly, limitations of the present 
work and avenues for extension and future research are suggested.   
The preceding chapters of this work are organised around cores that each focus on one or two self-
contained questions.  However, there are shared themes and goals that overarch these cores as well 
as common threads that weave the individual studies together.  These have not been discussed so 
far, as the earlier chapters dwelt on somewhat distinct research questions.  Thus, in this chapter, I 
attempt to cover this essential yet uncharted territory.  
 
6.1 Aims and objectives 
The main objective of this thesis is to examine the neural correlates of affective and cognitive 
processing in depression and how they change with treatment.  This is of interest due to the 
significant need for improving treatment strategies available for depression.  Using magnetic 
resonance imaging, it has been possible to examine the neuropsychological mechanisms of 
antidepressant drug action and psychotherapies that lead to clinical response.  This has particular 
implications in the development of novel treatment strategies or in the augmentation of existing 
therapeutic interventions.  So, this work seeks to investigate the dysfunctional brain activations in 
depression, and how it might normalise with treatment by leveraging fMRI technology. 
In order for neuroimaging findings to have tangible clinical applications, it is important that we are 
able to develop biomarkers that can predict therapeutic response in MDD with high accuracy at the 
individual level.  Therefore, another key focus in the thesis is to examine the potential of structural 
neuroimaging data to identify depression and predict clinical remission using machine learning 
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algorithms.  This is significant as it helps optimize treatment strategies at an early stage.  In 
particular, this means we can provide alternate treatment options early on for those who are less 
likely to benefit from conventional methods. 
 
6.2 Survey of extant work and motivation 
In the first chapter, longitudinal studies that examined the effects of antidepressant treatment and 
psychological therapies on the neural correlates of affective and cognitive processing are reviewed.  
These neuropsychological aspects are especially chosen since there is a sizeable body of research 
associating them with depression. 
With functional MRI, it has been possible to examine patterns of regional brain activations 
associated with affective and cognitive impairments in depression that contribute to the 
maintenance of the disorder and how they normalise with successful treatment.  Findings from 
previous studies suggest that antidepressants regulate dysfunctional activity in limbic regions, in 
particular the amygdala, as well as in subcortical and prefrontal regions in patients during 
processing of emotional and cognitive stimuli (Sankar & Fu, in press).  However, majority of these 
studies focussed on the SSRI class of antidepressants (meta-analysis: Delaveau et al., 2011).  Owing 
to the scarcity in longitudinal studies examining treatment strategies other than SSRIs, it is unclear 
whether the regional changes seen after treatment is specific to a class of pharmacotherapy; or 
whether such changes are common across different classes of antidepressant drugs and even across 
different treatment modalities.   
Three chapters in this work attempt to bridge this gap in the literature.  Chapter 2 investigated the 
effects of CBT on dysfunctional thinking in major depression.  The effects of a dual acting SNRI, 
duloxetine, on affective and cognitive impairments in depression were examined here in two 
separate branches of their own (Chapters 3 and 4). 
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Besides examining the differential neural effects of pharmacological and psychological therapies in 
depression, identifying clinically useful biomarkers of diagnosis and treatment response is also 
crucial.  Previous studies that examined the potential of neuroimaging measures, especially 
structural imaging data to identify biomarkers in depression have several limitations: homogenous 
ethnic group (Chinese: Gong et al., 2011; Liu et al., 2012; Qiu et al., 2014; Caucasian: Costafreda et 
al., 2009b; Mwangi et al., 2012), restriction to treatment-naïve MDD patients (Liu et al., 2012; Qiu 
et al., 2014), inclusion of medicated MDD patients (Mwangi et al., 2012), heterogeneous 
antidepressant treatment (Gong et al., 2011; Liu et al., 2012) and inclusion of grey matter only 
(Costafreda et al., 2009b).  These limitations have been addressed in Chapter 5 in the SVM analysis 
which included medication-free patients of white, Asian and African descent, incorporating both 
first episode MDD patients as well as those at a later stage of the disorder who were all initially 
medication-free during an acute depressive episode and who then received a stable dose of a single 
drug duloxetine belonging to the SNRI class, and investigating the potential of both grey and white 
matter in predicting diagnosis and prognosis. 
 
6.3 Propositions and findings 
In the following paragraphs, key findings from each Chapter are discussed in brief 
 
6.3.1 Chapter 2: Longitudinal fMRI study: neural effects of cognitive behavioural 
therapy on dysfunctional thinking in depression. 
6.3.1.1 Behavioural findings 
The present study supports a modifying effect of CBT on dysfunctional attitudes (Haaga et al., 
1991; Furlong & Oei, 2002) as patients endorsed a greater number of extreme responses to DAS 
statements during an acute depressive episode which normalised following CBT. 
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6.3.1.2 Neuroimaging findings 
 
Neural correlates revealed greater activations in depressed patients relative to controls in the left 
hippocampal gyrus, left inferior parietal lobule and the left precuneus, which are regions associated 
with attentional processing of emotional stimuli and episodic memory retrieval.  This suggests that 
when the DAS statements are presented, depressed patients, compared to controls, engage more in 
attentional processing of the statements, along with active retrieval of memories associated with 
them.  The hippocampus, precuneus (Fu et al., 2004; Ritchey et al., 2011) and inferior parietal gyrus 
( Fu et al., 2004; Fu et al., 2008; Wang et al., 2012) have also showed increased activity in patients 
relative to controls in response to sad facial processing (Fu et al., 2004) and negative pictures 
(Ritchey et al., 2011; Wang et al., 2012), perhaps reflecting a more general response to negative 
emotional stimuli, rather than a specific response to negative styles of thinking.  The group by time 
interactions for extreme attributions showed significant reductions in the parahippocampal gyrus in 
both groups at follow up scan, though to a lesser extent in MDD patients.  To date, there has been 
no fMRI study that has investigated the neural correlates of dysfunctional attitudes in depression, 
and therefore one cannot make direct comparisons to confirm the role of parahippocampal gyrus in 
dysfunctional attitudes.  However, the left parahippocampal activation seems to be especially 
associated with negative stimuli (Iidaka et al., 2002; Surguladze et al., 2005), and activation in this 
region in both patients and in controls during presentation of DAS statements supports the role of 
the left parahippocampal gyrus in processing negative information contained in the DAS 
statements.  The reduction in parahippocampal activation with time is consistent with increased 
familiarity with repetition of the task, although patients did not demonstrate the same extent in the 
reduction in activation.  This may perhaps reflect patients’ inability to recall the task in the same 




6.3.2 Chapter 3: Longitudinal fMRI study: effects of a dual serotonin-norepinephrine 
reuptake inhibitor (SNRI) duloxetine on the processing of sad and happy facial 
expressions. 
6.3.2.1 Behavioural findings 
 
Behavioural responses showed limited difference between the groups, especially for sad facial 
processing.  Although, evidence from previous studies suggest that MDD patients show biases in 
negative facial processing (Fu et al., 2004; Surguladze et al., 2005; Arnone et al., 2012), studies 
have also observed patients to perform as well as controls in tasks of negative facial processing (ex. 
Lee et al., 2008; Frodl et al., 2011) consistent with findings from the present study.   
6.3.2.2 Neuroimaging findings 
Longitudinal neuroimaging studies have showed normalisation of cortico-limbic activity, especially 
in the amygdala (Fu et al., 2004; Arnone et al., 2012), insula (Fu et al., 2004) and anterior cingulate 
(Fu et al., 2004; Victor et al., 2013) following treatment with antidepressants.  Contrary to these 
findings, the present study did not reveal any main effects of group or group by time interactions for 
sad facial expressions.  However, there was a main effect of time with increases in the posterior 
cingulate gyrus in MDD patients following 12 weeks of treatment with duloxetine.  This is in line 
with findings that show increases in this region with antidepressants that potentiate the 
noradrenergic systems (Kennedy et al., 2007; Brühl et al., 2010; Outhred et al., 2013).  In contrast, 
treatment with SSRIs is especially associated with decreases in the posterior cingulate gyrus (see 
meta-analysis: Delaveau et al., 2011).  
Happy facial expressions on the other hand have shown some evidence of decreased activation in 
MDD patients relative to healthy controls in the amygdala (Lawrence et al., 2004).  However, a 
considerable number of studies that examined neural correlates of positive emotional stimuli have 
also failed to observe significant group differences (Fu et al., 2007; Arnone et al., 2012; Rosenblau 
et al., 2012) or any group by time interaction effects (Davidson et al., 2003; Fu et al., 2007) in the 
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amygdala.  In the present study, there were no significant main effects of group or any group by 
time interaction effects in response to happy facial expressions.  The results from the happy and sad 
facial processing study may reflect some distinct effects of the SNRI class of antidepressants during 
sad facial processing; however, further placebo controlled investigation with a larger sample is 
required to confirm present findings.  
6.3.3 Chapter 4:  Longitudinal fMRI study: effects of a dual serotonin-norepinephrine 
reuptake inhibitor (SNRI) duloxetine on working memory  
6.3.3.1 Behavioural findings 
 
The behavioural responses in the present study did not reveal any significant difference between the 
groups in working memory, consistent with findings from previous studies using different working 
memory paradigms (ex. n-back: Harvey et al., 2005; Rose et al., 2006; Matsuo et al., 2007, 
Sternberg: Siegle et al., 2002).  Memory impairments in depression may be more likely in severely 
depressed patients who need hospitalization (ex. Sternberg et al., 1976).  The sample used in this 
study comprises patients with a less severe form of depression, and are representative of patients 
found in the community.  Another factor that influences cognitive impairment is the difficulty level 
of these tasks (Porter et al., 2003).  It is likely for MDD patients in this study to show impairments 
in working memory if they are assigned a more cognitively challenging task.  
6.3.3.2 Neuroimaging findings 
 
In this study, there were no significant differences between the groups during the encoding, 
rehearsal or retrieval stages.  However, during encoding, MDD patients showed a trend for 
reduction in regions associated with working memory, such as the prefrontal regions, middle and 
inferior temporal, cingulate and the inferior parietal gyri.  The results from this study are consistent 
with previous PET findings that showed reductions in MDD patients after treatment in the 
middle/superior frontal, inferior temporal gyrus, and parietal regions during encoding (Bremner et 
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al., 2007).  Findings from the present study only show a trend for significance in these regions, 
however variations in the imaging technique employed, and the use of what may be perceived as a 
more liberal threshold (p < 0.005 with extent threshold of 40 voxels) in Bremner et al. (2007) may 
have contributed to some of the differences in effect size.  Treatment related decreases during 
retrieval in this study were also seen in a similar network of regions encompassing the prefrontal, 
temporal and mid cingulate gyri (cluster level p FWE < 0.05); and decreased baseline activations in 
these regions during verbal working memory were associated with better clinical response (Walsh 
et al., 2007).   
The neural correlates also showed a significant group by time interaction during the long rehearsal 
phase such that there was a tendency for reductions in brain activations post treatment (week 12) 
relative to baseline (week 0) in controls in regions extending from the middle frontal, 
caudate/thalamus, mid cingulate, to the temporal and cerebellar areas, while no change was 
observed in patients.  There was also a group by time interaction in the superior temporal gyrus and 
this effect was due to patients showing a tendency for decreased activation in the final scan.  The 
neural correlates of n-back working memory in healthy controls constitute a network of region 
comprising the dorsal cingulate, medial and inferior frontal regions, premotor cortex, frontal poles 
and posterior parietal regions (Owen et al., 2005).  The present study found significant group by 
time interaction within this network.  Walsh et al. (2007) also found a group by time interaction in 
the caudate and thalamus with fluoxetine in response to a verbal working memory task, whereby 
controls showed a decrease in activation with time, while the opposite effect was seen in patients.  
In the present study, tendency for decreased activations in controls in the follow up scan is perhaps 
indicative of less recruitment of these regions with increased familiarity with the task, while no 
change in activation in patients may reflect persistent recruitment of regions associated with 
working memory to maintain task performance. 
Longitudinal imaging studies in working memory in depression are limited (ex. Bremner et al., 
2007; Walsh et al., 2007) and they have either not examined the effects of treatment on maintenance 
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related activations (ex. Bremner et al., 2007) or used the n-back task that did not differentiate 
activations associated with the different working memory processes (ex. Walsh et al., 2007).  The 
findings from the present study must be considered preliminary and further placebo-controlled 
investigations with larger sample are required to confirm present findings and delineate 
antidepressant effects from changes associated with clinical improvements.   
6.3.4 Chapter 5: Machine learning study: diagnostic and prognostic potential of 
structural neuroimaging data in depression using Support Vector Machines (SVM). 
6.3.4.1 Neuroimaging findings 
 
Structural neuroanatomy distinguished acutely depressed patients from healthy controls with an 
accuracy of 67.44 % using SVM (Sensitivity = 78.3%; Specificity = 55 %, p = 0.02).  With the 
inclusion of feature selection, the best classification rate obtained was 81 % with 47 features.  A 
relatively stable pattern with an accuracy of around 70 % was achieved with 50 - 70 features.  In 
previous studies that used structural MRI scans (see Table 5.1), the accuracy of diagnosis for 
depression has ranged from 58 % to 90 % (see Costafreda et al., 2009b; Gong et al., 2011; Liu et al., 
2012; Mwangi et al., 2012; Kipli et al., 2013; Qiu et al., 2014; Serpa et al., 2014).  In the present 
study, a widespread network of white matter encompassing frontal, parietal, occipital regions and 
cerebellum contributed towards diagnostic classification.  A meta-analysis examining neuroimaging 
biomarkers of schizophrenia revealed that patients could be differentiated from controls using 
structural MRI data with a sensitivity of 76.4 % and specificity of 79 % (Kambeitz et al., 2015).  In 
the present study, an accuracy of 81 % was achieved, although the most stable findings were at an 
accuracy of around 70 %.  One would expect a higher accuracy for the diagnosis of schizophrenia, 
which is associated with greater global brain volume reductions, extensive regional atrophy as well 
as white matter disruptions (Bora et al., 2011).  
In contrast with findings from the diagnostic predictions, whole brain structural correlates of 
depression showed limited potential as a prognostic marker.  In summary, the findings from this 
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study provide an important step in the development of neuroimaging-based tools for diagnosis as 
they demonstrate that the identification of depression is feasible within a multi-ethnic group from 
the community. 
 
6.4 Summary of key findings  
 In summary, the studies presented in the thesis examined the neural effects of treatment on 
different features of depression, namely affective biases, dysfunctional thinking and working 
memory impairments.  To mitigate concerns regarding effects of comorbid diagnoses or 
concomitant treatment on brain activity, that are often seen as limitations in other longitudinal 
neuroimaging studies, only those patients who were free of any psychotropic medication and 
psychological therapies for a minimum of four weeks, who were in an acute depressive episode, and 
who did not meet criteria for any comorbid psychiatric illness, or any medical disorders known to 
affect central nervous system structures or function such as diabetes, high blood pressure, HIV and 
glaucoma were included.  Hence, findings from baseline analyses performed in these studies are 
likely to accurately reflect brain changes associated with an acute depressive episode.  Due to 
ethical considerations, it was not possible to have a patient group arm receiving placebo, therefore it 
is difficult to conclude with certainty that the modulations in brain activations in patients during the 
follow up scan is as a result of treatment alone, rather than reflecting clinical improvements.  
Nevertheless, unlike many previous neuroimaging studies (ex. Robertson et al., 2007; Frodl et al., 
2011; Jiang et al., 2012; Wang et al., 2012), main effects of time and effects of repeated scans were 
accounted for by having controls also undergo scans at the same time points as patients.  Moreover, 
the statistical thresholds used in the duloxetine study to examine group differences and treatment 
related effects are in accordance with the most recent recommendations (Woo et al., 2014) to 
effectively minimise type I and type II errors.  
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In the present study, functional neuroimaging correlates showed antidepressant treatment related 
increases in the posterior cingulate in MDD patients during sad facial affect processing, in line with 
preliminary findings that show increases in this region with antidepressants that potentiate the 
noradrenergic systems.  No baseline group differences in either happy or sad facial affect 
processing was observed, suggesting poor test-retest reliability of such fMRI paradigms to detect 
limbic activity (Fu et al., 2015; Sauder et al., 2015).  The neural correlates of working memory, on 
the other hand, showed a significant group by time interaction during the long rehearsal phase, such 
that there was a tendency for reductions in brain activations at the follow up scan compared to 
baseline in controls in a network of brain areas extending from the prefrontal, to the cingulate, 
temporal and cerebellar regions, while no change was observed in patients.  This decreased 
activations in controls in the follow up scan is perhaps indicative of less recruitment of these 
regions with increased familiarity with the task, while no change in activation in patients may 
reflect persistent recruitment of regions associated with working memory to maintain task 
performance.  Findings from the study that examined the neural effects of CBT on dysfunctional 
attitudes showed less attenuation in patients relative to controls during follow up, perhaps reflecting 
improvements in dysfunctional thinking in patients with some persistent vulnerability.  Further 
placebo-controlled investigations with larger sample are required to confirm findings from the 
individual studies and delineate antidepressant effects from changes associated with clinical 
improvements.   
Another focus of the thesis was to examine whether structural neuroanatomy could identify 
depression and predict clinical remission using machine learning techniques.  The structural 
neuroanatomy showed limited potential for predicting clinical outcome.  Nevertheless, the present 
study showed that structural neuroanatomy combining white and grey matter distinguished patients 
from controls at the highest accuracy of 81% with the most stable pattern being at around 70%.  The 
study demonstrates that identification of depression is feasible using structural neuroimaging data in 
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a sample of wide ethnic diversity taken from the community, and provides an important step in the 




The study included medication-free patients who were, at the time of recruitment, in an acute 
episode of depression of at least moderate severity.  The sample exhibited features of depression 
most commonly observed in the community.  However, patients with any comorbid psychiatric 
illness were excluded, and the sample may not completely represent the general MDD profile as 
major depression is often associated with other comorbid illnesses such as anxiety disorders.  
Majority of the patients in the CBT as well as the duloxetine studies responded to treatment.  This 
in part reflected the increased likelihood of patients recruited from the community to engage with 
services.  None of the patients were recruited from secondary care who may be less responsive to 
treatment.  The high response rate in the studies presented in the thesis limited the power to detect 
neural differences between responders and those with a more chronic form of the disorder, which 
may be associated with distinct neural correlates (Fu et al., 2008a).  Another limitation is that the 
small sample size, although comparable to other studies (ex. Fu et al., 2004, 2007,2008; Fales et al., 
2009; Frodl et al., 2011; Ruhe et al., 2012 ), may have led to insufficient power to detect all neural 
differences.   
6.5.2 Methodological considerations 
There was no treatment group receiving placebo.  So, the attribution of changes to treatment 
(whether CBT or antidepressant) as opposed to temporal clinical improvement is not obvious.  
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However, potential effects of time were accounted for by having healthy participants undergo scans 
at the same time points as MDD patients.  
Although, in this thesis, the effects of both cognitive behavioural therapy as well as 
pharmacological treatment on the neural correlates of emotional processing in depression were 
examined, different functional tasks were used in the examination of these.  Comparison on a single 
task is desirable for a more accurate account of the common and distinct therapeutic mechanisms of 
action of both treatment modalities.  However, an advantage of the works presented in this thesis is 
that they extensively examine the neural effects of treatment on different features of depression (ex. 
affective biases, cognitive impairments and dysfunctional thinking) and therefore the different 
paradigms and findings from the individual studies complement each other.  
6.5.3 Task design 
In Chapter 2, the DAS 24 (Power et al., 1994) was used, which is a shortened version of the DAS 
(Weissman & Beck, 1978) consisting of twenty four statements.  Twenty four neutral statements 
were included as a control task for the present study, which were called control DAS (cDAS).  The 
new forty eight item scale was termed the ‘modified Dysfunctional Attitude Scale’ (mDAS-48).  
Additional investigation comparing neural responses during extreme attributions to positive 
statements with that of responses during negative statements would help understand the nature of 
dysfunctional thinking in relation to different valenced stimuli.  
In Chapter 3, the neuroimaging findings failed to show any significant pre-treatment differences 
between MDD patients and controls in amygdala activations in response to either happy or sad 
facial expressions, contrary to the study hypothesis.  This in part may be due to poor test-retest 
reliability of amygdala response to emotional facial paradigms (Sauder et al., 2013; Fu et al., 2015). 
In Chapter 4, an event related fMRI task, the Sternberg Item Recognition Task was used to 
examine working memory deficits in MDD patients.  Although such designs permit dissemination 
of encoding, maintenance and probe related activations, the task is designed in a way that the 
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different working memory processes immediately follow one another in time.  As an event, each of 
these working memory processes is discrete, however the associated BOLD response to each event 
may overlap with the successive event (Manoach et al., 2003).  To counter this problem, Manoach 
et al. (2003) used an event related approach whereby trials with only encoding and probe phases 
were subtracted from trials that incorporated all three working memory processes (i.e. encoding, 
delay and probe phases).  This method, along with Finite Impulse Response (FIR) models to 
estimate haemodynamic responses for the working memory trial, allowed separation of maintenance 
related activations from encoding and probe or retrieval associated activations (Narayanan et al., 
2005). 
 
6.6 Future directions 
Although the findings from this work cannot be taken as conclusive, it nevertheless provides 
compelling evidence for the neural effects of treatment on different features of depression (ex. 
affective biases, working memory impairments and dysfunctional thinking) and demonstrates that 
the identification of depression is possible within a multi-ethnic group from the community.  Yet, 
further studies are required to address some of the limitations found here.  In the present work, 
patients with comorbid illnesses were excluded, and the relatively small sample size and high 
response rate limited the comparison of neural responses in treatment non-responders in contrast to 
responders.  Future studies with a much larger sample size may benefit from including MDD 
patients with varied symptomatic profile and with comorbid illnesses such as anxiety as they often 
occur alongside major depression.  
Longitudinal studies in major depression provide initial evidence for neural targets of successful 
treatment.  It has been proposed that treatment with psychotherapy significantly impacts the brain 
regions involved in emotion processing disturbances in MDD patients.  Not only have such studies 
been limited in number, but they have contained variations with respect to treatment, treatment 
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duration, and task processing.  More work of greater homogeneity would appreciably supplement 
this area. 
The machine learning findings provide preliminary evidence to suggest that the identification of 
depression is possible within a multi-ethnic group from the general community.  Future research 
should aim to investigate whether integration of neuroimaging biomarkers based on multiple neural 
processes, such as affective and cognitive processing and structural neuroimaging, would achieve 
more accurate classification.  
Majority of the studies in depression have looked at diagnostic prediction using SVM based 
classifiers.  Other approaches, for instance, Random Tree classifier have also produced high 
predictive accuracy rates for diagnosis in depression using structural neuroanatomy (Kipli et al., 
2013).  There is a need for further research exploring possible classifiers that are better able to 
predict diagnosis and clinical response. 
Another possible avenue for research is examining neural correlates of cognitive processing in 
patients that differ in depression severity, as cognitive impairments, especially episodic memory, is 
correlated with severity (meta-analysis: McDermott & Ebmeier, 2008).  Moreover, the effect of 
CBT in cognitive functioning has not been previously examined and is of interest as one of the main 
aims of CBT is to alleviate attention and memory biases that lead to the maintenance of the disorder 
(Beck, 1979).  These findings could throw light on the extent of neural impairments in relation to 
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Supplementary material 1 
a. Behavioural results 
Figure S1.1: Number of extreme and regular attributions on the DAS task for MDD 
patients and healthy controls 
 












Figure S1.2: Number of extreme and regular attributions on the control DAS task for 
MDD patients and healthy controls 
 
Ext: Extreme attributions; Reg: Regular attributions; cDAS:  control statements 
 
b. fMRI results 
Main effect of group at baseline (week 0) 
MDD patients showed increased activations in the left cuneus relative to healthy control 
subjects (corrected p < 0.004) during an acute depressive episode at the baseline scan 
(Supplementary Table S1.1).  In contrast, controls showed greater activations than patients in 
the left cerebellum (corrected p < 0.004). 
Main effect of group at baseline (week 0) 
Following a course of CBT, the main effect of group revealed increased activations in patients 
in the left precuneus, left cerebellum and right lingual gyrus (all corrected p < 0.003) as 
compared with healthy controls.  Healthy controls showed increased activation in the superior 
frontal gyrus and right cerebellum (all corrected p < 0.003) at the follow up scan as compared 






Table S1.1:  Main effect of group at baseline and at follow up  
Cluster Region Cluster Size BA Talairach coordinates 
   (Volume)     x  y z 
Baseline (Week 0) 
     
Patients>Controls 
    
Left Cuneus 54 18 -7 -85    7 
Controls>Patients 
    
Left Cerebellum 12 18 -7 -70 -16 
 
Follow up (Week 16) 
     
Patients>Controls 
    
Right Lingual Gyrus 43 18    4 -74  -7 
Left Precuneus 37 19 -22 -63  49 
Left Precuneus 15 71    0 -59  53 
Left Cerebellum 15 18 -18 -74 -13 
 
Controls>Patients 
    
Right Cerebellum 52 30  14 -41 -20 
Right Superior Frontal Gyrus 42 32  11  48  33 
      
 
Main effect of task at baseline (week 0) 
All subjects showed significant activation in the left middle frontal gyrus, left fusiform gyrus, 
left lingual gyrus, right cuneus and right cerebellum in response to the DAS statements as 
compared to the cDAS statements.  Significant activations in the right cingulate gyrus and 
right superior frontal gyrus (all corrected p < 0.006) were observed in response to the cDAS 










Table S1.2: Main effect of task at baseline (week 0) 
Cluster Region Cluster Size BA Talairach coordinates 
   (Volume)     x  y    z 
DAS>cDAS 
     
Left Fusiform Gyrus 40 19 -33 -70 -13 
Left Lingual Gyrus 54 18    0 -78    4 
Left Middle Frontal Gyrus 57 72 -36  15  26 
Right Cuneus 29 18    4 -78  17 
Right Cerebellum 41 19  33 -63 -17 
      
cDAS>DAS 
     
Right Cingulate Gyrus 104 22  18  59  17 
Right Superior Frontal Gyrus 53 27    7 -37  33 
 
Main effect of task following CBT (week 16) 
All subjects showed significant activation in the left precuneus and bilateral cerebellum while 
viewing the DAS statements relative to the cDAS statements.  Significant activations in the 
right middle temporal gyrus, right posterior cingulate gyrus and left cerebellum (all corrected 
p < 0.006) were observed in response to the cDAS statements as compared to the DAS 
statements (Supplementary Table S1.3). 
Table S1.3: Main effect of task at follow up (week 16) 
Cluster Region Cluster Size BA Talairach coordinates 
   (Volume)     x  y  z 
DAS>cDAS           
Left Cerebellum 70 18 -18 -74 -13 
Right Cerebellum 78 18 22 -70 -20 
Left Precuneus 19 19 -25 -59 50 
      
cDAS>DAS 
     
Right Posterior Cingulate Gyrus 392 71 3 -59 23 
Left Cerebellum 130 70 -7 -33 -23 
Left Cerebellum 62 71 -7 -48 3 
Right Middle Temporal Gyrus 107 37 47 -59 17 
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Supplementary material 2 
Table S2.1: Sample response file generated for the facial expression paradigm  
Trial No Gender Response Reaction Time Accuracy Start Time of Trial 
1 Female Female 827 Correct 0 
2 Male Male 673 Correct 4.148 
3 Male Male 681 Correct 7.524 
4 Blank . . . 12.497 
5 Female Female 901 Correct 18.35 
6 Female Female 603 Correct 22.628 
7 Male Female 677 Incorrect 27.033 
8 Male Male 595 Correct 30.524 
9 Blank . . . 34.191 
10 Female Female 1369 Correct 37.679 
11 Female Female 619 Correct 42.121 
12 Male Male 693 Correct 46.641 
13 Female Female 896 Correct 53.019 
14 Blank . . . 57.36 
15 Male Female 935 Incorrect 61.001 
16 Female Female 947 Correct 65.788 
17 Male Male 643 Correct 74.069 
18 Female Female 580 Correct 78.009 
19 Male Male 771 Correct 82.093 
20 Female Female 537 Correct 89.286 
21 Blank . . . 95.139 
22 Female Female 674 Correct 99.037 
23 Male Male 1164 Correct 106.432 
24 Male Male 913 Correct 110.331 
25 Male Female 1364 Incorrect 113.971 
26 Female Female 942 Correct 118.459 
27 Female Female 514 Correct 121.816 
28 Female Female 685 Correct 128.7 
29 Male Male 743 Correct 132.03 
30 Blank . . . 137.868 
31 Male Male 556 Correct 141.225 
32 Male Male 1035 Correct 147.861 
33 Male Male 724 Correct 152.165 
34 Female Female 503 Correct 160.809 
35 Female Female 533 Correct 164.66 
36 Female Female 567 Correct 169.824 
37 Blank . . . 173.972 
38 Male Male 599 Correct 181.367 
39 Male Male 555 Correct 185.743 
40 Female Female 871 Correct 190.716 
41 Female Female 513 Correct 194.994 
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Trial No Gender Response Reaction Time Accuracy Start Time of Trial 
42 Blank . . . 199.399 
43 Male Female 853 Incorrect 207.68 
44 Male Male 544 Correct 211.171 
48 Blank . . . 229.178 
49 Female Female 535 Correct 232.965 
50 Male Female 601 Incorrect 237.306 
51 Blank . . . 241.093 
52 Female Female 583 Correct 245.177 
53 Male Male 675 Correct 253.458 
54 Female Female 684 Correct 257.398 
55 Male Male 669 Correct 261.482 
56 Female Female 697 Correct 268.675 
57 Blank . . . 274.529 
58 Female Female 529 Correct 281.721 
59 Male Male 604 Correct 289.116 
60 Male Male 1255 Correct 293.014 
61 Blank . . . 296.655 
62 Male Female 1102 Incorrect 300.595 
63 Female Female 1097 Correct 305.083 
64 Female Female 825 Correct 308.44 
65 Female Female 867 Correct 315.325 
66 Blank . . . 318.654 
67 Male Male 731 Correct 325.538 
68 Male Male 872 Correct 331.376 
69 Male Male 628 Correct 338.012 
70 Male Male 616 Correct 342.316 
71 Female Female 622 Correct 350.96 
72 Female Female 755 Correct 354.811 












Supplementary material 3 
Table S3.1: Sample response file generated for the modified Sternberg task 
Trial Cue Target 
Presence 
of 







1 N T X W V R n Yes . . . 0 8 
2 A Q B J H E o No . . . 15 33 
3 U D K M G Z j No Yes 1245 No 40 48 
4 I Y C S F L l Yes Yes 1864 Yes 55 73 
5 P R X O Q E x Yes Yes 1354 Yes 80 98 
6 T K A J N U f No No 1161 Yes 105 113 
7 V S H U Z B s Yes Yes 1136 Yes 120 128 
8 E Y L W F G j No No 1204 Yes 135 153 
9 X M I P R T r Yes No 1228 No 160 178 
10 J S C O Q A e No . . . 185 193 
11 K W N U H Z u Yes Yes 1104 Yes 200 208 
12 Y V F E G B b Yes No 1706 No 215 233 
13 M L D I R Q i Yes Yes 1193 Yes 240 258 
14 Z O J C X T n No No 1507 Yes 265 273 
15 B W H S V A m No No 1079 Yes 280 298 
16 N L K E I F g No No 1400 Yes 305 313 
17 D U P R S Q w No No 1633 Yes 320 338 
18 M G Y T X O y Yes Yes 1093 Yes 345 363 
19 F V C N I H d No No 1415 Yes 370 378 
20 W Z K A Q B q Yes Yes 1270 Yes 385 393 
21 G L E J S P r No No 1275 Yes 400 408 
22 O D T Y M U i No Yes 1240 No 415 433 
23 C R F H X A c Yes Yes 1067 Yes 440 448 
24 L N G I V K k Yes Yes 1031 Yes 455 473 
25 S Z E P M J u No No 1148 Yes 480 488 
26 Q P W B T D l No No 1563 Yes 495 513 
27 V O H J C F v Yes Yes 1170 Yes 520 528 
28 U X L A U G s No No 1855 Yes 535 553 
29 R K I Y S N z No No 1154 Yes 560 568 
30 H W E Q M B e Yes Yes 1193 Yes 575 593 
31 Z P C G A X g Yes Yes 970 Yes 600 608 









Table S3.2: Group by time interaction during delayed rehearsal phase. 
Region Group Mean fmri Activation     T P value 
(x,y,z coordinates)   Week 0 Week 12     
Right Superior Temporal Pols Patients -0.710 0.148 -1.290 0.210 
(46 16 -22) Controls 0.568 -0.378  2.080 0.050 
      
Left Middle Temporal Gyrus Patients 0.091 0.254 -1.130 0.271 
(-48 -2 -14) Controls 0.847 0.027  1.535 0.141 
      
Right Mid Cingulate Gyrus Patients 0.019 0.014 0.119 0.907 
(10 -26 34) Controls 0.441 0.106 2.079 0.051 
      
Left Middle Frontal Gyrus Patients -0.098 -0.053 -0.593 0.559 
(-20 46 16) Controls 0.461 0.018  2.024 0.057 
      
Left Caudate Patients 0.462 0.687 -1.632 0.117 
(-8 -4 18) Controls 1.870 0.938  2.270 0.035 
      
Right Caudate Patients 0.222 0.448 -1.480 0.153 
(8 0 12) Controls 1.757 0.974  2.158 0.044 
      
Right Thalamus Patients 0.133 0.554 -1.201 0.243 
(12 -22 10) Controls 0.245 0.138  1.686 0.108 
      
Left Superior Temporal Gyrus Patients 0.161 -0.073  2.483 0.021 
(-58 -50 -12) Controls 0.368 0.626 -1.270 0.219 
      
Cerebellar Vermis Patients 0.142 0.206 -0.587 0.563 










Figure S3.1: Group x time interaction during delayed rehearsal phase 
The group by time interaction graphs for the remaining regions are displayed here.  Effect 
sizes (β-weights) for the group by time interaction in the left middle temporal gyrus (x,y,z,= -
48,-2, -14; p(FWE corrected)  = 0.003), left middle frontal gyrus (x,y,z,= -20, 46, 16; p(FWE corrected) = 
0.001), left superior temporal gyrus (x,y,z,= -58, -50, -12; p(FWE corrected) = 0.002) right cingulate 
gyrus (x,y,z, = 10,-26,34; p(FWE corrected)  = 0.001), and right thalamus (x,y,z = 12,-22, 10; p(FWE 
corrected) =0.03). 
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Major depressive disorder is a leading contributor to the global burden of disease and is 
regularly identified amongst the top five disabling conditions worldwide (Murray & Lopez, 
2013).  Depression is diagnosed by a prolonged lowering of mood or an inability to 
experience the usual feelings of pleasure which are associated with additional impairments 
in cognition, psychomotor functioning, and neurovegetative symptoms (American Psychiatric 
Association, 2013).  The course of illness is typically characterised by recurrences and 
relapses, in which the risk of recurrence becomes more likely with an increasing number of 
previous episodes (Kessing, Hansen, Andersen, & Angst, 2004).  It has been proposed that 
the processes mediating relapse grow progressively independent and are less linked to 
environmental stressors leading to a cycle of more frequently recurring episodes (Kendler, 
Thornton, & Gardner, 2000).  Hence preventing relapse and recurrence is an essential 
feature of the clinical management of depression. 
The neuropsychological biases and abnormalities evident in major depressive disorder 
(MDD) may be related to its onset and recurrences.  In particular, MDD is associated with a 
negative affective bias in several neurocognitive domains.  MDD patients show a greater 
recollection of negative information relative to healthy controls, such as words (Bradley, 
Mogg, & Williams, 1995) and facial expressions (Ridout, Astell, Reid, Glen, & O'Carroll, 
2003).  There is a selective attention towards negative stimuli in MDD (Beck, 2008), 
including towards negatively valenced words (Donaldson, Lam, & Mathews, 2007) and 
negative, mood-congruent images (Eizenman et al., 2003), and away from positive stimuli, 
such as happy facial expressions (Leppänen, 2006), which is particularly evident when the 
target stimuli is presented over a relatively long duration of time allowing more extensive 
processing (Mogg & Bradley, 2005).  With facial expressions, MDD patients tend to 
misinterpret happy, neutral or ambiguous faces as being sad or less happy (Bourke, 
 
 
Douglas, & Porter, 2010).  The difficulties in discerning facial expressions have been 
purported to contribute to the interpersonal difficulties associated with MDD (Persad & 
Polivy, 1993).  Moreover, the selective attentional bias towards negative facial expressions is 
evident even in recovered patients (Bhagwagar, Cowen, Goodwin, & Harmer, 2004; 
Joormann & Gotlib, 2007), while the induction of a mild negative mood in recovered patients 
can reinstate some of the negative biases observed in acutely depressed patients (Gemar, 
Segal, Sagrati, & Kennedy, 2001).     
Both pharmacological and psychological treatments have demonstrated ameliorative effects 
on the negative emotional processing biases evident in depression.  A 2-week treatment with 
citalopram and reboxetine enhanced recognition of emotions in MDD patients (Tranter et al., 
2009), and a single dosage of citalopram normalised the bias towards fearful faces in MDD 
patients in remission (Bhagwagar et al., 2004).  Even in healthy controls, a single dose of 
citalopram had improved their attention towards positive words though had also increased 
their recognition of fearful faces (Browning, Reid, Cowen, Goodwin, & Harmer, 2007).  
Likewise, cognitive bias modification techniques, involving positive interpretations of auditory 
stimuli using imagery, were associated with improvements in mood and cognitive biases in 
medication-free MDD patients (Blackwell & Holmes, 2010).  Furthermore, enhancement of 
the recognition of happy faces following antidepressant treatment was linked with 
improvements in symptoms, wellbeing and social functioning (Tranter et al., 2009), indicating 
the potential for pharmacological as well as neuropsychological modulation of the negative 
biases rather than their being persistent, trait-related features of MDD.  
Functional magnetic resonance imaging (fMRI) studies have applied various experimental 
paradigms in order to delineate the networks underlying the affective biases and cognitive 
impairments in MDD (Frodl et al., 2009; Lawrence et al., 2004; Mitterschiffthaler et al., 2008; 
Surguladze et al., 2005; Wagner et al., 2006).  In order to distinguish state-specific from trait-
related neural features, it is important to consider the depressive state of the MDD sample 
(ex. acute depressive episode, in recovery, or in remission) and whether the sample consists 
 
 
of a cross sectional analysis of MDD subjects in a variety of states or whether the study is a 
longitudinal investigation of the same MDD patients following a variety of treatments.  For 
example, fMRI studies have investigated impairments during an acute depressive episode 
(Grimm et al., 2008; Harvey et al., 2005; Mitterschiffthaler et al., 2008) as well as the 
changes following treatment (Arnone et al., 2012; Fu et al., 2007; Fu et al., 2004; Fu, 
Williams, et al., 2008; Sheline et al., 2001; Victor, Furey, Fromm, Öhman, & Drevets, 2010; 
Walsh et al., 2007).  The majority of studies have examined the effects of pharmacological 
treatments (Arnone et al., 2012; Davidson, Irwin, Anderle, & Kalin, 2003; Fu et al., 2007; Fu 
et al., 2004; López-Solà et al., 2010; Rosenblau et al., 2012; Sheline et al., 2001; Stoy et al., 
2012; Victor et al., 2010; Walsh et al., 2007), while there have been fewer studies of 
psychological interventions (Buchheim et al., 2012; Dichter et al., 2009; Dichter, Felder, & 
Smoski, 2010; Fu, Williams, et al., 2008; Ritchey, Dolcos, Eddington, Strauman, & Cabeza, 
2011; Yoshimura et al., 2014).   
Longitudinal fMRI studies investigating affective processing have commonly used 
standardized series of facial expressions (ex. Ekman & Friesen, 1976) or pictures (ex. 
International Affective Picture System (IAPS); Lang, Bradley, & Cuthbert, 1999).  The 
emotional processing tasks applied in longitudinal fMRI studies may be considered to be 
engaging predominantly implicit or explicit processing.  For example, in a task involving the 
presentation of emotional faces, the explicit instruction may be to identify the gender of the 
presented face while the emotional expression is processed implicitly, or the explicit 
instruction may be to identify the emotion expressed by the presented face which becomes 
an explicit processing of the emotion.  Implicit affective processing tasks are often used in 
neuroimaging studies because they are associated with greater probability of engaging key 
limbic regions within the MDD network, such as the amygdala (Costafreda, Brammer, David, 
& Fu, 2008).  The majority of the longitudinal MDD studies have focussed on the functional 
correlates of treatment in response to emotional processing (Arnone et al., 2012; Davidson 
et al., 2003; Fu et al., 2007; Fu et al., 2004; Fu, Williams, et al., 2008; Ritchey et al., 2011; 
 
 
Victor et al., 2010).  Other emotional processes, such as reward (Dichter et al., 2009; Stoy et 
al., 2012) and painful stimuli (López-Solà et al., 2010), as well as cognitive processes, such 
as verbal working memory (Walsh et al., 2007) and cognitive control (Wagner et al., 2010), 
have also been investigated.  
In the present review, we discuss the functional neural correlates of the effects of 
pharmacotherapy as well as psychological therapy in MDD.  We also provide an overview of 
predictors of clinical response and the potential to develop neuroimaging-based biomarkers. 
Antidepressant treatment effects on regional brain activations 
Healthy emotional regulation depends on the interplay between frontal and limbic regions.  A 
frequently applied strategy of emotion regulation involves reinterpreting the meaning of a 
situation in order to reduce the affective impact, which may be termed cognitive reappraisal 
(Gross, 2002).  The neural correlates of the process of reappraisal involve cognitive control 
regions within the prefrontal cortex and modulation of emotion-related activity in the 
amygdala (Buhle et al., 2013).  The amygdala plays a key role in processing of emotional 
stimuli, both negative and positive, although there is a higher probability of amygdala 
responsivity to stimuli which evoke fear and disgust relative to those which give rise to 
happiness (Costafreda et al., 2008).  Studies of the neural correlates of emotional 
processing in MDD have demonstrated increased amygdala activation during an acute 
depressive episode as compared to controls in response to a variety of negative stimuli, 
such as sad faces (Arnone et al., 2012; Fu et al., 2004; Victor et al., 2010), fearful or angry 
faces (Ruhe, Booij, Veltman, Michel, & Schene, 2012; Sheline et al., 2001), and negatively 
valenced pictures (Anand et al., 2005; Rosenblau et al., 2012).  Following treatment, 
subsequent normalisation of this increase in amygdala activation has been widely observed 
(Arnone et al., 2012; Fu et al., 2004; Rosenblau et al., 2012; Sheline et al., 2001).   
These treatment studies have examined selective serotonin reuptake inhibitor (SSRI) class 
of antidepressant medications, such as sertraline (Anand, Li, Wang, Gardner, & Lowe, 2007; 
 
 
Sheline et al., 2001; Victor et al., 2010), fluoxetine (Fu et al., 2004), citalopram (Arnone et 
al., 2012), and escitalopram (Rosenblau et al., 2012).  Normalization of amygdala activity in 
patients following antidepressant treatment could reflect improvements in depression 
severity as well as, or alternatively, could be evidence of the effects of SSRI treatment on 
amygdala responses.  The mechanism may be consistent with the density of serotonin 
receptors within the amygdala (Xu & Pandey, 2000) which are a target of action for SSRIs 
(X. Jiang, Chen, Smerin, Zhang, & Li, 2011).  Short term administration of SSRIs in both 
healthy volunteers (Harmer, Mackay, Reid, Cowen, & Goodwin, 2006) and MDD patients 
(Godlewska, Norbury, Selvaraj, Cowen, & Harmer, 2012) had normalized amygdala 
responses to negative emotional stimuli, which preceded the clinical improvements 
(Godlewska et al., 2012), suggesting a therapeutic mechanism of SSRI treatment for MDD.  
The effects of antidepressants with more prominent noradrenergic mechanisms require 
further investigation as noradrenergic reuptake inhibitors may modulate the attentional 
regulation of emotional processing which are mediated by medial and prefrontal regions (Fu 
et al., 2001; Outhred et al., 2013). 
Functional MRI studies have examined amygdala activity in MDD patients in remission in 
order to delineate whether the observed response is a state- or trait-related feature.  In 
remitted MDD patients relative to controls, no significant differences in their amygdala 
activation during processing of sad, fearful or happy facial expressions have been reported 
(Arnone et al., 2012), suggesting that increased amygdala activation may be a state-
dependent marker in depression.  However, in response to masked faces, remitted MDD 
patients relative to controls did show elevated amygdala activity during masked sad facial 
processing, with a pattern of activations similar to acutely depressed patients (Victor et al., 
2010).  Although there is clear support for normalisation of amygdala activation following 
antidepressant treatment, the findings have not been wholly consistent.  It is also important 
to note the factors which affect the probability of amygdala response, including valence and 
form of presentation, as well as the type of analysis, as a region of interest (ROI) approach 
 
 
(Arnone et al., 2012; Rosenblau et al., 2012; Sheline et al., 2001) provides greater power to 
detect a difference relative to whole brain analyses (Costafreda et al., 2008). 
Antidepressant treatment has also been associated with an attenuation of activation in a 
wide distribution of limbic and subcortical regions that are dysregulated in MDD, reflecting 
impairments in associated neurocognitive functions, including in the dorsal anterior cingulate 
which is involved in conflict monitoring and cognitive control (Botvinick, Braver, Barch, 
Carter, & Cohen, 2001; Mitterschiffthaler et al., 2008), orbitofrontal cortex in reward 
processing (Rolls, 2000), and hippocampus in memory processing (Burgess, Maguire, & 
O'Keefe, 2002).  Acutely depressed MDD patients have shown increased activation in the 
anterior cingulate (Fu et al., 2004), insula (Fu et al., 2004), hippocampus (Victor et al., 2010) 
and putamen (Fu et al., 2004; Surguladze et al., 2005) during implicit processing of sad 
faces relative to controls, which was attenuated following pharmacological therapy (anterior 
cingulate: Fu et al., 2004; Victor, Furey, Fromm, Öhman, & Drevets, 2013; insula: Fu et al., 
2004; putamen: Fu et al., 2004).  In response to negative pictures, MDD patients similarly 
showed a normalisation of activation in the orbitofrontal and dorsolateral prefrontal cortices 
(Rosenblau et al., 2012), and in subcortical regions, including striatum (Anand et al., 2007).    
Antidepressants appear to promote a normalisation of activations within a network of limbic 
and subcortical regions which show increased responsivity to negative affective stimuli 
during an acute depressive episode.  Furthermore, a strong association between cortico-
limbic activations and clinical improvements has been observed, such that the patients who 
showed the most improvement also had the greatest reductions in activation with treatment 
(Fu et al., 2004). 
In response to positive facial expressions, the negative bias observed in MDD patients 
(Bourke et al., 2010) has also been linked to impairments in limbic and subcortical regions.  
Implicit processing of happy facial expressions in MDD patients relative to healthy controls 
has been associated with reduced activation in the amygdala and parahippocamapal regions 
(Lawrence et al., 2004), as well as in the posterior cingulate, precuneus, lingual gyri, and 
 
 
cerebellum, which improved following antidepressant treatment (Fu et al., 2007).  Happy 
facial expressions have also been associated with increased activations in the fusiform gyrus 
in MDD patients following treatment (W. Jiang et al., 2012).  Fusiform responses are greater 
for attended faces (Pizzagalli et al., 2002), and MDD patients show greater fusiform 
activation than controls when attending to negative emotional stimuli (versus a neutral 
baseline) but decreased fusiform responses during attentional processing of positive 
emotions (Groenewold, Opmeer, de Jonge, Aleman, & Costafreda, 2013).  These findings 
outline the functional network underlying the neurocognitive observations that MDD patients 
are more likely to attend to faces of increasing sadness in comparison to healthy controls 
(Gotlib, Krasnoperova, Yue, & Joormann, 2004; Joormann & Gotlib, 2007), who in turn 
attend more to happy facial expressions (Joormann & Gotlib, 2007), and suggest that 
antidepressant treatment may normalise the impairments.  
Antidepressants have additionally demonstrated regulation of impaired activations in 
prefrontal cortical regions which have been associated with more cognitive demands.  Using 
variations of the Stroop task to investigate neural correlates of executive control of attention, 
increases in rostral anterior cingulate (Mitterschiffthaler et al., 2008; Wagner et al., 2006), 
dorsolateral prefrontal (Wagner et al., 2006), as well as decreases in the precuenus, 
posterior cingulate, and occipital regions (Kikuchi et al., 2012) have been observed in 
acutely depressed MDD patients relative to controls.  Mitterschiffthaler et al. (2008) had used 
a variant of the Stroop which employed affective words, and Wagner et al. (2006) had 
presented the response as an option along with the target word to reduce memory demand.  
Modifications of the task were also made to accommodate the parameters of fMRI scanning 
including a button press response instead of vocalisation (Wagner et al., 2006; Kikuchi et al., 
2012), though Mitterschiffthaler et al. (2008) used a clustered fMRI acquisition sequence in 
order to allow overt verbal responses.  The effects of antidepressant treatment were 
attenuation of activations in the prefrontal, amygdala-hippocampal, and parietal regions in 
 
 
MDD patients (Wagner et al., 2010), further support the normalisation of cortico-limbic 
regional activations by antidepressant therapy. 
However, it is important to consider the factors which may contribute to the observed effects, 
including effects due to the form of treatment, ie. antidepressant treatment and potentially 
related to the specific class of antidepressant, to improvements in depressive symptoms, as 
well as to repeated performance of the tasks and scans.  In order to account for potential 
effects of time and repeated neuroimaging scans, studies have included healthy volunteers 
who had the same scans at the same time points as the MDD patients (ex. Davidson et al., 
2003; Fu et al., 2004; López-Solà et al., 2010; Rosenblau et al., 2012; Stoy et al., 2012; 
Walsh et al., 2007),  while others have not performed follow up scans on healthy control 
subjects, instead included only a single scan, usually done at the time of study entry (ex. 
Wagner et al., 2010; Wang et al., 2012).  The inclusion of a control group though bears 
added costs and the risk of subjects being unable to return for serial scans.  The addition of 
a MDD treatment arm with a placebo form of treatment would help to account for potential 
placebo-related effects and state-related changes.  A limited number of PET studies have 
examined the functional correlates of placebo effect in depression (ex. Mayberg et al., 1999; 
Mayberg et al., 2002), but to our knowledge, there have not been any longitudinal fMRI 
studies which have included a MDD patient group receiving a placebo treatment. 
Pharmacological treatment effects on neural connectivity  
In order to examine the relationship between regions, a connectivity analysis attempts to 
define the interaction between brain regions, which could potentially be excessively 
engaged, impaired or even unaltered in MDD.  The amygdala has connections with the 
subgenual anterior cingulate and receives connections from dorsal cingulate cortex 
(Aggleton & Saunders, 2000).  Reduced frontocortical and limbic regional connectivity has 
been observed in MDD (Anand et al., 2005; Chen, Suckling, et al., 2007; Costafreda et al., 
2013) which may worsen with increasing severity of depression (Friedel et al., 2009; 
 
 
Matthews, Strigo, Simmons, Yang, & Paulus, 2008) and improve following antidepressant 
treatment (Chen, Suckling, et al., 2007).  Activation of the lateral prefrontal and dorsal 
cingulate cortices suppresses amygdala activation, part of the process of voluntary 
emotional down-regulation (Carballedo et al., 2011; Costafreda et al., 2008).  These findings 
indicate that depression is associated with impairments in the inhibitory influence of cortical 
regions on limbic regions, which may be ameliorated by treatment. 
Neural effects of psychological therapy  
Fewer studies to date have investigated the neural correlates of psychological therapy.  
These studies have examined a variety of states and tasks, such as resting state (Brody et 
al., 2001; Goldapple et al., 2004; Martin, Martin, Rai, Richardson, & Royall, 2001), 
dysfunctional attitudes (Sankar et al., in press), cognitive control (Dichter et al., 2010), facial 
expressions (Fu, Williams, et al., 2008; Ritchey et al., 2011), and reward processing (Dichter 
et al., 2009), using positron emission tomography (PET) (Brody et al., 2001; Goldapple et al., 
2004; Kennedy et al., 2007), single-photon emission computed tomography (SPECT) (Martin 
et al., 2001), and functional MRI (Buchheim et al., 2012; Dichter et al., 2010; Fu, Williams, et 
al., 2008; Ritchey et al., 2011).   
Increases in baseline activations in the amygdala-hippocampal regions in MDD patients 
relative to healthy controls have been followed by significant reductions following treatment 
with cognitive behavioural therapy (CBT) (Fu, Williams, et al., 2008) as well as with 
psychodynamic psychotherapy (Buchheim et al., 2012).  Increases within the prefrontal 
regions in MDD patients, such as the medial prefrontal (Buchheim et al., 2012; Yoshimura et 
al., 2014), orbitofrontal (Dichter et al., 2010), dorsolateral and ventrolateral prefrontal 
cortices (Brody et al., 2001) also normalized following a variety of forms of psychological 
treatments, including CBT (Yoshimura et al., 2014), behavioural activation therapy (Dichter 
et al., 2010), interpersonal psychotherapy (IPT) (Brody et al., 2001) and psychodynamic 
psychotherapy (Buchheim et al., 2012).  In the anterior cingulate, several studies have 
 
 
demonstrated increased activation (Dichter et al., 2009; Fu, Williams, et al., 2008; Goldapple 
et al., 2004) but there have also been reports of decreases (Brody et al., 2001; Buchheim et 
al., 2012) in activation following psychological therapy.  
Investigations of the differential effects of pharmacological and psychological therapies on 
regional brain activity have compared CBT (Goldapple et al., 2004; Kennedy et al., 2007) or 
IPT (Brody et al., 2001; Martin et al., 2001) with antidepressant medications, such as 
paroxetine (Brody et al., 2001; Goldapple et al., 2004) and venlafaxine (Kennedy et al., 
2007; Martin et al., 2001).  MDD patients in an acute episode were assigned randomly to 
either psychological therapy or pharmacological intervention (Kennedy et al., 2007; Martin et 
al., 2001), and few studies used a nonrandomized design, in which treatment type was 
guided by patient preference (Martin et al., 2001) or CBT treatment group were compared 
post-hoc to an independent group of paroxetine responders (Goldapple et al., 2004).  Both 
antidepressant treatment and psychotherapy were associated with reductions in the 
prefrontal cortex, including the middle frontal (Brody et al., 2001), lateral orbitofrontal, 
dorsomedial (Kennedy et al., 2007) and ventral prefrontal (Goldapple et al., 2004) regions, 
as well as increases in the basal ganglia (Martin et al., 2001), temporal lobe (Brody et al., 
2001) and lateral inferior occipital region (Kennedy et al., 2007).  Antidepressants were 
specifically associated with decreases in limbic regions, such as the insula (Goldapple et al., 
2004), posterior (Kennedy et al., 2007) and ventral (Goldapple et al., 2004) subgenual 
cingulate regions, as well as increases in the posterior temporal lobe (Martin et al., 2001), 
brainstem and cerebellum (Goldapple et al., 2004).  Psychological therapies, on the other 
hand were associated with decreases in the thalamus (Kennedy et al., 2007), and in the 
prefrontal cortex, including orbitofrontal, medial and ventrolateral regions (Goldapple et al., 
2004), as well as increases in the subgenual (Kennedy et al., 2007) and dorsal (Goldapple et 
al., 2004) cingulate regions.  In the posterior cingulate region, however, there have been 
findings of both decreases (Goldapple et al., 2004) and increases (Martin et al., 2001) in 
activations following psychological therapy.  
 
 
 It has been proposed that cognitive therapy shows a cortical “top-down” mechanism of 
action, as it focuses on altering memory and attention processes that are involved in the 
mediation of cognitive biases and maladaptive processing of information (DeRubeis, Siegle, 
& Hollon, 2008).  There is growing evidence though to suggest that antidepressants may 
also show a similar mechanism of action to cognitive therapy whereby antidepressant 
modulate the negative biases and memory impairments in depression very early on in the 
course of treatment, even before patients report any change in their mood or anxiety 
(Harmer, Goodwin, & Cowen, 2009; Harmer, O’Sullivan, et al., 2009).  The common neural 
mechanisms of action of antidepressants and cognitive therapy may reflect their targeting 
similar underlying processes that lead to improvements in depressive symptoms.  The 
number of studies have been limited to date though, along with variations with respect to 
treatment, treatment duration, and task processing, as well as effects of improvements in 
symptom severity which must also be considered. 
Functional neuroimaging predictors of clinical response 
At the present time, the diagnosis of depression is based solely on clinical signs and 
symptoms, and there are no biological tests that are used to diagnose the disorder or to 
predict clinical response to a particular treatment or the course of the illness.  Building on 
investigations of the neural treatment effects in major depression, studies have also sought 
to identify the neural biomarkers that predict clinical response before initiation of treatment or 
early in the course of treatment.  Meta-analysis of pharmacological and psychotherapy 
treatment studies showed that increased baseline activity in the anterior cingulate, medial 
prefrontal and orbitofrontal regions was predictive of a better response to treatment, whilst 
activity in the right striatum and anterior insula was predictive of a poorer prognosis (Fu, 
Steiner, & Costafreda, 2013).  Increased anterior cingulate activity as being predictive of 
response to antidepressant medications, prior to the initiation of treatment, has been highly 
replicated, while the direction of the prediction for CBT has been more mixed (Fu et al., 
 
 
2013).  Elicitation of anterior cingulate in response prediction has been observed with 
numerous tasks, including resting state PET studies (Kennedy et al., 2007; Mayberg et al., 
1997) and with both cognitive (Marquand, Mourão-Miranda, Brammer, Cleare, & Fu, 2008; 
Roy et al., 2010) and emotional processing (Chen, Ridler, et al., 2007; Costafreda, Khanna, 
Mourao-Miranda, & Fu, 2009; Davidson et al., 2003; Keedwell et al., 2010) fMRI tasks.  
There have been as well some notable inconsistencies as some reports have indicated that 
greater anterior cingulate activity was predictive of a poorer clinical response to 
pharmacotherapy (Brody et al., 1999; Konarski et al., 2009) as well as to CBT (Konarski et 
al., 2009; Siegle, Carter, & Thase, 2006).  Increased anterior cingulate activity may indicate 
greater responsivity to reward processing (Rogers et al., 2004) and in turn predict a better 
clinical response.  The insula is engaged by negative emotional stimuli (Anand et al., 2005; 
Van Dillen, Heslenfeld, & Koole, 2009), in particular the anterior region for social stimuli with 
interoceptive integration of internal and external stimuli of emotional pain recognition (Singer 
et al., 2004).  More recently, baseline hypometabolic activity in the insula was associated 
with remission to CBT and poor response to escitalopram, whilst the opposite effect was 
seen with insula hypermetabolism (McGrath et al., 2013).  
For these findings to be applicable in clinical settings, it is important to identify diagnostic 
and prognostic markers with high predictive accuracy at the individual level (Fu & 
Costafreda, 2013).  It is possible to apply methods of analysis to neuroimaging measures in 
order to determine what would be expected for a particular individual along with a measure 
of how likely that outcome may be (Nouretdinov et al., 2011).  One set of analysis methods 
is machine learning, such as support vector machine (SVM) (Fu, Mourao-Miranda, et al., 
2008).  For example, we found that baseline neural activity during sad facial processing 
predicted remission to CBT with a sensitivity of 71 % and a specificity of 86% for individual 
patients (Costafreda et al., 2009).  Future research should also aim to investigate whether 
integration of neuroimaging biomarkers based on multiple neural processes associated with 
depression (ex. affective and emotional processing and structural neuroimaging) would 
 
 
achieve more accurate classification.  The investigation of neuroimaging data using pattern 
based classification methods to obtain clinically useful biomarkers with high predictive 
accuracy at the individual level would help to optimize treatment strategies at an early stage.  
This would be of particular benefit for patients whose illnesses may be less likely to improve 
solely with conventional treatment methods and who would benefit from an earlier initiation 
of alternative or combination therapies. 
Conclusions 
In summary, research has begun to elucidate the function of antidepressants and 
psychotherapy in modulating the regions involved in the emotional, cognitive and 
behavioural disturbances that underlie major depression.  Further placebo-controlled 
longitudinal fMRI studies would assist in distinguishing between the effects of treatment and 
changes associated with depressive state and to control for effects of time and test-retest 
with particular neuroimaging paradigms.  Additional investigations are also required to 
determine the common and distinct mechanisms of action of antidepressants and 
psychological therapies.  Pattern classification based analysis of neuroimaging data is 
beginning to delineate potential biomarkers for both diagnosis and prognosis with high 
predictive accuracy at the individual level which will aid in the development of clinically useful 
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Opinion Statement
Major depressive disorder (MDD) is associated with key regions of the brain involved in
emotional processing. The present meta-analysis revealed widespread structural reduc-
tions in limbic and prefrontal regions that occur in MDD, with no regions of increased
grey matter volume. Functional impairments involve many of the same regions with
dysregulated interactions between limbic and cortical structures. Longitudinal treat-
ment studies have predominantly investigated pharmacological therapies, and there
have been fewer studies of psychological treatments. Reports of increased hippocampal
volume and reductions in amygdala activation following treatment suggest implica-
tions for the course of illness and the impact of pharmacological as well as psycholog-
ical therapies. Measures of regional brain volume and activity during an acute
depressive episode prior to or early in the course of treatment offer the potential to
develop predictors of clinical response. High predictive accuracy at the level of the in-
dividual is essential for translation of these findings to clinical use. Development of
such biomarkers may help to guide treatment strategies, particularly for individuals
who may not benefit from current first-line therapeutic options, in order to preclude
a potential series of ineffective treatment trials.
Introduction
Major depression is one of the top contributors to the
global burden of disease [1, 2]. It is an often debilitating
disorder that typically follows a recurring and relapsing
course of illness. At present, the diagnostic criteria of de-
pression include an assessment of mood as well as cog-
nitive and somatic symptoms, and treatment decisions
are based on clinical characteristics such as severity and
course of the illness as well as past treatment response.
Evidence-based treatments for depression include anti-
depressant medications and psychological therapies, in-
dividually or in combination, but remission rates have
been relatively modest [3]. To date, there are no biolog-
ical markers that are used in clinical practice to diagnose
the disorder or to predict treatment response [4••, 5•].
Structural and functional magnetic resonance im-
aging (MRI) studies have sought to delineate the brain
abnormalities associated with depression and to ex-
amine the effects of treatment. Understanding the neu-
robiological mechanisms that contribute to the
pathogenesis of the disorder may also provide models
in the development of biomarkers for diagnosis, prog-
nosis, and response prediction [5•]. Often, fMRI stud-
ies in depression have used experimental paradigms
such as tasks of affective and cognitive processing to
engage the regions that may be impaired. Connectivity
analyses provide an additional understanding of the
interactions among brain regions. Longitudinal treat-
ment studies have predominantly focussed on antide-
pressant treatment, and selective serotonin reuptake
inhibitors (SSRIs) in particular, while there have been
fewer studies of psychological treatments [6••]. Identi-
fying neurobiological correlates of treatment response
and establishing biological markers of diagnosis and
response prediction will require high predictive accu-
racy at the individual level as well as a measure of
the confidence of the prediction [7]. In this way, treat-
ment strategies could be personalised, in particular to
identify patients with more severe forms of the disor-
der early in the course of their illness in order to pre-
vent a potential series of ineffective treatment trials.
Structural and Functional Neural Correlates of Depression
MRI studies have revealed structural and functional brain abnormalities asso-
ciated with MDD in limbic and prefrontal regions, key areas involved in
emotional processing and regulation. In our meta-analysis of grey matter ab-
normalities in MDD, we retrieved 34 studies from a systematic literature
search of five databases (PubMed, Scopus, Ovid MEDLINE, PsycINFO, and
Ovid EMBASE) between January 1995 and June 2012 [8](Table 1). The sub-
jects included a total of 1,341 MDD patients and 1,364 healthy controls. The
patient group comprised adults who were both on medication and not tak-
ing medication. Neuroimaging studies utilizing region-of-interest (ROI) as
well as voxel-based morphometry (VBM) methods were included in order
to determine to what extent the methods used in individual studies may have
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influenced the results of the meta-analysis. Studies that reported no signifi-
cant difference in grey matter volume (GMV) or density between patients
and control subjects were also included.
The whole-brain analysis revealed volumetric reductions of grey matter in
10 clusters across the brain comprising the right anterior cingulate cortex
(ACC), right medial superior frontal gyrus, right dorsolateral prefrontal cor-
tex (DLPFC), bilateral orbitomedial prefrontal cortex, right inferior frontal
gyrus opercular part and triangular part, bilateral insula, right claustrum,
and the right putamen.
The combined whole-brain and ROI analysis revealed more extensive grey
matter reductions across 18 clusters, including the bilateral anterior cingu-
late, bilateral medial superior frontal gyrus, right DLPFC, left superior frontal
gyrus, right inferior frontal gyrus opercular part, bilateral inferior frontal gy-
rus triangular part, bilateral insula, right claustrum, and right rectus gyrus, in
MDD patients compared to controls. In addition to the whole-brain findings,
grey matter reductions were also significant in the bilateral parahippocampal
gyrus, left thalamus, and left postcentral gyrus. Notably, there was no in-
creased grey matter volume found in any region in either the whole-brain
or combined whole-brain and ROI analyses.
The ACC is a region consistently implicated throughout the course of
MDD. Structural magnetic resonance imaging (sMRI) studies have demon-
strated total volume reductions present in the ACC in never-treated MDD pa-
tients [9, 10]. Studies of medication-naïve and medication-free samples may
provide further elucidation of brain abnormalities more directly related to
MDD itself, without potentially confounding effects of medication. Voxel-
based morphometry (VBM) analysis of sMRI data have shown that ACC grey
matter density is significantly reduced in medication-free and medication-na-
ïve patients [11–13]. Reduced white matter volumes have also been reported
in the right ACC [14].
There is evidence that such structural abnormalities have functional con-
sequences likely related to impairments in emotional processing [15]. For ex-
ample, increased activity of the ACC as well as in the amygdala, anteromedial
prefrontal cortex, parahippocampus, and insula regions in response to nega-
tive images has been observed in unmedicated depressed patients [16], and
altered functional connectivity has been reported in subgenual ACC net-
works of medication-naïve MDD adolescents when evaluating negative emo-
tional stimuli [17]. MDD is associated with dysregulated interconnections
within limbic–cortical structures, particularly between the ACC and amygda-
la [18, 19].
In the amygdala, reduced volumes have been reported in both region-of-
interest [20] and VBM [11, 21] studies. Functional activation tasks have dem-
onstrated abnormal and greater amygdala response to negative emotion
in MDD patients at baseline prior to antidepressant treatment as com-
pared to controls [4••, 16, 22–24]. Studies have revealed decreased func-
tional connectivity between the amygdala and PFC, including the ACC,
in response to negative emotional stimuli [19, 25], and the amygdala
and left anterior insula networks in whole-brain resting-state studies of
medication-naïve MDD [26]. It is clear that MDD modulates amygdala
responsivity and widespread functional connectivity to prefrontal cortical
regions [19].
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The DLPFC has been consistently implicated in MDD, with reduced
volume observed in the majority of studies [27–31], including in medi-
cation-naïve and medication-free MDD patients [32]. In a study of med-
ication-naïve subjects, Wu et al. [33] reported abnormalities in white
matter fibres compromising the connectivity within dorsolateral–prefron-
tal circuits. Healthy controls with a family history of MDD have also
been shown to exhibit smaller volumes of white matter in the DLPFC
[14]. As the DLPFC plays an important role in working memory and ex-
ecutive functions, disruptions of the DLPFC, in connection with other
cortical and subcortical regions as part of the limbic–cortical dysregula-
tion model, contribute to diminished cognitive ability and disturbances
in social behaviour and emotional regulation [34].
Reductions in orbitofrontal cortex (OFC) volume in MDD are
thought to be associated with functional alterations in the network of
emotion regulation [35]. In a study that combined fMRI and VBM
methods, unmedicated patients performing a Stroop task demonstrated
hyperactivation of the ACC that was inversely correlated with GMV re-
duction in the OFC [27]. Frodl et al. [36] reported decreased connectiv-
ity between the OFC and the ACC, thought to be associated with a
deficit in regulating self-schemas, and increased connectivity between
the OFC and the DLPFC, demonstrating greater neural response to neg-
ative stimuli in drug-free patients with MDD. In resting-state fMRI,
Zhang et al. [37] reported a decrease in functional activity in an affec-
tive network between the amygdala and OFC in first-episode medica-
tion-naïve MDD adolescents.
One of the most replicated findings in MDD is decreased hippocampal
volume [38, 32], which is evident at the first episode of depression [39]. Re-
current episodes can lead to further volume reductions in the hippocampus
over the course of the disorder, which may also contribute to symptoms of
cognitive decline in MDD [40].
MDD is also associated with increased GMV in the thalamus [31, 32, 41]
and the right insula [31] of medication-naïve first-episode MDD individuals.
Decreased grey matter density in the thalamus has been proven to be a sig-
nificant diagnostic marker of depression in medication-free MDD [42]. The
thalamus has extensive connections with cortical and limbic structures and
is believed to be involved in consciousness, awareness, and arousal. Abnor-
mal functioning of the thalamus may contribute to symptoms such as
disturbed sleep patterns. The insula is a structure that has been implicat-
ed in interoceptive awareness [43]. During an interoceptive attention
task, the dorsal mid-insula exhibited decreased activity in unmedicated
MDD subjects compared to controls [44]. Decreased activity has also
been associated with severity of depression and somatic symptoms in de-
pressed subjects.
Structural Changes with Antidepressant Treatment
Antidepressants such as selective serotonin reuptake inhibitors (SSRIs),
which are widely used in the treatment of depression, have been reported
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to alter the structure of frontal-subcortical circuits involved in the pathophys-
iology of depression [31, 45, 46•, 47, 48].
Increases in hippocampal volume have been reported following eight
weeks of treatment with citalopram [46•] as well as following three years
of treatment with various antidepressant medications [47]. Volume increases
have also been reported in the dorsolateral and orbitofrontal cortices follow-
ing treatment with fluoxetine [31]. The hippocampus is involved in declara-
tive or explicit memory function [49, 50], and these findings may be
consistent with the amelioration of memory impairments in depressed pa-
tients [51] following antidepressant treatment [52, 53].
However, not all studies have found alterations in brain volume of de-
pressed patients following antidepressant treatment [54, 55]). In addition,
a decrease in volume in the dorsolateral prefrontal cortex has been reported
[56]. More research is needed to delineate volume change and direction of
volume change associated with antidepressant treatment and improved
mood and function.
Functional Changes with Antidepressant Treatment
The effects of antidepressant treatment on affective processing networks have
been more widely studied, as there is a mood-congruent processing bias ev-
ident in patients with depression. This negative bias is evident in the process-
ing of facial expressions [57], and MDD patients show both implicit and
explicit attentional biases toward negative stimuli and away from positive
stimuli [58]. fMRI studies often use implicit emotional processing paradigms
such as a gender decision task, as these tasks are more likely to elicit activa-
tions in subcortical and extrastriate cortical regions [59].
Implicit processing of sad facial expressions has revealed abnormal ac-
tivations in corticolimbic regions such as the amygdala [24, 60], insula
and anterior cingulate [24] at baseline, followed by significant decreases
in the amygdala following treatment with antidepressants [24, 62]. Hap-
py facial expressions, on the other hand, tend to be associated with de-
creased corticolimbic activations in patients compared to controls, and
which normalize following antidepressant treatment [63]. Moreover,
amygdala activations are also observed during passive viewing of nega-
tive stimuli [16, 64] which attenuate with treatment [64]. Conversely, ex-
plicit labelling of emotions is likely to decrease the probability of
amygdala activation compared to passive viewing or implicit processing
[59]. There is also some evidence of a lateralization of amygdala activa-
tions in which the left rather than the right amygdala is more likely to
be activated during processing of evident unmasked emotional stimuli
[65–67], and therefore may be more functionally inclined to modulation
by antidepressants [67].
The fusiform gyrus is important in face processing [65], and is typically
engaged during explicit processing of emotional stimuli. Similar to
amygdalar responses, fusiform gyrus activations are seen in patients versus
controls during negative emotional processing, while decreased activations
have been observed in patients during processing of positive emotional stim-
uli [68]. Normalization of the fusiform gyrus activity after antidepressant
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treatment is seen during both positive [69] and negative [61] emotional stim-
uli, suggesting that antidepressants modulate regions that are associated with
emotion dysregulation in depression.
In addition to biases in emotional processing, depression is associated
with cognitive impairments leading to difficulties in memory and attention.
The anterior cingulate is more likely to be activated during tasks of cognitive
demand [24, 70], and fMRI studies of cognitive processing have shown in-
creased rostral anterior cingulate activity during Stroop tasks [71, 72] and
tasks of cognitive control [73]. Subregions of the anterior cingulate cortex
– namely the pregenual and the subgenual ACC – are important targets for
antidepressant action [74], and normalization of the frontocingulate activity
has been observed with antidepressant treatment [73].
It has been proposed that depression results from abnormal connections
between the limbic regions, such as the amygdala, and other parts of the
brain. Therefore, in addition to investigating regional brain activations, stud-
ies have also looked at the interaction between brain regions that are im-
paired in depression. Patients with depression show reduced functional
connectivity between the frontocortical and limbic regions [16, 19, 67],
which is improved following treatment with antidepressants [67].
Activation in the anterior cingulate and orbitofrontal cortex during an
acute depressive episode is predictive of subsequent clinical response [6••].
In addition, differences in functional orbitofrontal cortex connectivity prior
to treatment have been shown to distinguish responders from non-re-
sponders [75]. The anterior cingulate and orbitofrontal cortices play an im-
portant role in emotional processing, and the orbitofrontal cortex is
particularly associated with reward and hedonic experience [76]. Greater
pre-treatment activity in these regions may suggest better ability to process
emotions and greater responsivity to hedonic stimuli, and therefore predic-
tive of a clinical response [6••].
Functional Changes with Cognitive Behavioural Therapy
Fewer studies have investigated the neural correlates of emotional processing fol-
lowing psychotherapy. Most studies have investigated cognitive behavioural ther-
apy (CBT), an effective treatment for major depressive disorder, with rates of
efficacy comparable toantidepressantmedication [77], andwhich focusesonmod-
ifying dysfunctional thinking and behaviour that are common in depression [78].
Elevated baseline amygdala-hippocampal activity has been identified in
depressed patients in comparison to healthy controls during implicit process-
ing of sad facial expressions which ameliorates following a course of cogni-
tive behaviour therapy [60]. Other reported changes in depressed patients
following cognitive behavioural therapy have included decreased activation
in the medial prefrontal cortex (mPFC) and ventral anterior cingulate cortex
(vACC) in response to an emotional processing task [79] and during self-ref-
erential processing of negative words [80]. The medial prefrontal cortex is
thought to play an important role in self-referential processing of negative
stimuli [81], which is a central feature of rumination and depression [82].
These functional changes in activity following CBT treatment may reflect
an increased engagement of processes involved in modulating responses to
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affect-laden stimuli compatible with a “top-down” mechanism of action
[83].
This cortical top-down model of cognitive therapy focuses on altering
memory and attention processes that are involved in the mediation of cogni-
tive biases and maladaptive processing of information [84]. There is evidence
to suggest that antidepressants may have a mechanism of action similar to
cognitive therapy in modulating negative biases and memory impairments
in depression, occurring very early in the course of treatment, even before pa-
tients report any change in their mood or anxiety [85••, 86]. As such, these
treatments may have similar neurobiological mechanisms on common un-
derlying processes, leading to improvement in depression.
Clinical Neuroimaging Biomarkers in Depression
In addition to examining treatment effects in major depression, identifying
biomarkers of clinical response may aid in treatment recommendations as
well as in the development of novel strategies to augment existing treatment
methods. Our meta-analysis of both pharmacological and psychological
treatment studies revealed that higher pre-treatment anterior cingulate activ-
ity was a consistent predictor of clinical response, while reduced baseline hip-
pocampal volume and increased insula and striatum activity were indicative
of a poorer clinical response [6••]. Anterior cingulate activity as a predictor of
clinical response has been widely reported across different antidepressant
treatment studies using a variety of tasks, including resting-state [87, 88], emo-
tion processing [23, 74, 89], and cognitive [90] tasks. The predictive function of
the anterior cingulate is usually observed in response tonegative rather thanpos-
itive emotional stimuli [23, 74, 89].Whilst there is strong evidence for increased
baseline activation in the anterior cingulate as a predictor for antidepressant re-
sponse, the evidence for CBT has beenmoremixed [6••], in part due to the lim-
ited number of studies. Further investigation is warranted.
To translate these findings into clinical application, it is important to
identify clinical biomarkers with high predictive accuracy at the individual
level [5•]. Using neuroimaging measures, it has been possible to identify bio-
markers of clinical response even before the start of treatment. To date, there
are no biological markers that are used to diagnose the disorder or to predict
clinical response. Methods of analyses based on machine learning algorithms
have been applied to neuroimaging measures such as structural and func-
tional data to predict diagnosis, course of illness, and treatment prognosis
[7]. The pattern of baseline neural activity during sad facial expression accu-
rately classified 84 % of MDD patients and 89 % of healthy controls [4••],
while neural correlates of verbal working memory showed reduced accuracy
[90]. Baseline neural activity during sad facial processing predicted remission
to CBT with a sensitivity of 71 % and specificity of 86 % [91], while remis-
sion to antidepressants showed a trend towards significance [4••]. Evidence
from structural data, on the other hand, revealed that grey matter density pre-
dicted clinical response to antidepressant medication, in particular in the
anterior cingulate [42, 92]. Further investigation of neuroimaging as well
as other biological measures is required to develop clinically useful bio-
markers. This would help optimize treatment strategies, especially for
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those who may not benefit from current first-line treatment options that
are available for depression.
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Background. Dysfunctional attitudes are a feature of depression that has been correlated with receptor binding abnor-
malities in limbic and cortical regions. We sought to investigate the functional neuroanatomy of dysfunctional attitudes
in major depressive disorder (MDD) and the effects of treatment with cognitive–behavioural therapy (CBT).
Method. Participants were 16 patients with unipolar depression in an acute depressive episode (mean age 40.0 years)
and 16 matched healthy controls (mean age 39.9 years). Patients were medication free and received a course of treatment
with CBT. All participants underwent functional magnetic resonance imaging (fMRI) scans at baseline and at week 16,
prior to the initiation of therapy and following the course of CBT for patients. During each fMRI scan, participants indi-
cated their attributions to statements from a modiﬁed Dysfunctional Attitudes Scale (mDAS-48).
Results. MDD patients in an acute depressive episode endorsed a greater number of extreme responses to DAS state-
ments, which normalized following CBT treatment. Extreme attributions were associated with greater activation in
the left hippocampal region, inferior parietal lobe and precuneus in MDD patients as compared with healthy controls
as a main effect of group. An interaction effect was found in the left parahippocampal region, which showed less attenu-
ation in MDD patients at the follow-up scan relative to healthy controls.
Conclusions. Attenuation of activity in the parahippocampal region may be indicative of an improvement in dysfunc-
tional thinking following CBT treatment in depression, while persistent engagement of regions involved in attentional
processing and memory retrieval with extreme attributions reﬂects a trait feature of depression.
Received 29 June 2013; Revised 9 September 2014; Accepted 24 September 2014
Key words: Brain imaging, cognitive behavioural therapy, depression, dysfunctional attitudes, neuroimaging,
psychotherapy.
Introduction
Beck (1967) postulated that early detrimental life
events could lead to the development of negative sche-
mas which include themes of loss, failure and aban-
donment. Dysfunctional attitudes, such as ‘if I fail
partly, it is as good as being a complete failure’, are
activated during stressful life events and are character-
istic of a depressive episode (Haaga et al. 1991). It has
been proposed that depressive symptoms are pro-
moted by dysfunctional attitudes (Sheppard &
Teasdale, 2000) in a reciprocal causal relationship
(Burns & Spangler, 2001). In support, positive associa-
tions between depression severity and dysfunctional
attitudes have been observed (Beevers et al. 2003),
which revert to normal during remission (Haaga
et al. 1991), and the magnitude of dysfunctional think-
ing during a dysphoric mood state is predictive of a
subsequent depressive relapse (Segal et al. 2006).
High levels of dysfunctional thinking during a de-
pressive episode have been associated with greater
5-HT2 receptor binding potential in the anterior cingu-
late, prefrontal regions, thalamus, caudate and pu-
tamen (Meyer et al. 2004). Administration of the
serotonin agonist D-fenﬂuramine led to a reduction in
dysfunctional attitudes, suggesting that serotonin
agonism can reduce dysfunctional attitudes by in-
ducing neuronal release of serotonin in depression
(Meyer et al. 2003). Although a correlation with recep-
tor binding potential and attributions has been
observed, subjects were not actively engaged in a dys-
functional attitudes task during the brain scan.
An aim of cognitive–behavioural therapy (CBT) is to
address dysfunctional attitudes that contribute to the
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persistence of depressive symptoms (Dobson & Dozois,
2001). Following treatment with CBT, increased activity
has been noted in the anterior cingulate during a rest-
ing state (Goldapple et al. 2004), in response to sad
faces (Fu et al. 2008), and with self-referential proces-
sing to positive stimuli though not to negative stimuli
(Yoshimura et al. 2014). Additional neural correlates
of CBT in depression include normalization of amyg-
dala activity to sad facial expressions (Fu et al. 2008),
increases in ventromedial cortical activity (Ritchey
et al. 2011), decreases in dorsal frontal cortical activity
(Kennedy et al. 2007), and increases in hippocampal ac-
tivity during a resting state (Goldapple et al. 2004). The
changes in prefrontal, limbic and subcortical activity
are generally consistent with models of neurocognitive
circuits in depression and the effects of CBT (DeRubeis
et al. 2008).
However, the brain regions engaged by dysfunc-
tional thinking in depression and the effects of CBT
have not been examined. In the present study, we
sought to investigate the neural correlates of dysfunc-
tional attitudes in patients with depression during an
acute depressive episode and following treatment
with CBT. We expected that patients would show
greater endorsement of dysfunctional attitudes during
an acute depressive episode, which we expected would
improve following treatment with CBT. We hypothe-
sized that major depressive disorder (MDD) patients
would show greater activation in the anterior cingulate
and regions associated with attention and self-
referential processing with extreme attributions rela-
tive to healthy controls. We expected to observe
increased activity in regions associated with attentional
processing of negative stimuli in patients during an
acute depressive episode which would resolve follow-
ing CBT, including increased activity in the amygdala
which would normalize following CBT.
Method
Participants
All participants were right handed and ﬂuent in
English. Participants were recruited through local
newspaper advertisements. The study was approved
by the Institute of Psychiatry and South London and
Maudsley (SLaM) National Health Services (NHS)
Ethics Research Committee, and all participants pro-
vided written, informed consent. All procedures con-
tributing to this work comply with the ethical
standards of the relevant national and institutional
committees on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2008.
The patient group consisted of 16 participants [13
women, mean age 40.00 years (S.D. = 9.27)] who met
criteria for MDD by the Structured Clinical Interview
for DSM-IV (First & Gibbon, 1997) and a clinical inter-
view with a consultant psychiatrist. Inclusion criteria
were an acute episode of MDD, unipolar subtype
and a score of a minimum of 18 on the 17-item
Hamilton Rating Scale for Depression (HAMD;
Hamilton, 1960). The exclusion criteria were a current
neurological disorder, history of neurological trauma
resulting in a loss of consciousness, history of diabetes
or medical disorder, other Axis I disorders including
anxiety disorder or history of substance abuse within
2 months of participation in the study. All patients
were free of psychotropic medications for a minimum
of 4 weeks at the time of recruitment (8 weeks for
ﬂuoxetine) and remained medication free throughout
the treatment. HAMD score was measured at baseline
and following the course of CBT at the end of 16
weeks.
Healthy controls were 16 age-, sex- and intelligence
quotient (IQ)-matched healthy participants [13
women, mean age 39.94 years (S.D. = 9.48)] with
HAMD scores less than 8 and no history of previous
psychiatric illness, neurological disorder or head injury
resulting in a loss of consciousness. All healthy controls
were free of psychotropic medications. HAMD score
was measured at baseline and at the end of 16 weeks.
Dysfunctional Attitude Scale (DAS)
The DAS measures pervasive negative attitudes
towards the self, the world and the future. In the pres-
ent study, the DAS-24 (Power et al. 1994) was used,
which is a shortened version of the DAS (Weissman
& Beck, 1978) consisting of 24 statements. Also, 24 neu-
tral statements were included as a control task for the
present study, which we have called the control DAS
(cDAS). We have termed the 48-item scale as the ‘mod-
iﬁed Dysfunctional Attitude Scale’ (mDAS-48).
During the functional magnetic resonance imaging
(fMRI) scan, participants were presented with the
mDAS-48 task consisting of statements alternating
from the DAS and cDAS. Subjects were asked to re-
spond to each statement using seven-point Likert
scales, ranging from totally agree to totally disagree.
Extreme responses are a reﬂection of the endorsement
of dysfunctional attitudes (Power et al. 1994). The fMRI
task began with either a DAS or cDAS statement which
was presented in a counterbalanced order for consecu-
tive participants, and the same version was used for
the same participant. fMRI scans were acquired at
baseline (week 0) and upon study completion (week
16). Each MRI scan was up to 1.5 h in duration consist-
ing of fMRI tasks and structural MRI scans, and data
from an affective facial processing task have been pre-
sented (Fu et al. 2008).
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All behavioural data were recorded during the fMRI
scans and analysed using SPSS (version: PASW
Statistics 18). Repeated-measures analysis of variance
(ANOVA) was used to analyse the main effect of
group (patients v. controls), main effect of statement
(DAS v. cDAS), main effect of time (week 0 v. week
16) and group × time interactions (i.e. changes in re-
sponse between baseline and ﬁnal trials). Percentage
change in extreme attributions (total number of ex-
treme DAS scores at week 16− total number of ex-
treme DAS scores at baseline/total number of extreme
DAS scores at baseline × 100) was also calculated for
each subject.
CBT treatment
Patients received 16 sessions of CBT with experienced
therapists (Fu et al. 2008). The standard CBT proce-
dures as described by Beck et al. (1979) were followed,
and all therapists met the required level of training and
proﬁciency (Paykel et al. 1999). The CBT sessions were
audiotaped and reviewed to ensure adherence and
competence. HAMD scores were obtained from
patients at baseline and after 16 weeks of CBT. We
deﬁned treatment response as a minimum reduction
of 50% in HAMD score from baseline.
Image acquisition
Gradient echo single-shot echoplanar imaging data were
acquired on a neuro-optimized 1.5T IGE LX system
(USA) at the Maudsley Hospital, London. A total of
441 T2* weighted images depicting blood oxygenation
level-dependent (BOLD) contrast were acquired over
27 min. For each volume, 22 near-axial non-contiguous
3 mm planes parallel to the intercommissural plane;
time to echo (TE) = 40 ms; repetition time (TR) = 3.74 s;
in-plane resolution = 3.75 mm; interslice gap 0.3 mm;
and matrix size 64 × 64 voxels. Four dummy acquisitions
were acquired at the beginning of each scan to allow
magnetization to reach equilibrium amplitude.
fMRI data analysis
fMRI data analysis was conducted using XBAM soft-
ware (version 4.1; Institute of Psychiatry, King’s
College London). Images were ﬁrst realigned to mini-
mize subject motion and then smoothed using a
Gaussian ﬁlter (full-width half-maximum = 7.2 mm).
Responses to the experimental paradigms were
detected by carrying out time-series analysis using
two gamma variate functions with peak responses at
4 and 8 s, respectively. The best ﬁt between the
weighted sum of these and the time series at each
voxel was computed with a goodness of ﬁt at each
voxel. The ratio of the sum of squares (SSQ) of
deviations from the mean image intensity due to the
model over the whole time series to the SSQ of devia-
tions due to the residuals was computed, termed the
SSQ ratio. The data were then permuted by a wavelet-
based method which permits the calculation of the null
distribution of SSQ ratios under the assumption of no
experimentally determined response. This distribution
was used to calculate the SSQ ratio value and to ﬁnd
the threshold for the activation maps at type I error
rate of less than one voxel. The SSQ ratio data for
each individual were transformed into standard
space of Talairach & Tournoux (1988).
Group activation maps were computed using the
median SSQ ratio at each voxel in the observed and
permuted maps. Permutation methods and median
statistics were used to obtain the null distribution of
SSQ ratios and as well as the critical SSQ ratio to
threshold group activation maps at a cluster-level
threshold of less than one expected type I error cluster
per brain. For the present group analysis, less than one
false-positive cluster was expected at p < 0.05 for voxel
level and p < 0.01 at cluster level. Only those voxels at
which all subjects contributed data were included for
analysis (Fu et al. 2008).
In order to examine the neural correlates of dysfunc-
tional attributions, the fMRI time series corresponding
to attributions that corresponded to endorsements of 1,
2, 6 or 7 on the Likert scale were encoded. The fMRI
time series associated with regular attributions were
encoded by Likert scale responses of 3, 4 or 5. We
employed a 2 × 2 ANOVA to examine the main effect
of group (patients v. healthy controls across both
time points), main effect of time (week 0 v. week 16)
and the group × time interaction. The analyses were
examined for regular attributions made to DAS relative
to control DAS statements and for extreme attributions
made to DAS relative to control DAS statements.
Results
Demographics
There were no signiﬁcant group differences in
mean age, full IQ, verbal IQ and performance IQ (all
p > 0.05) (Table 1). All patients completed a full course
of 16 weeks of CBT. There was an expected signiﬁcant
difference in HAMD scores between the groups at
week 0 (F1,30 = 1765.21, p < 0.001) and at week 16
(F1,30 = 18.96, p < 0.001). Patients showed a signiﬁcant
reduction in mean HAMD scores from baseline to
week 16 (F1,15 = 118.45, p < 0.001).
Behavioural data
The extreme responses to the DAS statements
showed a signiﬁcant group × time interaction effect
Neural effects of cognitive–behavioural therapy on dysfunctional attitudes 3
(F1,30 = 7.434, p = 0.011), in which patients showed a
signiﬁcant reduction in mean number of extreme
responses following a course of CBT [t = 2.938, degrees
of freedom (df) = 15, p = 0.010] while healthy controls
did not have a change in extreme scores at the follow-
up scan as compared with baseline (t =−0.659, df = 15,
p = 0.520) (Table 1). There was also a trend towards a
signiﬁcant effect of time (F1,30 = 3.681, p = 0.065), as
both groups showed a reduction in extreme responses
at the follow-up scan. There was no signiﬁcant main
effect of group in extreme responses (F1,30 = 0.016,
p = 0.900) (Table 2).
In the control DAS statements, there were no signiﬁ-
cant main effects of time (F1,30 = 2.054, p = 0.162), group
(F1,30 = 0.140, p = 0.711) or group × time interaction ef-
fects (F1,30 = 3.343, p = 0.077).
There were no signiﬁcant correlations between the
change in HAMD scores and the change in the number
of extreme responses made to the DAS statements in
MDD patients (r = 0.465, p > 0.05, one-tailed test). We
were also interested in examining the relationship be-
tween changes in DAS scores and response to treat-
ment. However, the number of patients who did not
respond to treatment (n = 3) was insufﬁcient to com-
pare with those who responded. Hence, we report
the mean percentage change in extreme DAS scores
in responders (mean =−13.34, S.D. = 33.66) and non-
responders (mean =−12.8, S.D. = 15.75).
fMRI results
Neural responses to extreme attributions in DAS
A signiﬁcant group × time interaction effect for extreme
attributions to DAS statements was found in the left
parahippocampal gyrus [Brodmann area (BA) 37]
(Talairach coordinates: x, y, z =−36, −41, −7, cluster
size = 41 voxels, corrected p = 0.0027). This region
showed less attenuation in activation in MDD patients
as compared with healthy controls at the 16-week scan
(Figs 1 and 2).
There was a signiﬁcant main effect of group in which
patients showed greater activation in the left
Table 1. Demographic and clinical characteristics
Healthy controls MDD patients




Age, years 40.00 (9.27) 39.94 (9.48)
Full IQ 123.44 (10.63) 120.03 (14.02)
Verbal IQ 120.44 (11.98) 118.09 (15.95)
Performance IQ 122.31 (11.74) 118.34 (13.37)
Age of onset, years (range) N.A. 33.8 (18–53)
Number of previous episodes (range) N.A. 0.63 (0–2)
Duration of current episode, years (range) N.A. 1.64 (0.2–4)
Number of treatment trials for present episode (range) N.A. 0.13 (0–1)
HAMD scores at baseline 0.19 (0.05) 20.88 (1.89)
HAMD scores at week 16 0.56 (1.15) 6.37 (5.21)
Data are given as mean (standard deviation) unless otherwise speciﬁed.
MDD, Major depressive disorder; IQ, intelligence quotient; N.A., not applicable; HAMD, Hamilton Rating Scale for
Depression.
Table 2. Behavioural performance on the DAS task
Healthy controls MDD patients
DAS task
Week 0
Extreme attributions 13.94 (4.11) 15.82 (5.45)
Regular attributions 10.06 (4.10) 8.18 (5.62)
Week 16
Extreme attributions 14.44 (3.67) 12.94 (4.46)
Regular attributions 9.56 (3.67) 11.06 (4.46)
Control DAS task
Week 0
Extreme attributions 13.88 (4.44) 15.88 (3.84)
Regular attributions 10.12 (4.44) 8.12 (3.61)
Week 16
Extreme attributions 14.12 (3.91) 13.43 (3.85)
Regular attributions 9.88 (3.91) 10.57 (3.85)
Data are given as mean (standard deviation).
DAS, Dysfunctional Attitudes Scale; MDD, major depress-
ive disorder.
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hippocampal region (coordinates: x, y, z =−11,−33,−3,
cluster size = 27 voxels, corrected p = 0.0016), left inferior
parietal lobe (BA 40) (coordinates: x, y, z =−36, −33, 40,
cluster size = 55 voxels, corrected p = 0.0013) and left pre-
cuneus (BA 7) (coordinates: x, y, z =−14, −67, 33, clus-
ter size = 109 voxels, corrected p = 0.00006) as compared
with healthy controls, while in the left cerebellum
healthy controls showed greater activation relative to
patients (coordinates: x, y, z =−11, −44, −23, cluster
size = 45 voxels, corrected p = 0.0016) (Fig. 3).
In patients, a main effect of time was observed in the
right posterior cingulate gyrus (BA 30) (coordinates
x, y, z = 11, −44, 23, cluster size = 73 voxels, corrected
p = 0.006) which showed decreased activation from
week 0 to week 16, while no regions showed greater
activation from the initial to the ﬁnal scan. In healthy
controls, no regions showed decreased activation
from week 0 to week 16, but there was a signiﬁcant
main effect of time in the left cuneus (BA 18) (coordi-
nates x, y, z =−18, −78, 17, cluster size = 53 voxels, cor-
rected p = 0.005), which showed increased activation
from the initial to the ﬁnal scan.
Patients showed a signiﬁcant positive relationship
between changes in HAMD score and overall activity
in the left precentral gyrus (BA 6) (coordinates x, y,
z =−43, −4, 40; cluster size = 28 voxels, r = 0.739, cor-
rected p = 0.004), in which patients with the greatest
improvement in HAMD scores following CBT treat-
ment had the greatest increase in activity in the precen-
tral gyrus (Fig. 4).
Neural responses to regular attributions in DAS
There was no signiﬁcant main effect of group or any
group × time interaction effects in the neural responses
to regular attributions to the DAS statements.
In patients, no regions showed decreased activation
from the initial to ﬁnal scan, but there was a main ef-
fect of time in the left cerebellum (Talairach coordi-
nates x, y, z =−11, −74, −17, cluster size = 26 voxels,
corrected p = 0.0025), which showed increased acti-
vation from weeks 0 to 16. In healthy controls, main ef-
fects of time were observed in the left lingual gyrus
(BA 18), left parahippocampal gyrus and bilateral pre-
cuneus (BA 7) (corrected p < 0.006), which showed
reduced activation from the initial to ﬁnal scans and
in the left inferior frontal gyrus (BA 10) (coordinates
x, y, z =−36, 44, 3, cluster size = 36 voxels, corrected
Fig. 1. There was a signiﬁcant group × time interaction effect in the left parahippocampal region for extreme attributions to
Dysfunctional Attitudes Scale statements (corrected p = 0.0027). Both depressed patients and healthy controls showed a
decrease in activation in the left parahippocampal gyrus at the follow-up scans but to a lesser extent in patients. Transverse
sections of the brain are presented with the Talairach z-coordinates indicated.
Fig. 2. The graph presents the group × time interaction effect
in the left parahippocampal region. The boxes indicate
interquartile range. The horizontal lines in the boxes
represent medians. The limit lines indicate ranges excluding
outliers, and the circles represent outliers which are deﬁned
as points greater than 1.5 times the interquartile range from
the limits of the interquartile range. The y-axis sum of
squares (SSQ) values represent a normalized statistic of the
brain response.
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p = 0.003) which showed increased activation from the
initial to ﬁnal scans.
Main effects of the DAS task and group are pre-
sented in the online Supplementary material.
Discussion
The present study supports a modifying effect of CBT
on dysfunctional attitudes (Haaga et al. 1991; Furlong
& Oei, 2002) as patients endorsed a greater number
of extreme responses to DAS statements during an
acute depressive episode which normalized following
CBT. Dysfunctional attitudes are also seen to reduce
following antidepressant treatment (Shankman et al.
2012), suggesting that they may be a state feature of de-
pression. Parallel decreases in levels of dysfunctional
attitudes and the severity of depression following
CBT have also been noted (Persons & Burns, 1985),
although dysfunctional attitudes have also been
observed as a trait feature of depression (Roberts &
Gamble, 2001). However, we did not observe a corre-
lation between an improvement in depression severity
and a reduction in extreme DAS attributions, as all
patients showed an improvement in their extreme
attributions.
The neural correlates revealed that endorsement of
dysfunctional attitudes was associated with left para-
hippocampal activation in both depressed patients
and healthy controls, which decreased at the follow-up
scans in both groups but to a lesser extent in patients.
The parahippocampal region along with the hippo-
campus and association areas of the cerebral cortex
form the medial temporal lobe system (Eichenbaum
& Lipton, 2008). There is a bidirectional hierarchy of re-
ciprocal connections in which the cortical association
areas connect to the parahippocampal region and in
turn to the hippocampus. The output from the hippo-
campus is then returned to the parahippocampal re-
gion and to the cortical regions where the input
originated (Eichenbaum & Lipton, 2008). The parahip-
pocampal region is associated with contextual associa-
tions or episodic memory and shows a familiarity
effect during repetition of tasks, with greater activation
during novel as compared with familiar tasks (O’Kane
et al. 2005).
Depressed individuals have shown greater acti-
vation in the left parahippocampal gyrus relative to
controls, during encoding of an associative learning
paradigm (Werner et al. 2009) and in processing nega-
tive pictures (Sheline et al. 2009). Reductions in para-
hippocampal activation have similarly been observed
in MDD patient following treatment with antidepres-
sant medication (Kennedy et al. 2001; Delaveau et al.
2011). Behavioural studies of dysfunctional attitudes
also show higher endorsement of dysfunctional atti-
tudes by patients relative to controls during negative
mood induction (Lau et al. 2012) and signiﬁcant im-
provement in dysfunctional thinking in patients fol-
lowing CBT (Warmerdam et al. 2010). To date, there
Fig. 4. A signiﬁcant correlation was found between the
change in the severity of depression as measured by the
Hamilton Rating Scale for Depression (HAMD) scores and
activity in the left precentral gyrus. Patients who had the
greatest change in HAMD score following cognitive–
behavioural therapy showed the greatest increase in activity
in the left precentral gyrus during processing of
dysfunctional attitudes. The y-axis sum of squares (SSQ)
values represent a normalized statistic of the brain response.
Fig. 3. In the main effect of group, major depressive disorder patients showed signiﬁcantly greater activation in the left
hippocampus (corrected p = 0.0016), left inferior parietal lobe (corrected p = 0.0013) and left precuneus (corrected p = 0.0006),
relative to healthy controls. Healthy controls showed a greater activation in left cerebellum (corrected p = 0.0016) compared
with depressed patients. Transverse sections of the brain are presented with the Talairach z-coordinates indicated.
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has been no fMRI study that has investigated the
neural correlates of dysfunctional attitudes in de-
pression, and therefore we cannot make direct compar-
isons to conﬁrm the role of the parahippocampal gyrus
in dysfunctional attitudes. However, left parahippo-
campal activation seems to be especially associated
with negative stimuli (Iidaka et al. 2002; Surguladze
et al. 2005), and activation in this region in both
patients and in controls during presentation of DAS
statements supports the role of the left parahippocam-
pal gyrus in processing negative information contained
in the DAS statements. The reduction in parahippo-
campal activation at the follow-up scan for both
groups is consistent with increased familiarity with
repetition of the task, although patients did not dem-
onstrate the same extent in the reduction in activation.
This may perhaps reﬂect patients’ inability to recall the
task in the same manner as controls in part due to per-
sistent engagement and contextual associations to the
DAS statements.
In the main effect of group across both time points,
there was greater activation in a region that encom-
passed the left hippocampal gyrus, inferior parietal
lobe and precuneus in patients relative to healthy con-
trols. The inferior parietal lobe plays a prominent role
in attention (Pessoa et al. 2002), processing of written
language (Eckert, 2004), working memory of emotional
stimuli (Rämä et al. 2001), and during episodic mem-
ory retrieval (Maddock et al. 2001). The increased acti-
vation observed in MDD patients relative to controls in
the inferior parietal lobe may have reﬂected their
greater attention in the processing of DAS statements
along with the retrieval of associated memories. The
precuneus is implicated in the visual processing of in-
formation including the retrieval of episodic memory
which is modulated by attention (Cavanna &
Trimble, 2006). In depression, the precuneus has been
engaged by visual presentation of negative emotional
stimuli (Phillips et al. 2004) and by sad relative to
happy stimuli (Keedwell et al. 2005). The increased ac-
tivity in the precuneus in MDD patients probably
reﬂects increased attention during visual processing
of DAS statements. The circular causality hypothesis
(Burns & Spangler, 2001) proposes that dysfunctional
attitudes and negative emotions have a reciprocal cau-
sal effect, which may have been induced by the DAS
statements.
Furthermore, improvement in the severity of de-
pressive symptoms showed a signiﬁcant positive corre-
lation with left precentral activity. The precentral gyrus
plays an important role in successful response inhi-
bition, while patients in an acute depressive episode
tend to show impaired response inhibition (Schmid
et al. 2011). Increased activity in the left precental
gyrus has been reported in patients following
treatment with psychotherapy (Dichter et al. 2009).
Larisch et al. (1997) found signiﬁcant positive correla-
tions between dopamine (D2) binding changes in the
left precentral gyrus and an improvement in de-
pression scores following antidepressant treatment,
and the left precentral gyrus shows increased func-
tional connectivity with the orbitofrontal cortex at
baseline in subsequent responders to antidepressant
treatment relative to non-responders (Lisiecka et al.
2011). The positive association between precentral ac-
tivity and depression scores in the present study
could reﬂect the improvements in inhibitory control
in patients as they recovered from an acute depressive
episode.
It was notable that the group differences in neural
responses to extreme attributions to the DAS statements
were not found with the regular attributions to DAS
statements, reﬂecting the speciﬁcity of the neural effects
to extreme attributions. However, contrary to our hy-
pothesis, we did not ﬁnd evidence for increased amyg-
dala activity in MDD patients. The probability of
amygdala activation is greater during passive processing
of emotional stimuli rather than tasks involving any
form of attentional effort, and language is associated
with a signiﬁcant reduction in amygdala activity
(Costafreda et al. 2008). In the present study, DAS state-
ments were presented as sentences and participants
were required to make an active judgement in response,
which probably contributed to the low elicitation of
amygdala responsivity with the DAS statements.
Furthermore, the present study was limited by the lack
of a patient group who received a placebo treatment.
We are unable to conclude with certainty that the sign-
iﬁcant difference in brain activation in patients is as a re-
sult of treatment with CBT. Future research should also
investigate whether a reduction in dysfunctional think-
ing is evident with antidepressant treatment.
In summary, the present study supports ﬁndings that
dysfunctional thinking is characteristic of major de-
pression. Extreme attributions to DAS statements are in-
dicative of dysfunctional thinking, and MDD patients
showed a signiﬁcant decrease in extreme attributions fol-
lowing CBT. MDD patients demonstrated persistently
greater activity in regions associated with attentional
processing and memory retrieval that was induced by
the DAS statements. Attenuation of parahippocampal
activity was observed at the follow-up scans in both
groups, though to a lesser extent in the MDD patients,
perhaps reﬂecting an improvement in dysfunctional
thinking with some persistent vulnerability.
Supplementary material
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Abstract
Background: Longitudinal neuroimaging studies of major depressive disorder (MDD) have most commonly
assessed the effects of antidepressants from the serotonin reuptake inhibitor class and usually reporting a single
measure. Multimodal neuroimaging assessments were acquired from MDD patients during an acute depressive
episode with serial measures during a 12-week treatment with the serotonin-norepinephrine reuptake inhibitor
(SNRI) duloxetine.
Methods: Participants were medication-free MDD patients (n = 32; mean age 40.2 years) in an acute depressive
episode and healthy controls matched for age, gender, and IQ (n = 25; mean age 38.8 years). MDD patients received
treatment with duloxetine 60 mg daily for 12 weeks with an optional dose increase to 120 mg daily after 8 weeks.
All participants had serial imaging at weeks 0, 1, 8, and 12 on a 3 Tesla magnetic resonance imaging (MRI) scanner.
Neuroimaging tasks included emotional facial processing, negative attentional bias (emotional Stroop), resting state
functional MRI and structural MRI.
Results: A significant group by time interaction was identified in the anterior default mode network in which
MDD patients showed increased connectivity with treatment, while there were no significant changes in healthy
participants. In the emotional Stroop task, increased posterior cingulate activation in MDD patients normalized
following treatment. No significant group by time effects were observed for happy or sad facial processing,
including in amygdala responsiveness, or in regional cerebral volumes. Reduced baseline resting state connectivity
within the orbitofrontal component of the default mode network was predictive of clinical response. An early
increase in hippocampal volume was predictive of clinical response.
Conclusions: Baseline resting state functional connectivity was predictive of subsequent clinical response.
Complementary effects of treatment were observed from the functional neuroimaging correlates of affective
facial expressions, negative attentional bias, and resting state. No significant effects were observed in affective
facial processing, while the interaction effect in negative attentional bias and individual group effects in resting
state connectivity could be related to the SNRI class of antidepressant medication. The specificity of the observed
effects to SNRI pharmacological treatments requires further investigation.
Trial registration: Registered at clinicaltrials.gov (NCT01051466).
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Background
Major depressive disorder (MDD) is characterized by
a prolonged low mood, neurovegetative disturbances,
and cognitive impairments. Neuroimaging has aided
in the delineation of the neural circuitry of MDD
[1,2], determination of the effects associated with a
course of therapy [3-5], provision of novel insights for
neuropsychological models [2], and the potential for
the development of prognostic and diagnostic bio-
markers [6,7].
Within the neural circuitry of MDD, the intensity of
engagement and their regional distribution depend in
part on the emotional and cognitive features of the
particular task. For example, in response to negative
stimuli, MDD patients tend to show greater responsivity
in the amygdala, dorsal anterior cingulate and insula, but
reduced activity in the dorsolateral prefrontal cortex and
striatum relative to healthy participants, while measures of
resting state have most commonly revealed greater re-
gional cerebral blood flow in the thalamus [5]. Studies
have generally reported findings from a single task, while
concurrently acquired, multiple functional and structural
measures may provide a more comprehensive assessment
[1-6,8]. Furthermore, longitudinal treatment studies
have most frequently investigated the serotonin reuptake
inhibitors (SRI), in which reduced activity in subcortical
and limbic regions in MDD patients has been noted
following treatment [3-5]. However, the effects of the
SRI class of antidepressants may not necessarily be
extrapolated to norepinephrine reuptake inhibitors
(NRI) [9-12].
The present study is a multimodal investigation of the
functional and structural neuroanatomy of depression
in a prospective, longitudinal design with the dual
serotonin-norepinephrine reuptake inhibitor (SNRI)
duloxetine. MDD patients participated in MRI scans
during an acute depressive episode and during the course
of treatment, and healthy controls had the same scans at
the same time points. Our main hypothesis was that
treatment would be associated with normalization of
anterior cingulate and amygdala activation in response
to sad faces in MDD patients as compared with healthy
participants [3-5].
Methods
The study was approved by the Cambridgeshire 4 Research
Ethics Committee, NHS Research Ethics Committee,
National Research Ethics Service, NHS Health Research
Authority, and all participants provided informed written
consent. The study was conducted in conformity with the
Declaration of Helsinki and its amendments. Study proce-
dures and implementation were consistent with Good
Clinical Practice Guidelines and all applicable regulatory
requirements.
Participants
Participants were recruited from the general community
by newspaper advertisement. Inclusion criteria for all
participants were an age range of 25 to 65 years and
being right-handed. MDD patients met criteria for a single
episode of MDD or recurrent MDD, without psychotic
features, as defined by the Diagnostic Statistical Manual
of Mental Disorders, Fourth edition, text revision
(DSM-IV-TR) [13] and assessed with the Structured
Clinical Interview for DSM-IV Axis I disorders (SCID-IV)
[14]; were free of current antidepressant medication for a
minimum of 6 weeks for fluoxetine treatment or 4 weeks
for other antidepressant medication before the start of
treatment at baseline (week 0); and had a 17-item
Hamilton Rating Scale for Depression (HRSD-17) [15,16]
total score ≥ 18 at the screening assessment and baseline.
Healthy participants were matched by age, gender,
and intelligence quotient (IQ); had HRSD-17 total
score ≤ 7 at screening and baseline; and did not meet
criteria for MDD based on SCID-IV. IQ was evaluated with
the Wechsler Adult Intelligence Scale-III UK (WAIS-III
UK) [17].
Exclusion criteria were any significant comorbid medical
or psychiatric disorders, as defined by DSM-IV-TR Axis I
or II disorder including a history of substance abuse
or dependence within the prior 6 months, excluding
nicotine and caffeine; known Alzheimer’s disease or
mental retardation; serious suicidal risk or risk of
self-harm (Columbia-Suicide Severity Rating Scale)
[18]; history of electroconvulsive therapy, transcranial
magnetic stimulation, or vagus nerve stimulation within
the past year; abnormal thyroid stimulating hormone
concentration; or medical disorders known to affect
central nervous system structures or function.
Enrolled in the study were 32 MDD patients, having
a moderate to severe severity of depression (mean
HRSD-17 = 22.4 (standard deviation (SD) = 2.7)), and 28
healthy participants, with no significant between-group
differences in demographics (Table 1). Twenty-four MDD
patients and 23 healthy participants completed all the
serial MRI scans.
Study design
The protocol consisted of a 12-week treatment period
for MDD patients with duloxetine at a dosage of 60 mg
once daily for the first 8 weeks. At week 8, MDD
patients whose symptoms met criteria for remission
continued taking 60 mg once daily, while those who
did not had an optional dosage-increase up to 120 mg
once daily (Additional file 1: Figure S1).
At baseline, MDD severity was evaluated with the
following scales: SCID-IV [13], HRSD-17 [14,15], Hamilton
Anxiety Rating Scale (HAMA) [19], Columbia-Suicide
Severity Rating Scale (C-SSRS) [18], Clinical Global
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Impression of Severity scale (CGI-S) [20], Patient Global
Impression of Severity scale (PGI-S) [20], and Sheehan
Disability Scale (SDS) [21]. IQ was evaluated with the
WAIS-III UK [17] at weeks 0, 1, or 4. At each subsequent
visit, the following assessments were performed: clinical
assessment and administration of HRSD-17, HAMA,
CGI-S, SDS, and PGI-S by a consultant psychiatrist or
senior resident in psychiatry under supervision by a
consultant psychiatrist. Response to treatment was defined
as a minimum of 50% reduction from the week 0 (baseline)
HRSD-17 total score. Remission was defined as an
endpoint HRSD-17 total score of ≤ 7. During the study,
safety and tolerability to treatment was assessed
through collection and monitoring of discontinuation
rates, treatment-emergent adverse events, serious adverse
events, vital signs, laboratory analyses, and clinical assess-
ments including questioning of suicide-related behavior
and ideations using the C-SSRS.
Healthy participants were evaluated at baseline with
the following rating scales: SCID-IV, HAMA, and
WAIS-III UK. All visits were reviewed with a consultant
psychiatrist.
Functional and structural MRI data acquisition
Magnetic resonance imaging (MRI) scans were acquired
on a 3 Tesla GE SIGNA HDx (Milwaukee, WI, USA) at
King’s College London. MRI scans were acquired at
weeks 0, 1, 8, and 12 for all participants.
Structural MRI scan
A high-resolution 3-dimensional sagittal T1-weighted struc-
tural image was acquired at each session (Magnetization
Prepared Rapid Gradient Echo; resolution 1 mm3). The
functional MRI tasks included affective facial expressions
[4,22,23], negative attentional bias task (emotional Stroop)
[24], and resting state [8].
Affective facial expressions functional MRI task
The event-related functional MRI paradigm consisted of
facial expressions and baseline trials presented in a
random order [4,22,23]. Each facial stimulus was pre-
sented twice at each intensity (60 faces in total), along
with 12 baseline trials consisting of a crosshair for a total
of 72 presentations. Facial stimuli consisted of 10 faces
(5 females) adapted from Pictures of Facial Affect by
Ekman and Friesen morphed to represent varying inten-
sities: low, medium and high [25]. Each stimulus was
presented for 3 seconds. The interval between trials
varied randomly according to a Poisson distribution,
with a mean intertrial interval of 5 seconds, for a total
duration of 360 seconds (6 minutes). Participants were
instructed to specify the gender of the face (male, female),
and responses were made by pressing a button.
Gradient echo T2*-weighted echoplanar images were
acquired depicting blood oxygenation level-dependent
(BOLD) contrast. A total of 180 volumes were acquired
for each for the happy and sad facial tasks. For each vol-
ume, 39 oblique axial slices parallel to the intercommissural
plane were collected with the following parameters:
slice thickness: 3 mm, slice gap: 0 3 mm, echo time (TE):
30 milliseconds, repetition time (TR): 2000 milliseconds,
flip angle: 75°, field of view: 240 mm, and matrix size:
64 × 64.
Emotional Stroop functional MRI task
The emotional Stroop task consisted of 40 negative and
40 neutral words presented in alternating blocks of eight
words per emotional and neutral category, repeated
five times. Each word was presented only once with a
presentation time of 700 milliseconds per word. All
words appeared on a dark grey background in red,
blue, green, or yellow color, pseudo-randomized across
the two valence categories. Four different stimulus sets
which varied in the order of presentation of emotional
and neutral word category blocks were randomized
between scan sessions. The task was projected onto a
screen and viewed from a mirror inside the scanner.
Table 1 Demographics and baseline characteristics
MDD patients Healthy participants
Number 32 25a
Age 40.2 (11.2) 38.8 (9.9)
Age range 25.0-57.9 27.3-58.2
Male 19 (59.4 %) 12 (48.0 %)
Ethnicity
White 18 (56.3 %) 15 (60.0 %)
Asian 10 (31.3 %) 3 (12.0 %)
African descent 4 (12.5 %) 7 (28.0 %)
Current alcohol use 22 (68.8 %) 19 (76.0 %)
Current tobacco use 6 (18.8 %) 1 (4.0 %)
HRSD-17 22.4 (2.7) 0.5 (1.3)
HAMA 21.1 (5.8) 0.4 (0.9)
WAIS-III 107.4 (11.2) 109.2 (14.6)
CGI-S 4.4 (0.6) 1.0 (0.0)
PGI-S 3.8 (1.1) NA
SDS 19.3 (5.4) 0.2 (0.8)
All values are presented as mean and standard deviation in parenthesis,
except where indicated. Age is in years. Number of participants and
percentage of participants are presented for Male gender, Ethnicity, Current
alcohol and tobacco use. Total scores are presented for HRSD-17, HAMA,
WAIS-III and SDS. Participants were matched by age (p = 0.62), gender (p = 0.39),
and WAIS-III IQ (p = 0.61) with no significant difference between groups, similarly
for alcohol (p = 0.55) and drug use (p = 0.12). Abbreviations: CGI-S, Clinician Global
Impression of Severity scale; HAMA, Hamilton Anxiety Rating Scale; HRSD-17,
17-item Hamilton Rating Scale for Depression; MDD, major depressive disorder;
NA, not applicable; PGI-S, Patient Global Impression of Severity scale; SDS,
Sheehan Disability Scale; WAIS-III, Wechsler Adult Intelligence Scale third UK edition.
aexcluding 3 inadvertently enrolled healthy participants who did not meet
entry criteria.
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Participants were instructed to name the color of the word
as quickly as possible. A microphone was used to rec-
ord vocal responses and to provide auditory feedback
of vocal input. Reaction times to the onset of the
vocal responses were measured. Verbal responses during
the MRI scan were made in the absence of scanner
noise as a clustered fMRI image acquisition sequence
was used [24].
The emotional Stroop task was acquired in 133
T2*-weighted echoplanar images, for each volume: 39
oblique axial slices parallel to the intercommissural
plane collected over 2000 milliseconds, allowing for a
silent period of 2000 milliseconds in a clustered fMRI
acquisition. TE: 30 milliseconds, flip angle: 90°, slice
thickness: 3 mm, interslice gap: 0.3 mm, matrix size:
64 × 64. The first 4 volumes collected were acquisitions to
allow for T1 equilibrium effects.
Resting state functional MRI
Whole-brain functional resting state data were collected
while participants were instructed to stay awake with
their eyes closed and not to think of anything specific.
Scan duration was 8.5 minutes. T2*-weighted single-shot
gradient echo echoplanar sequence was acquired with
the following parameters: TE: 30 milliseconds, TR:
2 seconds, FA: 75°, voxel size, 3.75 × 3.75 × 3.3 mm.
Headphones and cushions were used to minimize
scanner noise and head motion, respectively.
Pre-specified primary outcome measure and secondary
analyses
The pre-specified primary outcome measure was the
mean percentage signal change in functional MRI BOLD
contrast response from baseline to week 12 in the mean
of the right and left amygdalae, in response to sad facial
affect processing, comparing MDD and healthy partici-
pants. The sample size for the study was based on effect
size estimates for this primary outcome, obtained from
our previous work on pre- to post- SRI treatment effects
on amygdala activation in MDD patients relative to
healthy controls [4].
Secondary outcomes included baseline-to-endpoint
changes in illness severity, as assessed by HRSD-17,
HAMA, CGI-S, Patient Global Impression of Improvement
scale, and SDS global functioning impairment score, and
their correlation with changes in structural and functional
correlates over sessions in the following regions of interest:
anterior cingulate cortices, amygdalae, and hippocampi.
Changes in functional MRI BOLD contrast response and
volumes of each region of interest from week 0 to weeks 1,
8, and 12 were analyzed using a restricted maximum
likelihood-based mixed-effects model repeated measures
(MMRM) approach. The model included the categorical
effects of group, visit, and group-by-visit interaction as well
as the continuous covariate of baseline measurement. Sig-
nificance tests were based on least-square mean changes
and Type III sum-of-square, implemented using SAS
PROC MIXED (SAS, version 9 1, Cary, NC, USA). Logistic
regression was also used to examine the association
between endpoint remission and changes in neural
correlates. The region-of-interest analyses were per-
formed in all enrolled participants, using MMRM
model or last observation carried forward (LOCF)
methodology for missing observations (eg. participants
who did not complete the study). No multiple compari-
sons correction procedures were applied to the MMRM
analyses as these were pre-specified.
As well, functional whole-brain image analyses were
conducted on a complete case basis involving each scan
session (ie. with participants who participated in all
four MRI scans) as standard software for whole-brain
neuroimaging analysis does not permit “missingness”
in the data set of images. As explained in detail
below, whole-brain image analyses were focused on
functional changes over time in the treatment and
control samples, as well as prediction of treatment
improvement (with HRSD-17 or HAMA) from baseline
functional measurements. Complete data available for
each task were varied due to scan acquisition difficulties,
such as excessive movement during the scan and late
arrival of participants leading to incomplete scan
sessions. The number of participants who completed
these tasks for all the scan sessions: happy and sad
faces (23 MDD and 23 healthy participants); emotional
Stroop (21 MDD and 20 healthy participants); and resting
state (21 MDD and 20 healthy participants). Behavioral
data are presented in the Additional file 1.
Functional and structural MRI analysis
Structural MRI analysis
Analysis of the structural images was performed with
Freesurfer 4.5.0 automated longitudinal stream to
obtain the volumes of a priori regions of interest:
anterior cingulate cortices, amygdalae, and hippocampi
[26]. Quality control was performed by visually assessing
each Freesurfer brain segmentation overlaid on the
original T1 image to ensure that cortical reconstructions
did not present major anomalies. The medial temporal
lobe region was assessed with coronal sections. All recon-
structions passed this qualitative control, and the original
Freesurfer outputs were used without manual correc-
tions. High intraclass correlations (ICC) for repeated
measurements were observed for all the volumetric mea-
surements in the healthy control participants (all > 0.91)
(Additional file 1: Table S1). Volumetric measurements of
the amygdalae, hippocampi and anterior cingulate were
included in second-level MMRM and logistic regression
models.
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Functional MRI analysis: task-related data
Statistical Parametric Mapping (SPM8, Wellcome
Department of Imaging Neuroscience, London, UK)
was used to preprocess and analyze the task-related
fMRI data. Images were realigned to correct for motion
artifacts, spatially normalized to the Montreal Neurological
Institute template, and smoothed using an 8-mm
full-width at half maximum Gaussian kernel filter.
Group analysis used a random effects model consisting of
a 2-stage hierarchical procedure with the first-level
analysis performed by using the general linear model,
accounting for serial autocorrelations by application
of an autoregressive model.
Affective facial expressions task
In the sad and happy faces tasks, stimuli presentations
were modeled as individual events, and the first-level
analysis produced contrast images relevant to the main
contrast of interest (sad faces or happy faces vs. crosshair
baseline). For the primary outcome measure, the MarsBar
SPM toolbox was used to estimate mean activation in the
a priori regions of interest.
Emotional Stroop task
In the emotional Stroop task, the first-level analysis pro-
duced individual mean images corresponding to the
main contrast of interest (negative > neutral) and the
time series was modeled as a block-design.
Second-level analysis of task-related functional tasks
For each task, its second-level analysis employed a
random-effects model to examine the main effect of
group (MDD vs. healthy participants across all time
points), main effect of time (linear changes over weeks 0,
1, 8, and 12) and the group by time interaction. T-tests
were also used to compare scanning data at a particular
time point between groups. Inference of whole-brain
statistical images was conducted using the general linear
model and cluster-wise family-wise error rate control with
p< 0.05 corrected for multiple comparisons. For post hoc
analyses only, in order to identify the direction of changes
responsible for an interaction effect, less conservative
thresholds were also employed as indicated in the
Results section.
Functional MRI analysis: resting-state data
Resting-state analysis was performed using FMRIB Software
Library (FSL) v5.0 (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/).
Preprocessing included motion correction, skull stripping,
spatial smoothing at 5 mm full-width at half maximum,
and registration to standard space. Extraction of resting-
state networks at the group level was conducted by
using FSL Multivariate Exploratory Linear Optimized
Decomposition into Independent Components (MELODIC)
[27]. MELODIC was set to estimate 25 components
to extract stable connectivity estimates of the default
mode networks (DMNs) [8]. Five independent components
depicting DMN activity were identified (Additional file 1:
Figure S2) [28], encompassing the canonical default mode
inclusive of the two core regions (anterior medial prefrontal
and posterior cingulate cortices), dorsomedial prefrontal
subsystem (dorsomedial prefrontal cortex, lateral temporal
cortex, and temporoparietal junction), and medial temporal
lobe subsystem (ventromedial prefrontal cortex including
ventral cingulate, parietal lobule, retrosplenial cortex, and
hippocampal formation) [29,30]. Dual regression was used
to generate participant-specific and scan session–specific
versions of group-level DMN spatial maps in two stages,
resulting in a set of participant-specific spatial maps for
each scan session and participant. Second-level analysis of
resting-state data: Scan-specific maps were used to estimate
contrast maps depicting linear changes across succes-
sive scans for each participant. These statistical maps
(one per participant) were entered in a higher-level
general linear model analysis, and statistical inference
was performed with nonparametric permutation testing
[31]. Correction for multiple comparisons was conducted
using threshold-free cluster enhancement with family-




MDD patients showed a significant improvement in
their depression, as assessed by changes in HRSD-17
(−13.9 [7.0]); HAMA (−11.5 [8.6]); SDS global functioning
impairment score (−9.8 [8.9]); and CGI-S (−2.2 [1.3]).
Upon study completion at week 12, 18 MDD patients
(75.0% of MDD completers) fulfilled criteria for remission
and 19 MDD patients (79.1%) fulfilled criteria for clinical
response. Applying the last observation carried forward
analysis with inclusion of all enrolled participants, there
were no significant differences in the history of depression
between responders (n = 20, median 1 episode, mean
2.7 [4.43]) and non-responders which included MDD
participants who did not complete the study (n = 7,
median 2 episodes, mean 6.14 [10.53]) (p = 0.43). The
frequency and nature of adverse events were consistent
with the known profile of duloxetine [33], and there
was one serious adverse event of retinal pigment
epitheliopathy which was not judged to be related to
the study or duloxetine.
Structural magnetic resonance imaging
There were no significant group by time effects nor any
baseline differences in anterior cingulate cortices, amygda-
lae, or hippocampi volumes (Additional file 1: Table S1).
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Affective facial expressions
Contrary to our hypothesis, there were no significant
between group differences in the change in BOLD response
from baseline to sad faces as analyzed with the MMRM
approach nor any significant group by time effects from the
whole-brain analysis. There were no significant differences
between groups at baseline (Additional file 1: Table S1).
Within the MDD group, a main effect of time was
observed in which there was a significant increase in
the BOLD response to the mean of the medium and
high intensity of expressions in the posterior cingulate/
precuneus (x = −3, y = −43, z = 19; 221 voxels; peak
T = 4.50; p (FWE corrected) = 0.010), while healthy
participants showed a trend towards a decrease in the
orbitofrontal region (x = 45,y = 29, z = 11; 118 voxels,
T = 4.61, p (FWE corrected) = 0.068).
Similarly, no significant group by time effects or any
baseline differences between groups were observed in
the happy faces task. There were no main effects of time
in the MDD patients, but healthy participants showed a
significant decrease with time in response to the mean
of medium and high intensity of expressions in the
anterior cingulate (x = 9, y = 29, z = 40; 315 voxels,
peak T = 4.27; p (FWE corrected) = 0.002) and precentral
region (x = −51, y = 11, z = 34; 190 voxels; T = 4.08; p (FWE
corrected) = 0.018), as well as approaching significance in
the thalamus (x = 3, y = −13, z = 10; 118 voxels; T = 4.12;
p (FWE corrected) = 0.070).
Emotional Stroop
A significant group by time interaction was observed in
the left posterior temporoparietal junction involving the
parahippocampal cortex (x = −18, y = −40, z = 1; 414 -
voxels; peak T = 4.11; p (FWE corrected) = 0.014) as well
as precuneus and posterior cingulate cortex (subordinate
peaks at x = −24, y = −52, z = 22 and x = −21, y = −70,
z = −10) during the processing of negative relative to
neutral words (Figure 1). The interaction effect was
found to be driven by reductions observed in MDD
patients (significant at p = 0.001 uncorrected) with
successive scans relative to healthy participants who
showed no significant changes with time. At baseline,
there was a main effect of group in which MDD patients
showed greater activation relative to healthy participants
in a region including the posterior cingulate cortex and
precuneus bilaterally (right: x = 9, y = −43, z = 19; left:
x =−15,y =−43, z = 4, and x = 15, y =−49, z = 13; -134 voxels;
peak T = 4.51; p (FWE corrected) = 0.026).
Resting state
No significant group by time effects were found, but
main effects of time were observed within each group.
MDD patients showed decreased connectivity with suc-
cessive scans (Figure 2) between DMN components and
bilateral prefrontal cortices, namely with right dorsolateral
(IC06; x = 52, y = 10, z = 18; 118 voxels; T = 3.9; 117 voxels;
p (FWE corrected) = 0.034), right superior frontal premotor
cortex (IC06; x = 22, y = −2, z = 64; T = 4.25; 41 voxels;
p (FWE corrected) = 0.030), and left inferior frontal
gyrus (IC06; x = −54, y = 14, z = 16; T = 4.79; 36 voxels;
p (FWE corrected) = 0.018), as well as decreased con-
nectivity between DMN components and auditory
processing cortex (IC10; x = −57, y = −48, z = 19; T = 5.85;
1078 voxels; p (FWE corrected) = 0.007), and primary
visual and extrastriate regions (IC20; x = 2, y = −78, z = 4;
T = 4.88; 492 voxels; p (FWE corrected) = 0.005). Increases
in connectivity between components of the DMN in
MDD patients were found with medial prefrontal regions,
including pregenual and subgenual cingulate and the
frontal pole (IC08; x = 10, y = 30, z = −8; T = 5.04;
7287 voxels; p (FWE corrected) = 0.007), right hippocam-
pus (IC24; x = 42, y = 14, z = −36; T = 4.13; 30 voxels; p
(FWE corrected) = 0.023), parahippocampal gyrus (IC24;
x = 42, y = −30, z = −20; T = 4.05; 431 voxels; p (FWE
corrected) = 0.035), angular gyrus (IC08; x = 54, y = −46,
z = 24; T = 4.99; 190 voxels; p (FWE corrected) = 0.010),
and middle occipital gyrus (IC08; x = 10, y = −102, z = 8;
T = 5.69; 263 voxels; p (FWE corrected) = 0.009). Healthy
participants showed decreased connectivity with time
between the DMN with the posterior hippocampus
extending into the fusiform region (IC06; x = 30, y = −38,
z = 0; T = 4.83; 45 voxels; p (FWE corrected) = 0.027).
There was also increased connectivity with time in healthy
participants between the DMN and posterior cingulate
(IC08; x = 6, y = −50, z = 8; T = 3 78; 85 voxels; p (FWE
corrected) = 0.030), fusiform gyrus (IC08; x = 34; y = −38,
z = −12; T = 4.61; 375 voxels; p (FWE corrected) = 0.010),
superior medial frontal gyrus (IC08; x = 2; y = 34, z = 36;
Figure 1 Emotional Stroop. A significant group by time effect was
found for the emotional Stroop in the posterior cingulate extending
into the precuneus.
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T = 3.85; 91 voxels; p (FWE corrected)- = 0.029), premotor
cortex (IC08; x = −26; y = 10, z = 52; T = 4.19; 91 voxels;
p (FWE corrected) = 0.025), and parietal lobule (IC08;
x = 50; y = −54, z = 44; T = 4.30; 808 voxels; p (FWE
corrected) = 0.006).
Predictors of clinical response
Baseline resting-state activity within the orbitofrontal
component of the DMN in MDD patients, before
treatment was initiated, was negatively correlated with
improvement with treatment as measured by HRSD
(Figures 3 and 4). MDD patients with reduced
connectivity in the orbitofrontal component of the
DMN (BA10/25/47) (left subgenual anterior cingulate
(BA 25/11): x = 6, y = 30, z = −10; T = 6.84, 691 voxels;
p (FWE corrected)- = 0.003; right subgenual/pregenual
anterior cingulate: x = 12, y = 42, z = 8; T = 5.56;
83 voxels; p (FWE corrected)- = 0.021) showed the
greatest improvement with treatment. No other functional
MRI or structural baseline measures were correlated with
changes in HRSD or HAMA based on the whole-brain
analysis.
From the MMRM model, which accounted for par-
ticipants who had not completed all the scans with a
last observation carried forward methodology, an early
increase in left hippocampal volume after 1 week of
treatment predicted clinical remission following
12 weeks of treatment (odds ratio 1.01 (95% CI: 1.00, 1.02)
p = 0.031) (Additional file 1: Table S2- S3). High intraclass
correlations for repeated measurements were observed
for all the volumetric measurements in the healthy
control participants (all > 0.91), which were 0.976 and
0.961 for the right and left hippocampi, respectively
(Additional file 1: Table S1).
Discussion
Distinct neural effects of treatment with duloxetine were
revealed in resting state connectivity, affective facial
processing, and negative attentional processing. Contrary
to our hypothesis, we did not find any group by time
Figure 2 Resting-state functional magnetic resonance imaging. Linear changes in resting-state functional fMRI with successive scans, Areas with
reductions in connectivity to the default mode network (DMN) regions with time are shown in blue, and areas with increased connectivity to the
DMNs are depicted in red.
Figure 3 Baseline connectivity in ventral cingulate and orbitofrontal resting state network. Decreased baseline connectivity in ventral cingulate
and orbitofrontal resting-state network predicted an improved response in correlation with the normalized change in HRSD-17 score from week 0
to week 12 corrected for multiple comparisons.
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interaction effects in the neural responses to sad facial
expressions [3-5]. Instead, marked effects in the posterior
cingulate cortex were evident in response to a task
designed to engage the negative attentional bias in MDD
[24], and there were time-dependent changes in the DMN
in MDD patients in which increased connectivity towards
limbic regions but decreased connectivity with lateral
cortical regions emerged as treatment progressed.
Furthermore, baseline resting state connectivity within
the orbitofrontal component of the DMN, namely in the
bilateral anterior cingulate regions, was a significant a
predictor of clinical response.
Normalization of limbic hyper-responsiveness has
been commonly reported in MDD [3-5] and appears to
be specific to sad facial expressions [34]. However, we
did not observe increased amygdala activation to sad
faces in the acutely depressed MDD participants nor any
significant group by time effects following treatment.
Potential confounds include factors related to the sample
and task. In the present group, the depressive symptoms
was of a moderate to severe severity which is comparable
to previous samples in which increased amygdala responses
have been observed [3-5,34]. The present task used implicit
affective processing in order to increase the potential to
engage amygdala responsivity, while a masked presentation
may have more fully captured amygdalar automatic
processing [35,36], and the number of subjects and the
design of the task, which was an event-related design
rather than a blocked design, may have limited the power
to observe a significant effect [35]. Furthermore, most
studies to date have examined the effects of the SRI class
of antidepressants [3-5,34]. Single doses of SRI medica-
tions in healthy participants have been associated with
decreased amygdala responses to emotional faces, while
single-dose NRIs lead to increased activation in medial
and frontal regions [11]. It is unclear whether the effects
of different classes of antidepressants are comparable as it
has been proposed that SRIs have an early attenuating
effects on emotional reactivity while NRIs have a more
modulatory effect on attention regulation of emotional
processes and may not necessarily have a direct impact
on amygdala responsivity which would be observed in
addition to potential state effects related to acute depres-
sive states as compared to states of remission [9-11,37].
In order to examine the negative attention bias in
MDD [38], we applied an emotional Stroop task [24,39].
We found a significant interaction effect in the posterior
cingulate cortex in which increased baseline activation
in MDD showed a linear normalization with successive
measures following treatment as compared to healthy
participants who underwent the same scans. The posterior
cingulate cortex is involved in the DMN, which has a cen-
tral role in many situations whereby attention is internally
directed such as in episodic memory retrieval and inner
Figure 4 Association between baseline connectivity and change in depressive severity. Scatter plot of baseline resting-state fMRI baseline
connectivity activity in subgenual cingulate and clinical response to 12 weeks of treatment with duloxetine as measured by the normalized
change in HRSD-17 score from week 0 to week 12.
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reflection [40]. Increased posterior cingulate activation in
MDD patients while acutely depressed may be understood
as reflecting a failure to attenuate self-referential activity,
perhaps leading to interference in task performance.
With treatment, attenuation of posterior cingulate activity
may reflect an improvement in selective attention and the
ability to focus.
In parallel, the resting-state functional connectivity in
MDD patients showed increased connectivity over the
course of treatment within the anterior DMN in the
subgenual anterior cingulate and regions involved in
attention-processing, namely the superior frontal and
parietal cortices, while reduced connectivity was observed
in the prefrontal regions linked to the DMN. Anand et al.
[41] also found increased connectivity with the anterior
cingulate and limbic regions following treatment with a
variety of antidepressant medications, and Li et al. [42]
have proposed that persistent increased functional con-
nectivity in anterior DMN reflects a trait effect of MDD
and a potential risk for relapse.
The present findings bring into question the potential
for amygdala responsivity as a state marker of MDD
because no significant differences were found during
an acute episode or following 12 weeks of treatment
in which the majority of patients’ symptoms fulfilled
criteria for clinical remission reflecting the numerous
factors which impact on amygdala responsivity [35].
Rather the negative affective bias appears to have been
more strongly detected by the emotional attention
processing task which revealed a significant group by
time effect with normalization of activation in the
posterior cingulate. The corresponding increase in
resting state connectivity in MDD patients with treatment
highlights potential links between the negative affective
bias that is characteristic of MDD and the resting state
network [37]. Moreover, there are persuasive indications
that these effects may be related to the NRI class of anti-
depressant medication [9-12,37] although this requires
further investigation.
As a potential marker of clinical response, we found
that MDD patients with reduced functional connectivity
with the subgenual anterior cingulate showed the greatest
clinical improvement following treatment. The subgenual
anterior cingulate has a key role in MDD [43], and activity
in this region has been consistently implicated as a
predictor of clinical response [7,44]. Increased functional
connectivity with the subgenual anterior cingulate has
been associated with increased length of illness [45], and
the neuropsychological mechanisms of rumination and
brooding have been correlated with increased connectivity
between the subgenual anterior cingulate and posterior
cingulate [46], including in treatment-naïve MDD patients
with increased functional connectivity in the medial
prefrontal and subgenual anterior cingulate [47]. Anterior
cingulate-limbic white matter tracts have also been pre-
dictive of clinical response [48], though the degree to
which white matter tract structural connectivity form the
basis of resting state functional connectivity requires
further validation [49].
From the MMRM model, an early increase in left
hippocampal volume after 1 week of treatment predicted
subsequent clinical response. Although the volume change
was small, the high intraclass correlations in hippocampal
volumes with the repeated measures in the healthy partici-
pants indicate a high reliability of the measure. Sämann
[50] reported that increased left hippocampal gray matter
volume was predictive of treatment response to a variety
of antidepressant medications, and our meta-analysis
supported the observation of reduced right hippocampal
volume being predictive of a poorer clinical response [7].
Increases in hippocampal volume have been observed
following short term [51] and long term [52] treatments
with antidepressant medications. Our finding suggests
that antidepressant medications can increase hippocampal
volume early in the course of treatment, such increases
may be predictive of clinical response, and provides
some corroboration for hippocampal neurogenesis as
a mechanism for the effects of antidepressant therapy [53].
Limitations
The high response rate in this open study though has
limited the power to detect differences between responders
and MDD patients with a more treatment-resistant form of
depression, which may be associated with distinct neural
correlates [41]. The absence of a placebo-control treatment
arm limits our attribution of effects to the antidepressant
medication as opposed to changes associated with clinical
improvement, although possible confounds of time were
accounted for by healthy participants having the same serial
scans. Furthermore, we did not find any significant
differences between MDD patients and healthy participants
in response to the happy and sad faces stimuli, perhaps in
part reflecting the poor test-retest reliability of amygdala
response to these emotional faces [54], while resting-state
fMRI data show greater robustness and reproducibility
[55]. Test-retest reliability of a neuroimaging measure
becomes particularly important in the development of
biomarkers for prognosis and diagnosis [44].
Conclusions
In summary, multimodal functional and structural neuro-
imaging correlates demonstrated significant effects of
treatment in the anterior DMN associated with resting
state connectivity and in response to negative attentional
biases, but not in response to happy or sad facial expres-
sions. Moreover, anterior cingulate functional connectivity
predicted clinical response. Our findings reflect the dis-
tinct effects of the SNRI class of antidepressants as well as
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methodological factors of test-retest reliability and repro-
ducibility of fMRI tasks. Further investigation is required
to examine the specificity of the SNRI effects.
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